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Oxidative phosphorylation disorders 
 
Mitochondrial disorders are characterized by a broad spectrum of multisystem clinical 
features, sometimes clustered into a syndrome but more often not. They affect at least 
1 in 5000 individuals and are associated with a deficiency of the oxidative 
phosphorylation (OXPHOS) system [1]. Therefore, they will be further referred to as 
OXPHOS disorders. Mitochondrial OXPHOS is essential for aerobic energy production 
in virtually all cells. During this process, oxidation of electron carriers nicotinamide 
adenine dinucleotide (NADH) and flavin adenine dinucleotide (FADH2), reduced during 
metabolism of carbohydrates, fatty acids and proteins, drives the production of ATP. 
The OXPHOS system is composed of five complexes of which the subunits are 
encoded by both the mitochondrial and nuclear DNA (except for complex II, which is 
entirely encoded by nuclear DNA). Accordingly, OXPHOS disorders can be caused by 
mutations in both genomes. Because mitochondria are the main providers of energy, 
tissues with high energy demands are affected most often in OXPHOS disorders. 
These organs include the brain, heart, liver and muscle [2]. The consequences of 
pathogenic mutations can be tissue specific as different metabolic thresholds, 
depending upon the energy demand, apply for the different tissues [3]. However, this is 
not the sole factor involved and the mechanism behind the tissue specificity is not 
entirely clear. Thus, OXPHOS 
disease is usually multisystemic and 
the variety of clinical features 
includes, among others, 
encephalopathy, stroke, epilepsy, 
optic atrophy, deafness, neuropathy, 
myopathy, cardio-myopathy, exercise 
intolerance,  diabetes and liver failure 
(figure 1.1) [4]. A few specific 
syndromes could be defined (table 
1.1) but most often OXPHOS disease 
is not so well delineated [4]. 
Furthermore, there is most often no 
cure and the treatment options for 
even delaying OXPHOS disorders are 
limited. 
 
 
 
 
 
Figure 1.1. Potential clinical features 
associated with OXPHOS disease 
(adapted from [5]). 
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Mitochondrial DNA 
 
The mitochondrial genome is a double-stranded, circular molecule consisting of 16.569 
base pairs and coding for 13 subunits of the OXPHOS complexes, two rRNAs and 22 
tRNAs, required for mitochondrial translation (figure 1.2). The mitochondrial DNA 
(mtDNA) has a number of unique characteristics that discriminate it from nuclear DNA 
(nDNA).  
x The mtDNA is polyploid. A mitochondrion contains five to ten copies of mtDNA and 
a cell can contain hundreds to thousands of mitochondria. All mtDNA molecules can 
be identical (homoplasmy) or mixtures of wild and mutant type base pairs can be 
present in a cell (heteroplasmy).  
x mtDNA encoded genes do not have introns and several of them are overlapping. 
Less than ten percent of the genome is non-coding and is predominantly located in 
the displacement (D)-loop, involved in the replication and transcription of the 
mtDNA. Transcription of mtDNA can occur on both (heavy and light) strands, 
starting from the mitochondrial promotors, and produces polycistronic precursor 
RNA. This RNA is subsequently processed into individual tRNA, rRNA and mRNA 
molecules.  
x mtDNA is maternally inherited.  
x Replication of mtDNA is called relaxed as it is not connected to the cell cycle.  
x mtDNA molecules lack histones and other protective proteins. In combination with 
its location nearby the reactive oxygen species (ROS)-producing OXPHOS system 
and less efficient DNA repair mechanism, this leads to higher mutation frequencies 
in mtDNA compared with nDNA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2. The mitochrondrial 
genome.  Complex I (ND) genes 
are shown in green, the complex III 
Cyt b in red, complex IV (COX) 
genes in light blue, complex V 
(ATPase) genes in grey, rRNA 
genes in yellow and tRNA genes in 
black. Adapted from [7]. 
 General introduction |1 
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Clinically relevant mtDNA variations fall into five categories: 1) de novo or maternally 
inherited deleterious point mutations (mainly substitutions); 2) ancient adaptive 
polymorphisms that predispose individuals to disease in different environments; 3) 
single or multiple mtDNA deletions affecting multiple mtDNA encoded genes; 4) 
duplication of part of the mtDNA molecule [8] and 5) differences in mtDNA copy 
number, which when extremely decreased is called mtDNA depletion. These variations 
can occur separately or in combination (e.g. m.3243A>G and reduced mtDNA copy 
number [9]).  
As a result of the exclusive maternal inheritance of mtDNA, OXPHOS disease due to 
mtDNA mutations is transmitted through the maternal lineage. The majority of 
pathogenic mtDNA variations are heteroplasmic, although a growing list of 
homoplasmic pathogenic mutations, including the more frequent occurring LHON 
mutations, exists. However, the variable penetrance of homoplasmic pathogenic 
mutations implies the presence of modifiers. Modifiers can be of mtDNA or nDNA origin 
and probably involve one or more polymorphisms that do not necessarily induce 
pathology on themselves [10]. For heteroplasmic mutations, a certain heteroplasmy 
threshold level is necessary before respiratory defects or tissue dysfunction become 
apparent, depending on the aerobic energy need of a tissue. Often, a higher proportion 
of mutant mtDNA will lead to a more severe biochemical defect and/or clinical 
phenotype [11], but an exact correlation is lacking [12]. When new mtDNA variants are 
identified in patients, a number of criteria (box 1) are checked to determine their 
pathogenicity. However, there are many examples of pathogenic mtDNA variants in 
literature that do not fit all of the current pathogenicity criteria, which particularly 
challenges the genetic counseling of families [13, 14].  
 
Box 1. Pathogenicity criteria for mtDNA point mutations [14] 
x Mutation must be present in patients and absent in controls 
x Mutation must be found in different mitochondrial genetic backgrounds 
x Mutation must be the best mtDNA candidate variant to be pathologic 
x The percentage of the mutation must correlate with the phenotype 
x Mutation must affect highly evolutionary conserved nucleotides 
x Mutation must affect functionally important domains 
x The transfer of the mutated mtDNA to another cell line must be accompanied by the transfer of 
the cell or molecular defect 
 
 
Nuclear genes involved in oxidative phosphorylation 
 
In contrast to the extensively studied and characterized mitochondrial genome, the list 
of nuclear encoded OXPHOS-related genes is less complete. Nuclear genes involved 
in OXPHOS function code for structural components of the OXPHOS complexes (e.g. 
NDUFV1, NDUFS4, SDHA), assembly factors of OXPHOS complexes (e.g. SURF1, 
C20orf7, BCS1L), factors involved in mtDNA replication and maintenance (POLG1, 
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TWINKLE, mtSSB) and proteins involved in the mitochondrial nucleotide balance 
(ANT1, DGUOK, TK2, TP, SUCLA2), mtDNA transcription (e.g. POLRMT, TFAM) and 
translation (e.g. PUS1, EFG1, MRPS16). Furthermore, there are also several nuclear 
genes that are indirectly related to respiration and energy production by mitochondria. 
This group includes genes coding for mitochondrial metalloproteases, mitochondrial 
import/export proteins, mitochondrial iron-storage proteins and proteins associated with 
mitochondrial fusion and fission. Mutations in these genes are  associated, among 
others, with spastic paraplegia (SPG7), Friedreich’s ataxia (FRDA), X-linked 
sideroblastic anemia and ataxia (ABC17) and optic atrophy (OPA1) [15]. 
 
 
Diagnostic strategy in suspected OXPHOS disease 
 
Because of the variety in clinical manifestations of OXPHOS disease, diagnosis often 
requires a multidisciplinary approach. No single symptom is specific for OXPHOS 
disease or is able to distinguish it from other disorders, but when combinations of 
common chronic and unexplained symptoms (such as migraine, diabetes, deafness) 
occur, the possibility of OXPHOS disease should be considered [16, 17]. When clinical 
suspicion of OXPHOS disease arises, a number of investigations, including 
histochemical, biochemical and genetic analysis, can lead to the eventual diagnosis 
(figure 1.3).  
 
Figure 1.3. Diagnosis of OXPHOS disease needs a multidisciplinary approach. SDH = succinate 
dehydrogenase, COX = cytochrome C oxidase, EM = electron microscopy 
 
 
Histochemical investigations 
Histochemical assays are used to detect abnormal focal accumulation of mitochondria 
or low activity of respiratory chain enzymes in skeletal muscle biopsies. The red Gomori 
trichrome staining visualizes accumulation of focal subsarcolemmal mitochondria such 
as the so-called ragged red fibers (RRFs) which presumably denote a decrease of 
 General introduction |1 
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energy production [18]. However, RRFs have also been described in healthy individuals 
and are only seldom observed in young children with mitochondrial disease, making 
interpretation by an expert necessary [17, 18]. Combined histoenzymatic reactions for 
succinate dehydrogenase (SDH) and cytochrome c oxidase (COX) typically result in a 
mosaic appearance of abnormalities but may be helpful in visualizing COX-negative 
fibers with mitochondrial proliferation (increased SDH staining). Histochemical 
investigations can provide additional evidence for a diagnosis of OXPHOS disease. 
 
Biochemical assays 
An initial biochemical examination in patients suspected of OXPHOS disease is a 
metabolic screening including the measurement of the metabolites lactate, pyruvate 
and alanine in blood, urine or cerebrospinal fluid and the measurement of organic acids 
in urine [16]. OXPHOS dysfunction leading to a disturbed oxidation ratio of NADH to 
NAD+ results in feedback inhibition of pyruvate metabolism in the mitochondria. The 
excess pyruvate is transported back into the cytosol. Here it is metabolized into lactate 
or converted into alanine, which leads to an increase of these metabolites in body fluids 
[16]. The increase in the NADH/NAD+ ratio or the reduced oxidation rate of FADH2 may 
also lead to a metabolic arrest of the Krebs cycle leading to an increase and 
subsequent excretion of intermediates of the citric acid cycle in urine. Furthermore 
elevated levels of ethylmalonate and 3-methylgluconate are frequently found in 
mitochondrial patients [19]. However, due to the limited specificity of the initial screen, 
definite biochemical investigations are performed, preferably in a skeletal muscle 
biopsy or in fibroblasts when no muscle sample is available. Biochemical investigations 
in muscle may include the measurement of overall oxygen consumption, radio-labeled 
substrate oxidation or ATP synthesis by the OXPHOS system in fresh muscle biopsies 
and measurement of the activities of individual respiratory chain enzymes in frozen 
muscle homogenates. Assessing overall oxygen consumption, substrate oxidation and 
ATP synthesis in mitochondria require an intact mitochondrial membrane and is thus 
only applicable in fresh muscle biopsies [16]. The spectrophotometric assays of the 
activities of the individual complexes in muscle/fibroblast homogenates are based on 
the specific kinetic measurement of the velocity of the oxidation or reduction of the 
physiological substrates by the use of specific inhibitors of the individual complexes 
[18]. Interpretation of the individual complex measurements is rather difficult because 
there is only a narrow margin between control and patient ranges.  Due to a large 
variation of absolute activities in samples which may be due to a large variation in the 
amount of mitochondria, the activity of the different complexes is expressed relative to 
the activity of another respiratory chain complex (usually complex II or IV) or citrate 
synthase. The severity of the enzyme deficiency is not necessarily linked to the severity 
of the clinical phenotype, therefore it is also important to detect even mild deficiencies. 
Furthermore, it is important that the different complexes or electron carriers are in a 
strict equilibrium for a sustained continuous and efficient substrate oxidation. Any 
imbalance can result in increased superoxide production or a decrease in respiration 
[18]. Available methods to measure superoxide production and its consequences are 
mainly based on HPLC analysis [20], probe (e.g. hydroethidine) oxidation [21, 22], 
mass spectrometry [23] and immunology [21]. 
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Genetic analysis 
In general, according to the clinical phenotype of a patient, a standard mtDNA analysis 
is performed first. This includes screening for common mtDNA point mutations 
(m.3243A>G, m.8344A>G, m.8993T>G/C and LHON mutations) in blood using 
restriction fragment length polymorphism (RFLP) analysis or pyrosequencing, which 
allow for the accurate quantification of heteroplasmy levels. Furthermore, the presence 
of mtDNA deletions in blood or muscle can be detected with long range PCR. The 
mtDNA copy number is determined by quantitave PCR (QPCR) and is represented by 
the ratio of the number of copies of a mtDNA-encoded gene (e.g. 12S rRNA) and the 
number of copies of a nDNA-encoded gene (e.g. RNAP). A decrease of the copy 
number below 35% of the copy number of age matched controls is called mtDNA 
depletion [24]. The detection of mtDNA depletion by QPCR and multiple mtDNA 
deletions by long range PCR warrant the screening of nuclear genes associated with 
mtDNA replication and/or the clinical phenotype. When the initial mtDNA analysis is 
negative, the whole mtDNA genome will be analyzed e.g. using the Affymetrix mtDNA 
resequencing chips (MitoChip), preferably in muscle samples. mtDNA variants detected 
by this method are usually confirmed by conventional Sanger sequencing. In the 
absence of pathogenic mtDNA mutations or based on the clinical phenotype, nuclear 
OXPHOS genes are being screened. In case the phenotype resembles that of patients 
for which a pathogenic mutation has been described previously (e.g. POLG1, ANT), the 
corresponding gene is screened by direct sequencing of the exonic regions. When no 
good candidate gene can be found in literature and multiple individuals of a family 
present a similar phenotype, linkage (single nucleotide polymorphism (SNP)) analysis 
can be performed to identify new candidate genes. Usually, this results in multiple 
candidate genes which are screened for mutations by direct sequencing. Recently, 
exome sequencing is used on itself or in combination with linkage studies to find 
pathogenic DNA variations in a high throughput manner [25]. Once a pathogenic 
mutation (mtDNA or nDNA) is identified, family members of the index patient will be 
examined and for mtDNA mutations, accurate heteroplasmy levels will be determined.  
 
 
Pathophysiology 
 
The clinical manifestation of OXPHOS disorders can occur immediately at birth, 
deteriorate progressively during life or be triggered by a number of events. These 
triggers of full-blown OXPHOS disease include viral infections [26, 27] and adverse 
effects of drugs, e.g. valproic acid induced liver failure in patients with mutations in 
POLG1 [28], mtDNA depletion due to nucleotide reverse transcriptase inhibitors 
(NRTIs) for the treatment of human immunodeficiency virus (HIV) [29]).  
There are a number of approaches to study the pathophysiology of OXPHOS disorders. 
In the past, pathophysiology was mainly studied in a ‘hypothesis-driven’ manner. A 
hypothesis was posed based on existing incomplete knowledge and tested in carefully 
designed experiments. Accordingly, the hypothesis could be falsified and rejected or 
supported by the data. At present, the use of ‘discovery-driven’ research is 
emphasized. This includes a systems biology approach, studying the interactions of 
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large numbers of molecules (DNA, mRNAs or proteins) that constitute the biological 
system and using data mining to generate (new) hypotheses by induction. High-density 
measurement technologies such as whole genome gene expression microarrays, high 
performance liquid chromatography and mass spectrometry are indispensible for this 
approach. Ultimately, the new hypotheses and theories that arise inductively should be 
tested in a ‘hypothesis-driven’ manner to lead to valid knowledge [30]. Finally, animal 
models have been very useful to study pathophysiology in vivo and to examine the 
effect of potential therapeutic or adverse drugs [31-35]. 
 
So far, research on OXPHOS pathogenesis has led to the identification of a number of 
biological processes that are assumed to play a role in OXPHOS disorders. Altogether, 
a dysfunctional OXPHOS system can increase the production of ROS [22, 36], can lead 
to abnormal mitochondrial fission/fusion [37] and a disturbed mitochondrial membrane 
potential [38] and will be unable to supply sufficient ATP to meet cellular needs (figure 
1.4). Part of this ATP is necessary to fuel cellular import and export of key metabolites 
and inorganic ions such as calcium [39]. Eventually, increased oxidative stress, a 
dysfunctional mitochondrial membrane potential and impaired calcium homeostasis can 
culminate in apoptosis [40] (figure 1.4). In general, changes in oxidative stress and 
apoptosis co-exist with a deficiency of at least one OXPHOS complex [41-44], but the 
OXPHOS deficiency is not required for their involvement in the pathogenesis [45].  
 
Figure 1.4. Physiopathological processes involved in OXPHOS disease. 
 
Oxidative stress 
Although ROS are generated by multiple other enzymes and processes in a cell, e.g. 
NADPH oxidases and lipid metabolism, it has been estimated that mitochondria 
produce most (~90%) of cellular ROS at complexes I and III [46]. In the process of 
oxidative phosphorylation, oxygen is consumed for the production of ATP. In 
physiological conditions, approximately 0.2% of the total consumed oxygen is 
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converted to ROS (superoxide anion and hydrogen peroxide). Any disturbance of the 
electron transport chain can increase the production of ROS [46]. Previously, ROS 
were considered to be merely harmful because of their capacity to oxidize DNA, lipids, 
carbohydrates and proteins [47]. Oxidation of these macromolecules will lead to 
mutagenesis [48], diminished functioning [49, 50] and loss of structural integrity [49]. 
However, ROS per se are not always a negative given. Nowadays, ROS are also 
believed to play a role as redox messengers in several signaling pathways leading to 
cellular adaptation, e.g. muscle fiber adaptation in response to both increased 
contractile activity and prolonged periods of muscle disuse [51]. 
To keep a balance between its role in signaling and toxic effects, ROS levels are tightly 
monitored and regulated by the antioxidant defense system. An overview of the most 
familiar contributors to the mitochondrial antioxidant defense system is depicted in 
figure 1.5. Superoxide (O2Â) produced at sites from complex I and III will be dismutated 
to hydrogen peroxide (H2O2) by superoxide dismutase (SOD) in the mitochondrial 
matrix (Manganese (Mn) SOD) or cytosol (Copper/Zinc (Cu/Zn) SOD). Hydrogen 
peroxide can be converted by catalase (CAT) in the cytosol and the glutathione and 
thioredoxin detoxification systems in the mitochondrial matrix. Hydrogen peroxide that 
is not converted to water can lead to the formation of highly reactive hydroxyl radicals 
(OHÂ) through the Fenton reaction. 
 
 
Figure 1.5. Mitochondrial antioxidant defense system. OMM = outer mitochondrial membrane, IMS 
= inner membrane space, IMM = inner mitochondrial membrane, GSH = reduced glutathione, GSSG = 
oxidized glutathione, GPx = glutathione peroxidase, GR = glutathione reductase, NNT = nicotinamide 
nucleotide transhydrogenase, TRxred/TRxox = reduced and oxidized thioredoxin, respectively, TPx = 
thioredoxin peroxidase, TR = thioredoxin reductase. 
 
 
Since OXPHOS disorders are characterized by disturbances in the electron transport 
chain, various studies have examined the role of oxidative stress in their pathogenesis 
(table 1.2). Although some addressed the question whether or not oxidative stress is 
actively involved in causing disease phenotypes, their results do not always 
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correspond.  Several reasons can be given for this. First of all, some studies examined 
only two or three similar oxidative stress parameters. In order to get an impression of 
the oxidative status of a cell or tissue, three categories of parameters, i.e. ROS levels, 
antioxidant system levels and oxidative damage levels, should be documented. 
Especially the last read-out will give valuable information on how patients suffer from 
the consequences of oxidative stress. Another problem for comparing different 
experiments is the variety of protocols to measure one specific parameter, e.g. DNA 
oxidation can be determined by HPLC, ELISA, mass spectrometry, western blot and 
immunohistochemistry, each with its own advantages, disadvantages and limitations. 
Measurements with different protocols do not always give comparable results [47]. 
Finally, the examined tissue and the small sample size of the cohorts can also 
contribute to conflicting results. Conclusively, as can be appreciated from table 1.2, 
some OXPHOS disorders (MELAS, MERRF and NARP) show more evidence for the 
presence of oxidative stress and concomitant damage than others (POLG1 and SURF1 
mutations). As there is no consensus, it is recommended to analyze a number of 
carefully chosen stress parameters, as indicated above, in parallel using the same 
methods in different OXPHOS disorders [52]. As a result, one will be able to compare 
the involvement of oxidative stress in each of those diseases and thus evaluate the 
relevance of antioxidant therapy. 
 
 
 
 
 
 
 
 
 
 
 
Table 1.2 legend. The involvement of oxidative stress parameters (production, defense and damage) in 
different OXPHOS disorders as documented in literature. 
Ç = increased, È = decreased, N = normal, MnSOD = mitochondrial superoxide dismutase, CuZnSOD 
= cytosolic superoxide dismutase, GPx = glutathione peroxidase, GR = glutathione reductase, GST = 
glutathione S transferase, GSSG = oxidized glutathione, GSH = reduced glutathione, 8-OHdG = 8-
hydroxy-2deoxy guanosine, 4-HNE = 4-hydroxynonenal, MDA = malondialdehyde  
+ F = fibroblasts, M = muscle, C = cybrids, Bl = blood, L = lymfocytes, My = myoblasts, Br = brain, Mi = 
mice 
* p = number of patients, m = number of different mutations, cl = number of cell lines with different 
heteroplasmy percentage 
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Apoptosis  
Mitochondria are at the crossroads of apoptosis (programmed cell death) regulation. 
The intrinsic mitochondrial apoptosis pathway can be initiated by a number of signals 
including DNA damage, growth factor deprivation and oxidative stress [75]. In short, 
mitochondrial outer membrane permeabilization leads to the release of soluble 
mitochondrial intramembrane proteins, such as cytochrome c, that trigger the 
proteolytic caspase cascade and cause inactivation of the electron transport chain [76]. 
Multiple studies have shown the involvement of apoptosis in muscle of patients with 
OXPHOS disorders (PEO [72, 77, 78], MELAS [45, 72, 78], MERRF [45, 78] and KSS 
[77]). However, patients with comparable phenotypes did not show equal signs of 
apoptosis in other studies [79-81]. Apoptosis was shown to be the central mechanism 
of tissue dysfunction in a mtDNA mutator mouse model (POLG1 D257A knock-in) [33], 
but embryonic fibroblasts from transgenic mice with the same mutation were not more 
susceptible to undergo oxidative stress induced apoptosis than wild type mouse 
embryonic fibroblasts [69]. 
Altogether, the current results on the role of apoptosis in OXPHOS disorders are not 
straightforward and point to a dysregulation of apoptotic decisions rather than 
increased apoptosis on itself. One theory could be that damaged cells which should 
die, sometimes fail herein whereas some healthy cells become apoptotic without valid 
reason. This compromises physiological functions and could also favor replicative 
senescence [82]. 
 
 
Examples of pathophysiological models for OXPHOS disorders  
 
In the next three paragraphs, three of the most frequent OXPHOS disorders will be 
described in more detail, including clinical phenotype, genetic cause and recent 
research on the molecular processes involved. Patients with isolated complex I (CI) 
deficiency, mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes 
(MELAS) patients and polymerase gamma (POLG1) patients represent three different 
disease classes i.e. defects in OXPHOS enzyme activity, mitochondrial protein 
translation due to a tRNA mutation and mtDNA maintenance, respectively. As a 
relatively high number of patients presents with these disorders, it is relevant to study 
their pathophysiology in order to improve their treatment options.  
 
Isolated CI deficiency 
CI deficiency leads to a number of clinical features including basal ganglia and/or 
brainstem lesions, respiratory abnormalities, muscular hypotonia, failure to thrive, 
seizures and lactic academia [83]. Most patients have a normal prenatal development 
and birth, but will develop symptoms within their first year of life, which are often fatal 
[38], or less severe symptoms later in life (e.g. Leber hereditary optic neuropathy 
[LHON]). CI deficiency is diagnosed when CI activity in muscle or skin biopsies is 
decreased compared to control specimen. Decreased CI activity can be caused by 
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mutations in both the mtDNA and nuclear genes, but often the genetic mutation leading 
to the deficiency cannot be identified [84].  
LHON (table 1.1) is associated with multiple mtDNA mutations, but those most frequent 
are m.3460G>A, m.11778G>A and m.14484T>C in the ND1, ND4 and ND6 genes of 
CI, respectively [85]. LHON mutations are usually inherited and homoplasmic [86]. In 
mutant LHON cells CI redox activity has been shown to be normal or reduced [87, 88], 
but the interaction between CI and its ubiquinone substrate (CoQ) might have been 
affected by the three LHON mutations. This led to a decreased CI dependent ATP 
synthesis and the overproduction of ROS [85].  
In case nuclear genes are involved, the reduced CI activity is primarily caused by lower 
levels of normal functioning CI instead of a decrease in intrinsic activity of the complex 
[89]. In resting fibroblasts of CI deficient patients, the overall cellular ATP levels were 
normal, which suggests that in the normal situation, ATP derived from glycolysis and/or 
residual CI activity is sufficient in fibroblasts. However, the same study showed that the 
reduced CI activity led to a depolarization of the mitochondrial membrane potential and 
reduced Ca+ content in the endoplasmic reticulum (ER). The authors hypothesized that 
the ATP supply to the ER Ca+ (SERCA) pumps was insufficient to maintain normal ER 
Ca+ levels which probably influences cellular calcium homeostasis [39]. Furthermore, in 
CI patients it has been shown that residual CI activity was inversely correlated with the 
production of ROS (superoxide and superoxide-derived ROS) [22]. Notably, whenever 
a certain threshold of residual CI activity (and thus ROS production) is passed, 
mitochondrial morphology changed. In fibroblast cell lines with a relatively ‘mild’ CI 
deficiency, mitochondrial morphology was normal or even more elongated, whereas 
patient cell lines with a severe CI deficiency (and thus higher ROS levels) showed a 
fragmented mitochondrial morphology. These differences probably coincide with a 
decreased probability to compensate for increased ROS levels or ROS related damage 
[38]. An unbiased approach, such as gene expression analysis, will help integrating the 
current knowledge into a pathophysiological model that might be able to distinguish 
cause from effect.  
 
MELAS 
 Although tRNA sequences comprise only a small fraction (~10%) of the mtDNA, more 
than half of the known pathogenic mtDNA mutations are found within the tRNA genes 
(MITOMAP database; www.mitomap.org/MITOMAP). The MELAS syndrome is the 
most common mitochondrial disorder and in 80% of the cases, patients carry the 
m.3243A>G mutation in the tRNA Leu(UUR) gene [90]. Clinical features associated 
with MELAS include recurrent strokes, CPEO, retinitis pigmentosa, optic atrophy 
deafness, dementia, extrapyramidal features ataxia epilepsy, myoclonus myopathy, 
cardiomyopathy, neuropathy, diabetes mellitus, gastrointestinal features (malabsorption 
and/or dysmotility), short stature and lipomata [11]. In a large patient cohort, a 
correlation could be observed between clinical features which occurred in >15% of the 
cases and the level of mutant mtDNA in muscle (n=111) but not in blood (n=73). A 
positive correlation with mutation percentage was identified for the frequency of 
recurrent strokes, dementia, epilepsy and ataxia, whereas an inverse correlation was 
detected for CPEO myopathy and deafness [11]. Another study could not find a 
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correlation between the percentage of mutated mtDNA and patient characteristics, 
which could be due to the smaller sample size (n=22). However, they did find a 
significant inverse correlation between the m.3243A>G mutant load and age of onset 
and CI activity [91]. Additionally, the m.3243A>G mutation percentage was positively 
correlated with hyperglycemia in diabetic patients [92]. 
The m.3243A>G mutation leads to incorrect tRNA processing and enzyme maturation 
due to disruption of the tertiary tRNA structure. Furthermore, the m.3243A>G mutation 
impairs taurine modification of the anticodon wobble position which is responsible for 
precise and efficient codon recognition [93, 94]. Eventually, mitochondrial translation is 
impaired because of a decreased steady-state of the normal aminoacylated tRNA [95]. 
The decreased protein synthesis rate will cause decreased enzyme activity and severe 
respiratory defects [90]. A gene expression study in muscle of symptomatic and a-
symptomatic mutation carriers identified increased protein turnover, oxidative stress, 
apoptosis and complement activation [21]. In a-symptomatic carriers, the amount of 
protein regeneration and OXPHOS stimulation seemed sufficient to prevent the 
occurrence of symptoms. However, in symptomatic carriers, excessive protein damage 
presumably leads to termination of repair/adaptive processes and a switch to muscle 
regeneration, indicated by stronger complement activation [21]. A more in depth 
analysis of the oxidative stress (production, scavenging and damage) might be able to 
fine-tune the current model of MELAS pathogenesis. 
 
POLG1 patients 
DNA polymerase gamma (pol Ȗ) is the only DNA polymerase involved in maintenance 
of the mtDNA and consists of a catalytic subunit and a homodimeric accessory subunit, 
encoded by the POLG1 and POLG2 genes, respectively [96, 97]. Over 150 mutations, 
which can be of a dominant or a recessive nature, have been detected in the POLG1 
gene (Human DNA Polymerase Gamma Mutation Database 
http://tools.niehs.nih.gov/polg/). Only recently, Euro and colleagues were able to cluster 
the recessive mutations into five distinct modules based on the recently solved crystal 
structure of the enzyme [98]. Mutations in POLG1 are associated with a series of 
disorders such as PEO (table 1.1), Alpers-Huttenlocher syndrome, childhood 
myocerebrohepatopathy spectrum (MHCS) disorders, ataxia neuropathy spectrum 
(ANS) disorders, myoclonus epilepsy myopathy sensory ataxia (MEMSA) and sensory 
ataxic neuropathy with dysarthria and ophtalmoplegia (SANDO) [99, 100]. Additionally, 
POLG1 mutations have been found to play a role in nucleoside reverse-transcriptase 
inhibitor (NRTI) [101] and valproic acid [28] toxicity and premature ovarian failure (POF) 
[102, 103].  
Mutations in the exonuclease and polymerase domain of POLG1 or combinations are 
associated with decreased mtDNA copy number in liver, muscle and fibroblasts of 
POLG1 patients [104]. Decreased nucleotide insertion specificity [105], decreased 
catalytic activity [105], loss of interaction between the catalytic and accessory subunits 
[106] due to POLG1 mutations have been observed in vitro.  Furthermore, the 
accumulation of heteroplasmic mtDNA point mutations, which can [107] or cannot [108] 
stimulate mtDNA deletion formation, in skeletal muscle [107, 108] and cultured human 
cells expressing POLG1 fusion proteins [109] have been reported. Whereas complete 
 General introduction |1 
 
27
 
knockout mice died prenatally [110], transgenic proofreading deficient mouse models 
(D257A POLG1 knock-in) showed accelerated ageing phenotypes with increased levels 
of mtDNA point mutations without evidence for the involvement of oxidative stress [33, 
34]. Human studies are limited to in vitro characterization of purified or recombinant 
enzymes [111], in vivo analysis of the functions of the pol Ȗ protein and its domains in 
cultured cells [109] and large scale screening of mtDNA molecules in skeletal muscle 
and fibroblasts [104, 107, 108]. These studies point out a higher probability of 
accumulating mtDNA mutations and/or depleting mtDNA when POLG1 is mutated. In 
addition, deficiencies in respiratory chain enzymes have been described in muscle of 
POLG1 patients [112]. Up to now, the more integrative studies of POLG pathogenesis 
are performed solely in mouse. An unbiased top-down approach (e.g. whole genome 
gene expression) may help elucidating processes involved in human POLG 
pathogenesis. The obtained results will indicate if the same disease mechanisms apply 
for rodents and human beings. 
 
 
Therapy in OXPHOS disorders 
 
Although knowledge on OXPHOS disorders and their underlying pathological 
mechanisms is emerging, a cure remains unavailable for most of them. Treatment is 
usually based on preventing complications, minimizing disability (symptoms) and 
providing prognostic and genetic counseling [113]. Additionally, the use of certain 
medication might be contra-indicated in some OXPHOS disorders, e.g. valproic acid for 
the management of epileptic seizures in case of POLG1 mutations [114]. Furthermore, 
the efficacy of other pharmacological agents is highly anecdotic. Nevertheless, various 
treatment cocktails of vitamins and cofactors (e.g. riboflavin, thiamine, folic acid, L-
carnitine and creatine monohydrate, coenzyme Q10) are administrated to patients with 
OXPHOS disease because they are presumed harmless [114]. 
Recently, exercise-based therapies were tested for the treatment of OXPHOS disorders 
[115]. On the one hand, endurance training was shown to improve oxidative capacity in 
patients with mtDNA mutations but did not decrease the percentage of mutated mtDNA 
(so-called ‘gene shifting’) [116-118]. On the other hand, resistance training lead to 
muscle regeneration through the activation of satellite cells which did not harbor the 
mutant mtDNA [17]. After muscle regeneration, less muscle fibers contained the mutant 
mtDNA and initial studies showed improved biochemical activity [119, 120]. These 
preliminary results are encouraging for minimizing disability in patients with OXPHOS 
disorders. 
 
 
Aim and outline of this thesis 
 
The components of the OXPHOS system are encoded by both the mitochondrial and 
nuclear DNA. Mutations in genes encoding structural OXPHOS elements or factors 
involved in the maintenance or assembly of the OXPHOS system lead to a number of 
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diseases, in general referred to as OXPHOS disorders. The underlying pathological 
mechanisms of these diseases are not entirely understood and there is a lack of 
efficient therapies. The central aim of this thesis is to study the pathophysiology of a 
number of specific OXPHOS disorders and to create new models and identify new 
potential targets for therapeutic interventions. Therefore, microarray gene expression 
profiling was applied as an unbiased approach to find clues for biological processes 
that are affected by the individual diseases and that can be monitored or targeted by 
new therapeutic strategies. Additionally, oxidative stress has generally been considered 
to be an important pathogenic factor in OXPHOS disorders although the efficacy of 
antioxidant therapy is highly anecdotic. Hence, the involvement and extent of oxidative 
stress in a number of different OXPHOS disorders was interrogated. Characterized cell 
lines can be used as model systems to test compounds that have potential to 
ameliorate or slow down progression of the disease. 
 
Altogether, the aim of this thesis is to create models or approaches to: 
- Facilitate diagnostics of mtDNA-based OXPHOS disorders by determining the 
non-pathogenic variation of mtDNA in the general population. 
- Gain knowledge on primary and secondary biological processes involved in 
OXPHOS disorders which have an impact on prognosis and therapy.  
- Explore the extent to which different pathogenic mtDNA and nuclear DNA 
mutations induce oxidative stress and the consequences of this. 
 
Chapter 2 describes the analysis of the mtDNA of 730 European subjects and presents 
novel data regarding the distribution of homoplasmic variants across the mtDNA. This 
comprehensive overview of mtDNA polymorphisms distinguishes between regions and 
positions which are likely not critical, pathogenic mutations targeting mainly conserved 
regions and regions containing no mutations at all. These data provide valuable 
information for evaluating the pathogenicity of mtDNA variants and counseling families. 
To improve prognosis and therapy options after genetic diagnosis, molecular disease 
pathways were identified in chapter 3 and 4 using microarray gene expression profiles 
in skeletal muscle of POLG1 patients and fibroblast cell lines of complex I patients, 
respectively. Both chapters indicated a role of oxidative stress in OXPHOS pathology. 
Therefore, chapter 5 evaluated the effect of pathogenic mtDNA mutations (in ND1, ND5 
and tRNALeu) and mtDNA maintenance defects (POLG1 mutations) on oxidative 
stress. This resulted in disease and patient specific signatures that indicate which 
parameter should best be used, i.e. oxidative damage, to evaluate which patients might 
benefit from antioxidant therapy. The cell line models of chapter 4 and 5 are now 
available for preliminary testing of the therapeutic effect of small compounds. The 
relevance of the results presented in chapter 2 to 5 in respect to the development of 
therapeutic strategies for OXPHOS disorders will be discussed in chapter 6. 
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Abstract 
 
The mitochondrial DNA (mtDNA) is highly variable, containing large numbers of 
pathogenic mutations and neutral polymorphisms. The spectrum of homoplasmic 
mtDNA variation was characterized in 730 subjects and compared with known 
pathogenic sites. The frequency and distribution of variants in protein coding genes 
were inversely correlated with conservation at the amino acid level. Analysis of tRNA 
secondary structures indicated a preference of variants for the loops and some 
acceptor stem positions. This comprehensive overview of mtDNA variants distinguishes 
between regions and positions which are likely not critical, mainly conserved regions 
with pathogenic mutations and essential regions containing no mutations at all.  
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Introduction 
 
Mitochondria are essential for the production of ATP, the main source of cellular 
energy, by the process of oxidative phosphorylation (OXPHOS). Part of the enzyme 
complexes involved are encoded by the mitochondrial DNA (mtDNA). The human 
mtDNA consist of 16,569 base pairs and contains 13 OXPHOS protein encoding 
genes, two ribosomal RNA genes and 22 tRNA genes [1]. It is generally considered 
that the mtDNA has a higher mutation rate compared to the nuclear DNA (nDNA) which 
is thought to be due to a combination of less extensive repair mechanisms, the lack of 
protective histones and closer proximity to a major source of mutation-inducing agents, 
i.e. the reactive oxygen species (ROS) [2]. The mtDNA is present as multiple copies 
within the mitochondria of each cell and altered nucleotides can be present in either the 
homo- or heteroplasmic state [3]. Not long ago it was generally accepted that the most 
deleterious pathogenic mutations were heteroplasmic, while homoplasmic variants 
were less severe risk factors or neutral polymorphic variants [4]. However, recent work 
has revealed a growing list of pathogenic homoplasmic mtDNA variants [5, 6], and most 
common pathogenic mutations are also present in the general population but usually 
far below the threshold level for phenotypic expression [7]. This presents a particular 
challenge when novel genetic variants are detected in patients with mitochondrial 
disease - conventional criteria cannot reliably determine which variants are 
phenotypically neutral, and which are actually causing disease. This is especially the 
case for variants in the protein coding genes and the tRNA genes, the latter 
compromising more than half of the published pathogenic mtDNA mutations [4, 8]. 
Pathogenic rRNA have been described to lesser extent, implicated in for example 
hearing loss [9]. A number of criteria and tools have been described to facilitate the 
classification of variants [10, 11], but a final conclusion regarding the pathogenicity of a 
certain variant is not always easy to achieve.  
 
The availability of techniques to generate mutation and/or sequence information of 
complete mtDNA genomes at a rapid pace has opened new possibilities for the 
detection and classification of variable and conserved parts of the mtDNA, based on 
large data sets of mtDNA sequences [12-17]. So far these studies have not been 
consistent on the frequency and distribution of variants in the mtDNA, both in human 
and mice. Some report specific hotspots for positions that are altered [11], while others 
show a more random distribution of variants across the mitochondrial genome [18]. 
Therefore, we chose to analyze the mtDNA in a large population of 730 European 
individuals with one technology. We applied the GeneChip® Mitochondria 
Resequencing array from Affymetrix (MitoChip) as a fast and reliable method to detect 
homoplasmic variants in the mtDNA [9, 13, 19]. As different approaches to analyze 
MitoChip data have been described with different sensitivity and specificity for the 
detection of mtDNA variants [19-21], we had to optimize our procedure. The study 
cohort contained 218 patients with mitochondrial symptoms, who could also carry 
pathogenic mutations in the mtDNA, which would create a risk of incidentally including 
non-neutral variants in the analysis. To minimize this risk we systematically checked all 
variants identified in this group for pathogenicity. All pathogenic and potentially 
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pathogenic mutations, identified in 30 patients, were excluded from analysis and only 
polymorphisms and, based on the scoring system, predicted benign variants were 
included. This, together with the size of the entire cohort in majority of individuals with 
no mitochondrial disorders, prevents that the analysis is influenced by inclusion of 
pathogenic mutations.  In our paper, we present novel data regarding the distribution of 
homoplasmic variants across the mtDNA and we provide clues to help distinguish 
neutral (homoplasmic) variants from highly deleterious pathogenic mutations in the 
tRNA genes. 
 
 
Material and methods 
 
DNA extraction 
Total cellular DNA was isolated from muscle or blood from 730 subjects (supplementary 
table 2.1) according to standard procedures. Of these, 400 subjects were inhabitants 
with age-related hearing impairment from a residential village of Antwerp (Belgium), 
between 54 and 66 years old, invited through population registries [22]. A total of 218 
subjects were patients with a variety of mitochondrial symptoms and ages between 0 
and 50 years, referred to the Clinical Genetics department in Maastricht (the 
Netherlands). For those subjects, the pathogenic or likely pathogenic mutation, when 
found, was added to supplementary table 2.1 and was not included in the further 
analysis. The remaining 112 subjects (with age from 54 to 75) were sequential 
admissions to the Critical Care Unit in Newcastle upon Tyne (United Kingdom). This 
cohort had an identical haplogroup distribution to the background population from the 
same geographical region, and thus is considered to be a random sample of individuals 
living in the North East of England [23]. All known or likely pathogenic mutations 
(supplementary table 2.2) in the entire cohort were excluded from the analysis.  
 
MitoChip and experimental procedure 
GeneChip® Mitochondria Resequencing 2.0 Arrays (Affymetrix, Santa Clara, CA, USA) 
were used to determine the sequence of the 730 DNA samples. In short, the entire 
mtDNA was amplified using the Expand Long Template system (Roche, Almere, the 
Netherlands) in 2 fragments (A and B) of 8207 bp and 8545 bp in length, with an 
overlap of 183 bp. The primers for fragment A were forward primer [5’-
cgttccagtgagttcaccct-3’] and reverse primer [5’-ggtaagaagtgggctagggc-3’], and for 
fragment B forward primer [5’-taaacctagccatggccatc-3’] and reverse primer [5’-
tgtggctaggctaagcgttt-3’]. PCR products were purified using the QIAQuick PCR cleanup 
kit (Qiagen). Equimolar amounts of the amplified fragments A and B were pooled and 
fragmented, labeled and hybridized on a pre-hybridized GeneChip according to the 
GeneChip CustomSeq Resequencing Array Affymetrix protocol. Chips were washed 
and stained on the GeneChip fluidics station 450 (Affymetrix) using the preprogrammed 
wash and stain protocol (Mini_DNAARRAY_WS5_450). The chips were scanned using 
the Affymetrix GeneChip scanner 3000 creating CEL files for subsequent analysis.  
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Data analysis 
After generation of the cell intensity (CEL) files by GeneChip® Operating Software 1.4 
(GCOS 1.4), raw sequence data was obtained by the GeneChip® Sequence Analysis 
Software 4.1 (GSEQ 4.1, Affymetrix) and Sequence Pilot – module SeqC (JSI medical 
systems) according to the flow chart depicted in figure 2.1. GSEQ uses an objective 
statistical framework, based upon the ABACUS algorithm [24] to assign base calls to 
each position which meets quality criteria in the mitochondrial genome, based on 
consistent calls of both strands. GSEQ analysis was performed using the haploid model 
with quality score threshold (QST) 3. SeqC automatically uses all previously made 
analyses as controls for the actual samples and therefore is able to anticipate the 
shape of every peak in the software output. Dissimilarity scores are calculated for every 
peak and are a measure for the deviation of the peak areas from the statistical average. 
A warning is displayed for any peak with an abnormal high dissimilarity score. The 
SeqC software was used with the standard parameters. The eventual mtDNA 
sequences were compared with the revised Cambridge reference sequence to list all 
homoplasmic variants.  
 
Figure 2.1. Data analysis flow chart. 
 
The haplogroups were determined according to the presence or absence of the 
haplogroup variants listed in supplementary table 2.3. The best fitting haplogroup was 
assigned. The sequences of the seven species used for examining conservation of the 
mitochondrial genes were derived from NCBI: H. sapiens NC_012920; C. lupus 
NC_002008.4; B. taurus NC_006853.1; M. musculus NC_005089.1; R. norvegicus 
NC_001665.2; G. gallus NC_001323.1; D. melanogaster NC_001709.1. A filtered list of 
pathogenic tRNA and protein mtDNA mutations was created from a list of disease 
associated mtDNA mutations in the MITOMAP database (www.mitomap.org/MITOMAP, 
supplementary table 2.2). Variants of which the pathogenicity status was listed in 
Mitomap as ‘unclear’, ‘polymorphism’, ‘synergistic’, ‘conflicting reports’, ‘secondary’, 
‘haplogroup marker’ or ‘warrants further study’, or was ‘unconvincing’ in the 
corresponding publication were not included. All inherited pathogenic mutations 
(Mitomap ‘confirmed’) were included. For the remaining variants (Mitomap ‘reported’), a 
pathogenicity score was calculated for the tRNA and protein coding mutations 
according to a checklist. For protein coding genes, the scoring system described 
previously [25] was used. Additionally, the conservation of the variant position (mtSNP 
http://mtsnp.tmig.or.jp/mtsnp/index_e.shtml; Alamut, Interactive Biosoftware) and the 
effect of the variant on polarity, protein structure/function (PolyPhen 
http://genetics.bwh.harvard.edu/pph/; SIFT http://sift.jcvi.org/www/ 
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SIFT_BLink_submit.html; InterProScan http://www.ebi.ac.uk/Tools/InterProScan/; 
UniProt http://www.uniprot.org/ uniprot/; TMHMM http://www.cbs.dtu.dk 
/services/TMHMM/; MSOP  http://npsa-pbil.ibcp.fr/cgi-bin/npsa_automat.pl?page= 
npsa_sopm.html) were evaluated. For the tRNA genes, another scoring system was 
used [11]. Additionally, the conservation of nucleotide and the effect of the variant on 
secondary or tertiary interactions (Mamit-tRNA http://mamit-trna.u-strasbg.fr/) within the 
tRNA molecule were evaluated. For all variants, the presence of the variant in general 
databases (mtSNP, mtDB http://www.genpat.uu.se/mtDB/, OMIM, PubMed, Google) 
was checked. Variants that were scored definitely or highly likely pathogenic were 
included in the list of pathogenic mutations and excluded from further analysis. 
Correlation between the number of variants and the variant intensity of guanine (G) 
residues in the protein coding genes was analyzed using the linear regression function 
of SPSS.   
 
 
Results 
 
Analysis of the entire mtDNA sequence in 730 subjects 
The mtDNA of 730 subjects was sequenced using the MitoChip and sequences were 
compared with the revised Cambridge Reference Sequence (rCRS). Because of the 
lower sensitivity and specificity of the MitoChip for the detection of heteroplasmic 
variants [19], the analysis was restricted to homoplasmic variants. After analysis with 
GSEQ, 1.3 % (standard error 0.03) of the 16544 nucleotides in the 730 samples gave a 
no call. The main reason was a low signal, a repetitive sequence or a C-stretch in one 
of the two strands (data not shown). These regions were predominantly located in the 
D-loop of the mtDNA and less in the protein and RNA coding genes. The D-loop was 
excluded from the analysis. The distribution of no calls was not homogeneous and 
some genes (e.g. ATP8) showed a significantly higher percentage of nucleotides that 
were not called than others (e.g. ND4L) (table 2.1). Therefore, to reduce the number of 
bases with a no call, Sequence Pilot – module SeqC was used for the positions that 
were not called by GSEQ. Additional variants called by SeqC were checked visually. 
Variants scored by SeqC were only called confirmed when both forward and reverse 
strand clearly showed the mutant and no wild type peak. When a wild type peak was 
visible on one of the strands, the variant call from SeqC was depicted as ‘doubtful’. 
When both GSEQ and SeqC could not call a position, it remained a ‘no call’. SeqC 
analysis decreased the percentage of no calls from 1.096 to 0.001 (excluding the D-
loop) without adding many extra different homoplasmic variants or doubtful calls. The 
distribution of the no calls over the different genes was more homogeneous (table 2.1). 
Five randomly chosen additional SeqC variants were conventionally sequenced and 
confirmed (data not shown). 
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Table 2.1. Results of variant and ‘no call’ analysis using the GSEQ and SeqC analysis pipeline. 
Gene 
GSEQ analysis  SeqC analysis a 
# different 
variants 
# no 
calls 
% ntds with 
no callb 
 # different 
variants 
# no 
calls 
% ntds with 
no call 
# doubtful 
calls 
ATP6 89* 16809 3.381  91* 68 0.014 8 
ATP8 26* 9276 6.139  27* 3 0.002 2 
CYB 115 10615 1.274  115 9 0.001 6 
COI 129 8245 0.732  130 4 <0.001 3 
COII 53 9473 1.897  57 11 0.002 2 
COIII 69 3442 0.601  71 0 0.000 9 
ND1 95 9344 1.338  96 5 <0.001 16 
ND2 113 10518 1.383  114 16 0.002 53 
ND3 45 1383 0.548  45 2 0.001 10 
ND4 112 9126 0.907  114 15 0.001 10 
ND4L 29 228 0.105  29 1 <0.001 2 
ND5 185 15900 1.202  187 3 <0.001 12 
ND6 51 6562 1.712  55 1 <0.001 174 
TRNF 2 329 0.635  2 2 0.004 0 
TRNV 1 4 0.008  1 0 0.000 1 
TRNL1 1 1 0.002  1 0 0.000 0 
TRNI 4 322 0.639  4 2 0.004 0 
TRNQ 3 58 0.110  4 0 0.000 3 
TRNM 3 104 0.210  3 0 0.000 0 
TRNW 4 19 0.038  4 0 0.000 0 
TRNA 4 29 0.058  4 0 0.000 1 
TRNN 0 1 0.002  0 0 0.000 0 
TRNC 9 3 0.006  9 0 0.000 0 
TRNY 2 8 0.017  2 0 0.000 0 
TRNS1 2 353 0.711  2 1 0.002 23 
TRND 3 244 0.492  3 0 0.000 4 
TRNK 2 35 0.068  2 0 0.000 1 
TRNG 4 26 0.052  4 0 0.000 0 
TRNR 3 579 1.220  3 1 0.002 20 
TRNH 5 23 0.046  5 2 0.004 0 
TRNS2 2 255 0.592  2 0 0.000 0 
TRNL2 2 163 0.314  2 0 0.000 2 
TRNE 5 0 0.000  5 0 0.000 0 
TRNT 16 96 0.199  16 0 0.000 0 
TRNP 0 75 0.151  0 0 0.000 0 
RNR1 38 3340 0.480  39 0 0.000 0 
RNR2 79 3852 0.338  80 5 <0.001 5 
Total 
analyzedc 1317 123582 1.096  1341 150 0.001 394 
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Table 2.1 legend 
aPositions which were not called by GSEQ analysis were analyzed with the SeqC software and newly 
identified variants were checked visually. When the SeqC call was wrong, the position was recorded as 
a ‘doubtful call’. 
bAverage percentage of nucleotides that were not called for 730 subjects (total number of no 
calls/[length of the sequence x 730 subjects] x 100) 
cThe mtDNA sequence was analyzed from position 577 to position 16023.  
* ATP6 and ATP8 have 8 variants in common 
 
 
Characterization of variants in the mtDNA 
General features of the variants identified 
A total of 12,063 homoplasmic variants (average 16.5 variants per subject) were 
detected relative to the rCRS, of which 1,341 (average 1.8 per subject) were different 
variants at 1,321 (average 1.8 per subject) different positions in the mtDNA 
(supplementary table 2.4). The large amount of total variants is due to the presence of 
European haplogroup variants which were present in a high proportion of the subjects 
(haplogroup and number of subjects: H 307, U 99, K 59, HV 52, J 64 and JT 73; 
supplementary table 2.1). The haplogroup distribution was comparable among the 
three cohorts (supplementary table 2.5), pointing to a generally European population, 
and therefore the three cohorts were merged for further analysis. Furthermore, to 
minimize confounding by the haplogroup variants, variant numbers mentioned in the 
analyses are based on the 1,341 different variants. 
 
Table 2.2. Overview of observed variants by nucleotide. 
Observed number of variantsa Number of 
nucleotideb 
Variant  
Intensityc ref\var A G C T Total 
A - 383 23 19 425 4785 1.03 
     (32%) (31%)  
G 228 - 7 2 237 2017 1.35 
     (18%) (13%)  
C 31 13 - 239 283 4810 0.68 
     (21%) (31%)  
T 13 16 367 - 396 3833 1.19 
     (30%) (25%)  
Total 272 412 397 260 1341 15446  
a Observed number of different variants according to the revised Cambridge Reference Sequence 
(rCRS) 
b The number of nucleotide x in the mtDNA excluding the displacement loop (position 577-16023) 
c Variant intensity is calculated as follows: (observed number of variants nucleotide x/total number of 
nucleotide x)/(total number of variants/total number of nucleotides) 
 
The observed frequency of variants for each of the different nucleotides (A, C, G, T) 
according to the rCRS are shown in table 2.2. Variants changing nucleotide A were 
most frequent. To correct for differences in the total number of the four nucleotides in 
the mtDNA regions tested, the variant intensity  [26] was calculated. This variant 
intensity corrected for the presence of the nucleotide in the mtDNA (excluding the D-
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loop) by comparing this value with the prevalence of all variants in the entire mtDNA 
(excluding the D-loop) (formula: [number of variants nucleotide x/total number of 
nucleotide x]/[total number of variants/total number of nucleotides]). The variant 
intensity is depicted in table 2.2 and is increasing in the order C<A<T<G. Although 
nucleotide G showed the smallest number of variants, it had the highest variant 
intensity.  
 
Protein coding variants 
The number of variants in the different protein coding genes was assessed (figure 
2.2A). After correction for the length of the gene, differences in the prevalence of 
variants could be observed. On average, 10.4% of the nucleotides in the protein coding 
genes showed a variant in one of the 730 subjects (0.104 variants/base pair) While 
ATP6, ATP8 and ND3 showed the highest number of variants, COI, COII and ND4 
contained fewer variants per base pair. These differences were mainly due to 
differences in variant numbers on codon position 1 and 2 (figure 2.2A). In general, it 
was observed that the number of variants at codon position 1 (0.070 variants/base pair) 
and 2 (0.036 variants/ base pair) was lower compared with the 3rd position (0.192 
variants/base pair) (figure 2.3). Codon position 3 variants predominantly consisted of 
synonymous amino acid changes, whereas codon position 1 showed only a small 
proportion of synonymous variants and codon position 2 variants consisted entirely of 
non-synonymous variants. 
The frequency of Cs (lowest variant intensity) or Gs (highest variant intensity) in the 
sequence of the genes (all positions or only third codon positions) could not explain the 
discrepancy in the number of variants between the different genes (data not shown). 
However, there was a significant (p = 0.004) correlation between the number of variants 
and the variant intensity of G in the protein coding genes (figure 2.2B). ND6 was not 
included in the analysis as this gene is transcribed from the L-strand and the G content 
differs from the H-strand. To check for a role of evolutionary conservation in the 
distribution of the variants, COI (low number of variants/bp) and ATP6 (high number of 
variants/bp) were examined in more detail in seven species (H. sapiens, G. gallus, C. 
lupus, B. taurus, M. musculus, R. norvegicus and D. melanogaster). Whereas more 
than half of the nucleotides in the COI gene were conserved in seven species, 
approximately half of the variants were located at positions conserved in less than four 
species (figure 2.4A). In contrast, the ATP6 sequence was less well conserved (figure 
2.4A) but the preference of the variants for the less conserved positions in ATP6 was 
lower compared with COI variants (figure 2.4A). However, no such difference could be 
observed when only the third codon positions were analyzed (figure 2.4B). The same 
trend in sequence conservation was shown for COII and COIII (low number of 
variants/bp) and ATP8 and ND3 (high number of variant/bp) but the preference of 
variants for less conserved first and second positions between the genes was less 
discriminating (supplementary figure 2.1). The 67 pathogenic mutations that passed our 
filter were all, except for five deletions, located on first and second codon positions and 
were mainly targeting highly conserved positions (57/67 conserved in at least 6 
species; supplementary table 2.2). 
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Figure 2.2. Variant distribution by protein coding gene. A The observed number of variants in the 
whole cohort is expressed as the number of variants per base pair to correct for the length of the genes 
and is shown for the total gene as well as for the three different codon positions. B Significant (p = 
0.004) correlation between the number of variants and the variant intensity of guanine in the protein 
coding genes (excluding ND6). 
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Figure 2.3. Variant distribution in protein coding genes by codon position, tRNA and rRNA genes 
and non-coding nucleotides. The observed number of variants in the whole cohort is expressed as the 
number of variants per base pair of each sequence type. The proportion of synonymous and non-
synonymous variants is indicated.  
 
 
tRNA variants 
In the 730 samples, only 78 different homoplasmic tRNA variants were detected. On 
average, 5.3% of the positions showed a variant in one of the 730 subjects (0.053 
variants/base pair), in between the rate observed for codon positions 1 and 2 of the 
protein coding genes (figure 2.3). The location and positional conservation of these 
variants were compared with a list of known pathogenic tRNA mutations 
(supplementary table 2.2) to detect discriminating characteristics (table 2.3). For the 
homoplasmic variants, approximately half (52%) of the variants were located in the 
loops of the tRNA whereas only 32% of the pathogenic mutations were located here. 
Homoplasmic variants were representing, among others, poorly conserved mismatch to 
Watson–Crick base pair (WC) changes and both poorly and highly conserved mismatch 
to mismatch changes in the tRNA stems, which were not present among the 
pathogenic mutations. While three pathogenic mutations changed WCs into severe 
mismatches (not AÂC, CÂA, GÂU or UÂG) on conserved positions, no homoplasmic 
variants caused such changes. Furthermore, when examining the conservation of the 
base pairing (conserved WC, GÂU or mismatch base pairs), pathogenic mutations 
predominated in conserved base pairs compared with the homoplasmic variants (34/90 
pathogenic mutations versus 7/78 homoplasmic variants).  
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Figure 2.4. Conservation of total gene sequence and variant positions in COI and ATP6 for all 
codon positions (A) and third codon positions (B). The human sequence of both genes was aligned 
with the sequence of six other species: G. gallus, C. lupus, B. taurus, M. musculus, R. norvegicus and 
D. melanogaster. 
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Table 2.3. Location and conservation characteristics of homoplasmic tRNA variants and 
pathogenic tRNA mutations.  
Location Changea 
Positional 
conservationb 
homoplasmic variants pathogenic mutationsc 
total # 
(%) 
# conserved 
pairingd 
total # 
(%) 
# conserved 
pairingd 
loop  <100% 37 (47)  11 (12)  
  100% 4 (5)  18 (20)  
stem MM>WC <100% 13 (17) 2 0 (0)  
 MM>WC 100% 1 (1) 1 2 (2) 1 
 MM>MM <100% 3 (4)  0 (0)  
 MM>MM 100% 1 (1)  0 (0)  
 WC>mMM <100% 16 (21) 1 31 (34) 13 
 WC>mMM 100% 3 (4) 3 25 (28) 20 
 WC>sMM <100% 0 (0)  0 (0)  
 WC>sMM 100% 0 (0)  3 (3)  
Total   78 7 90 34 
Underlined data represent types of variants only present in the homoplasmic variants or pathogenic 
mutations group 
a MM>WC = mismatch base pair to Watson-Crick base pair (WC) 
 MM>MM = mismatch base pair to another mismatch base pair 
WC>mMM = WC to a mild mismatch base pair, mild mismatch base pairs are AÂC, CÂA, GÂU and UÂG 
WC>sMM = WC to a severe mismatch base pair, severe mismatch base pairs are all mismatch base 
pairs excluding AÂC, CÂA, GÂU and UÂG 
b as determined in 31 mammalian mitochondrial genomes [27]  
c see supplementary table 2.3 for detailed list 
d conserved pairing: 100% conserved WC or >90% GÂU and UÂG as determined in 31 mammalian 
mitochondrial genomes [27]  
 
Finally, a heat map of all 22 tRNA secondary structures was generated according to the 
tRNA numbering to examine positional differences between homoplasmic variants and 
pathogenic mutations in more detail. In this way, the homoplasmic variants and 
pathogenic mutations in all tRNA molecules could be visualized in one figure (figure 
2.5). Homoplasmic variants were located more often in the tRNA loops (except for the 
anticodon) and some positions of the acceptor stem compared with the pathogenic 
mutations (figure 2.5A and B). Again, it is clear that pathogenic mutations in the stem 
almost always cause WC to mismatch changes while a significant proportion of 
homoplasmic variants represents mismatch to mismatch or mismatch to WC changes 
(figure 2.5A and B). It can be observed that pathogenic mutations are dominating the 
anticodon, the anticodon stem, the D stem and part of the acceptor stem of the tRNAs 
(figure 2.5C).F 
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Figure 2.5 
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Figure 2.5. Composite of all 22 tRNA secondary structures with variant/mutation locations. All 
tRNAs are merged into one figure according to tRNA number. Frequencies of homoplasmic variants (A) 
and pathogenic mutations (B) are appointed to each tRNA position with different colors. Stripes and 
dots represent the proportion of mismatch to WC or mismatch to mismatch changes, respectively, 
comparable to the area that is indicated. No indication means WC to mismatch change. C depicts the 
difference in number of homoplasmic variants and pathogenic mutations for each tRNA position. 
 
rRNA variants and non-coding regions 
The 12S and 16S rRNA genes showed variants with a density of 0.041 and 0.051 
different variants/base pair, respectively. These numbers are only half of the average 
protein coding genes but are in the same range as the average variant density in tRNA 
genes and codon position 1 and 2 of the protein coding genes (figure 2.3), indicating a 
comparable selective pressure. Non-coding nucleotides (n=58) between protein coding, 
rRNA and tRNA genes showed the highest number of variants with an average of 0.345 
different variants per position (figure 2.3).  
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Discussion 
 
In this study, the mtDNA of 730 subjects was analyzed using the Affymetrix MitoChip 
v2.0. Sequence data analysis was improved to increase the call rate without increasing 
the number of false positives or false negatives significantly. Homoplasmic mtDNA 
variants were scored to explore variable and evolutionary conserved regions. 
 
Pipeline for identifying and analyzing mtDNA mutations 
Compared with conventional sequencing, MitoChip resequencing is a fast and cost 
effective method to screen the whole mtDNA for homoplasmic and heteroplasmic 
mutations [13]. The mtDNA of 730 subjects was resequenced using the Affymetrix 
MitoChip v2.0 and base calling was performed by the GSEQ software. It has been 
shown previously [19] that the MitoChip has lower sensitivity and specificity in the 
detection of heteroplasmic variants. In our diagnostic experience (data not shown) the 
call rate of the MitoChip is >98% and the sensitivity to detect heteroplasmic mutation 
ranges from 5 to 30%, which may differ for different nucleotide positions. This implies 
that the in muscle DNA most relevant causal heteroplasmic mutations will be 
detectable. Massive parallel sequencing technology will provide an alternative, 
especially when prices will drop and the required coverage can be reached in a cost-
effective way. By massively parallel sequencing-by-synthesis, it was observed that in 
nearly all of the normal tissues, somatic low level heteroplasmic variants (>1.6% 
heteroplasmy) were present [28]. However, the relevance of detecting such low 
heteroplasmy levels in relation to phenotypic expression is debatable. The MitoChip 
has been used in studies concerning the influence of homoplasmic polymorphisms on 
disease (progression) [29, 30] and anthropological studies [19]. We also concentrated 
on homoplasmic variants only [4]. Highly deleterious pathogenic mutations will very 
rarely reach homoplasmy because homoplasmy is likely to be lethal at the cellular level 
[18]. This is in contrast to neutral or adaptive heteroplasmic variants, which become 
homoplasmic or are lost within 70 cell divisions [31]. 
 
GSEQ has been reported to generate very few false negatives and false positives but a 
high number of no calls [19, 32], as was also observed in this study. The alternative 
local context probes on the MitoChip v2.0 did not provide a solution for this problem, 
since these probes were mainly located in the D-loop. The use of additional algorithms 
or masks following GSEQ analysis has been shown to improve the average call rate 
[19-21, 32]. In our study, the combination of the haploid model of GSEQ followed by 
analysis using SeqC (with a higher call rate [33]) turned out to be a sensitive and 
efficient approach. A key difference between the software programs with respect to the 
number of no-calls is the ability of SeqC to call a position based on one strand, where 
as GSEQ requires consistent calls on both strands. Furthermore, SeqC uses all 
previously analyzed samples as controls for the actual samples which enables a 
statistically validated continuous software learning process. To control for false 
positives, we used both software tools and all additional variants called by SeqC were 
checked visually. Conclusively, the current protocol was feasible for the number of 
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MitoChips studied, making this method applicable for the analysis of MitoChip data in a 
large cohort of subjects. 
 
Characterization of mtDNA variants 
General features  
In 730 subjects, 12,063 homoplasmic variants were detected in the mtDNA excluding 
the D-loop. D-loop variations (especially the hypervariable segments) have been 
characterized extensively to study variation within and between human populations [34-
37] and were not considered further in this study. The variant intensity analysis 
indicated that nucleotides G and C proportionally presented with the highest and lowest 
variant intensities compared with A and T, respectively. This is in agreement with 
previously published results that showed guanine to be the least stable nucleotide and 
cytosine the most stable nucleotide while adenine and thymine had intermediate 
stability [26, 38]. Differences in variant intensity however can only occur when there are 
strand-specific biases in substitution rates. This theory is reinforced by the deviation 
from the theoretical A=T and G=C nucleotide composition within each strand when no 
strand-specific bias would exist [39]. Multiple other studies have shown strand 
asymmetry in mutation rates [40]; this is probably due to periods of separation of the 
two DNA strands during replication, which may lead to increased mutability, and 
transcription-coupled repair [41, 42]. 
 
Protein coding variants 
Our data confirmed not unexpectedly the strong negative selection against variants on 
codon position 1 and 2 due to the non-synonymous nature of variants at these positions 
[43, 44]. Not all protein coding genes accumulated the same number of variants which 
was correlated with a heterogeneous guanine mutation rate. Previously, it was 
suggested that different mutation rates of mitochondrial genes are at least partly 
independent of protein structure and function and a property of the mtDNA itself [26]. 
The authors based their theory on segmentation of the mtDNA by differences in 
nucleotide composition and that the segments showed a heterogeneous guanine 
mutation rate. Our study indicated that the heterogeneous guanine mutation rate not 
only applies to the different mtDNA segments described previously [26], but also plays 
a role in the individual genes. The protein coding gene results largely correspond with a 
previous study using data from the mtDNA mutator mice and the human mtDB 
database [43].  
 
The differences in variant accumulation in the protein coding genes may also be due to 
differences in selective pressure at the functional (amino acid) level. For the highly 
conserved COI gene, variants were mainly located on less conserved positions 
whereas the less well conserved ATP6 gene showed weaker preference for variants on 
these positions. If only third codon positions were considered in the analysis, then no 
differences were observed between the genes. Conclusively, the hypothesis of stronger 
selection against variants in genes with a high level of sequence conservation and 
more tolerance for variants in less well conserved genes [43], seems valid in this data 
set but it only applies for functionally relevant first and second codon positions. In 
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agreement with this, differences in variant numbers between the different genes are 
reflected by differences in variant numbers on codon positions 1 and 2, whereas variant 
numbers on positions with minor effect on protein function (codon position 3) are more 
or less comparable among all genes. The role of functional preservation and 
conservation is further emphasized by the location of the filtered list of pathogenic 
mutations (supplementary table 2.2) of which most were on highly conserved 
functionally relevant positions.  
 
tRNA, rRNA and non-coding region variants (except D-loop) 
The position and effect of the 78 different tRNA variants in the present data set were 
compared with the position and effect of the known pathogenic mutations 
(supplementary table 2.2). As mentioned previously [11, 45], for many mtDNA variants 
listed as pathogenic mutations in the MITOMAP database, insufficient evidence is 
presented to confidently ascribe pathogenicity to these variants. For example, 40 of the 
171 different mutations listed as pathogenic, also appeared to be polymorphisms in the 
same database and original source data should be checked [10, 45]. The major 
differences between the pathogenic mutation and homoplasmic variant sets were that 
the different homoplasmic variants (a) were located more often in the tRNA loops 
(41/78 compared with 29/90 for pathogenic mutations), (b) changed less WCs into 
mismatches in the tRNA stems (19/78 compared with 59/90 for the pathogenic 
mutations) and (c) affected less conserved base pairs (7/78 compared with 34/90 for 
the pathogenic mutations). Smaller studies based on database sequences also pointed 
to these differences between polymorphisms and pathogenic mutations [11, 18, 46]. 
The relation between conservation and pathogenicity was further demonstrated by 
evolutionary selection in 14 different primate species [46]. Pathogenic loop and stem 
mutations were under higher evolutionary pressure than polymorphisms. For the latter, 
the stem was under greater selective constraint than the loop. Additionally, the 
mismatches in the tRNA stem were under lower selective constraint than WCs and it 
has been proposed that mismatch to WC changes might be adaptive in nature [46]. The 
tRNA secondary structure heat map showed that pathogenic mutations were 
dominating the D stem, acceptor stem, anticodon stem and anticodon but the 
homoplasmic variants showed also some hot spots in these regions. The D loop and T 
loop were predominantly targeted by homoplasmic variants. Others also showed 
hotspots for pathogenic mutations in the acceptor and anticodon stems in smaller 
studies [11]. In contrast, another group [18] reported a random distribution of 
pathogenic mutations and polymorphisms across the tRNA structure. The different 
results of the latter publication may be due to the inclusion of different or more 
‘pathogenic’ mutations in their analysis compared with ours. Although the amount of 
data on tRNA variants in the mtDNA has increased during the past years, absolute 
conclusions regarding the pathogenicity of mitochondrial tRNA molecules can still not 
be provided for every variant in those genes.  
 
The rRNA genes showed a frequency of variants in the same range of tRNA genes and 
codon position 1 and 2 of the protein coding genes. From this and the relatively low 
number of pathogenic rRNA mutations published, it appears that homoplasmic variants 
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in these genes are not tolerated, which would increase the likelihood that a rRNA 
variant is pathogenic. However, this is in contrast with results from a mice study [43]. 
There, in offspring from mtDNA mutator mice, purifying selection against non-
synonymous mutations in protein coding genes was evident after two generations. The 
rRNA and tRNA genes experienced less intense germline selection, comparable with 
the third codon position in protein coding genes [43]. The difference between the 
studies is probably due to the inclusion of heteroplasmic mutations in the mice study. 
The authors suggest that tRNA mutations at low heteroplasmy levels are more 
compatible with life than some protein coding mutations and are therefore subjected to 
a less rapid form of purifying selection. Although less rapid, the mechanism of 
purification seems to be equally important as this study showed comparable selection 
against variants in tRNAs, rRNAs and first and second codon positions on the 
population level.  Since the rRNA results are comparable with the tRNA results in these 
studies, the same mechanism might be acting on both, although in contrast to tRNAs 
not many pathogenic heteroplasmic rRNA mutations have been reported. Examining if 
heteroplasmy is more tolerated in RNA genes than protein coding genes will give 
valuable information in the near future.  
 
As expected, the 58 non-coding nucleotides in between the protein coding, rRNA and 
tRNA genes experienced the lowest selective pressure with the highest number of 
variants per base pair. This means that even the third codon position of genes is not 
entirely free of selection. Probably this is due to amino acids that do not allow for 
synonymous substitution (methionine and tryptophan) or have only limited third codon 
position possibilities (cysteine, aspartic acid, glutamic acid, phenylalanine, histidine, 
lysine, asparagine, glutamine, and tyrosine). So, based on functional conservation, it 
could be expected that for part of the changes on the third codon position selection 
occurs.  
 
 
Conclusion  
 
Factors such as guanine mutation rate and (functional) conservation have been shown 
to affect the amount and location of homoplasmic variants in the different mitochondrial 
genes. All coding sequences, including the third codon position, showed evidence of 
negative selection against variants when compared with the non-coding nucleotides 
between the genes. This meta analysis provided valuable information for the 
improvement of pathogenicity criteria and for minimizing the amount of variants that 
require functional follow-up. However, larger cohorts are still necessary to classify novel 
variants solely using mutation screening. Extension of our approach in the future, will 
lead to a detailed map of the mtDNA with regions and positions that are targeted by 
polymorphisms or pathogenic mutations or never show variation. The latter situation 
probably points to mutations that are not compatible with life and will never be detected. 
Altogether, this will provide valuable information for evaluating the pathogenicity of 
mtDNA variants and counseling families.  
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Supplementary data 
 
Supplementary table 2.1. Subject information (origin and haplogroup). 
Supplementary table 2.2. Variants used to determine the haplogroup of the samples. 
Supplementary table 2.3. Pathogenic tRNA and protein mtDNA mutations according 
to the criteria that are listed in the Material and methods. 
Supplementary table 2.4. All homoplasmic variants that were detected in 730 subjects 
according to the revised Cambridge reference sequence. 
Supplementary table 2.5. Comparison of the haplogroup distribution of the different 
cohorts. 
Supplementary figure 2.1. Conservation of total gene sequence and variant positions 
in COII, COIII, ND3 and ATP8 for all codon positions (A) and third codon positions (B). 
 
Supplementary tables are available online at doi:10.1016/j.mito.2011.09.003 
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Supplementary figure 2.1. Conservation of total gene sequence and variant positions in COII, COIII, 
ND3 and ATP8 for all codon positions (A) and third codon positions (B). The human sequence of both 
genes was aligned with the sequence of six other species: G. gallus, C. lupus, B. taurus, M. musculus, 
R. norvegicus and D. melanogaster. 
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POLG1 defects lead to muscle abnormalities, oxidative stress in 
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Abstract 
 
Background. DNA polymerase gamma (pol Ȗ) is the only polymerase responsible for 
the replication and maintenance of mitochondrial DNA (mtDNA). Mutations in the 
catalytic subunit of pol Ȗ (POLG1 gene) are associated with a broad variety of clinical 
symptoms. Fatal complications usually involve brain and liver but muscle abnormalities 
have also been observed. The pathogenic mechanism of POLG1 mutation is only partly 
understood. We intend to characterize molecular pathways in POLG1 pathology.   
Methods. Light and electron microscopy, mtDNA copy number and rearrangements 
and whole genome gene expression (Affymetrix) profiles were evaluated in skeletal 
muscle biopsies of POLG1 patients. Apoptosis and oxidative stress were examined in 
different human tissues. 
Results. Most patients showed decreased mtDNA copy number, accumulation of 
mtDNA deletions and/or decreased OXPHOS activity in skeletal muscle. Morphological 
changes were observed in the majority of patients’ skeletal muscles biopsies. 
Transcriptomics revealed lower expression of fatty acid beta oxidation, increased 
expression of electron transport chain subunits and decreased expression of 
uncoupling proteins 2 and 3. Increased apoptosis was shown in the brain and liver and 
increased oxidative stress was measured in fibroblast cultures in part of the patients. 
Conclusion. Except for two patients, all POLG1 patients showed muscle abnormalities 
for at least one of the investigated parameters, indicating that any of these observations 
can be suggestive for defects in POLG1. Oxidative stress and apoptosis were identified 
as pathological processes in part of the patients and may be counterbalanced by a 
genetic-background-dependent yet unidentified mechanism. 
 
Key words 
 
POLG1, oxidative stress, apoptosis, gene expression 
  
Human POLG1 pathology | 3 
 
 
61
 
Introduction 
 
Mitochondrial diseases are among the most frequently inherited neurological disorders 
[1]. DNA polymerase gamma (pol Ȗ) is the sole DNA polymerase involved in the 
replication and maintenance of the mtDNA. POLG1 mutations have been reported to 
cause a broad variety of phenotypes, such as Alpers-Huttenlocher syndrome, ataxia 
neuropathy syndrome (ANS), epilepsy and chronic progressive external ophtalmoplegia 
(CPEO) [2]. Phenotypes involving hepatopathy usually manifest early in life, while 
isolated myopathy affects older individuals and brain abnormalities can occur at any 
age [3]. The correlation between genotype and phenotype in patients with POLG1 
mutations is sometimes tight but more often variable [3]. The pathological mechanism 
explaining the diverse clinical manifestations of POLG1 mutations is only partly 
understood. Human studies have focused on in vitro characterization of purified or 
recombinant enzyme [4], in vivo analysis of the functions of the pol Ȗ protein and its 
domains in cultured cells [5] and large scale screening of mtDNA molecules in skeletal 
muscle and fibroblasts [6, 7]. These studies showed a higher probability of 
accumulating mtDNA mutations and/or depletion of mtDNA when POLG1 is mutated.  
The aim of this study is to identify molecular mechanisms involved in human POLG1 
pathogenesis by examining skeletal muscle, fibroblast cultures and (post mortem) liver 
and brain specimens of POLG1 patients. This is the first study combining gene 
expression analysis with physiological measurements and staining in human patients. 
Identification of pathology associated processes is important to decipher the clinical 
heterogeneity, to identify new treatment approaches and improve prognosis.    
 
 
Material and methods 
 
POLG1 patients 
Characteristics of eleven patients homozygous or compound heterozygous for POLG1 
mutations are described in table 3.1. Blood lactate levels of the patients at rest and 
enzyme activities of the OXPHOS complexes derived from muscle biopsies are 
presented when available (table 3.1). Not all assays could be performed for all patients 
due to the limited material available. Ethics approval was not required according to 
Dutch legislation as residual material of previous diagnostic investigations has been 
studied. 
 
Skeletal muscle morphology 
Muscle biopsies were taken from the quadriceps muscle. Samples were split for light 
microscopy (LM) and electron microscopy (EM). Skeletal muscle histology - HE 
(haematoxolin and eosin), trichrome, periodic acid–Schiff (PAS) and ORO (oil red O) 
staining - and enzyme histochemistry - acid phosphatase, ATPase (adenosine 
triphosphatase),  NADH (nicotinamide adenine dinucleotide), SDH (succinate 
dehydrogenase) and COX (cytochrome oxidase) - were evaluated. Ultrastructural 
studies were performed as described previously [8]. 
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Mitochondrial DNA copy number and large scale deletions 
DNA was isolated using the Wizard Genomic DNA Purification Kit (Promega, Leiden, 
NL). Mitochondrial DNA copy number was determined as described previously [8]. To 
detect mtDNA deletions, 50 ng of DNA was amplified into two overlapping fragments of 
16.1 (I) and 16.0 (II) kb using Phusion Hot Start DNA polymerase (Finnzymes) and 100 
ng forward and reverse primer corresponded to nucleotide positions (nt, 5’ to 3’, 
according to Cambridge sequence) FwdI 314-343 ; RevI 16382- 16411; FwdII 1330- 
1355; RevII 756- 778). The PCR conditions were as follows : 30 sec at 98qC ; 30 cycles 
of 10 sec at 98qC and 8 min 15 sec at 72qC ; 10 min at 72qC. PCR products were first 
analyzed on a 1% agarose gel and next for 32h on a 0.7% agarose gel.  
 
Microarray procedure 
Skeletal muscle needle biopsies were immediately frozen in liquid nitrogen from six 
subjects carrying a POLG1 mutation and twelve controls (table 3.2). Total RNA was 
isolated using the TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and purified with the 
RNeasy clean-up kit (Qiagen, Hilden, DE). RNA quantity and purity were determined 
spectrophotometrically using the Nanodrop ND-1000 (Nanodrop Technologies) and 
RNA integrity was assessed by determining the RNA 28S/18S ratio using the 
Bioanalyser 2100 (Agilent Technologies, Santa Clara, CA, USA). 150 ng of muscle 
RNA was reverse transcribed into cDNA and amplified in a two-round amplification 
reaction according to the manufacturer’s protocol (Affymetrix, Santa Clara, CA, USA). A 
mixture of cDNA and added hybridization controls was hybridized on Affymetrix HG-
U133 Plus 2.0 chips, followed by staining and washing steps in the GeneChip fluidics 
station 400 (Affymetrix) according to the manufacturer’s procedures. To assess the raw 
probe signal intensities, chips were scanned using the GeneChip scanner 3000 
(Affymetrix). 
 
Microarray data analysis  
Images of the Human Genome U133 Plus 2.0 arrays were quantified with GCOS 
software (Affymetrix). The microarray data reported in this manuscript have been 
deposited in NCBI Gene expression omnibus (GEO), accession number GSE18715.  
The chip description file (CDF) used for the analysis was an update created and freely 
distributed by the microarray lab of the university of Michigan 
(http://brainarray.mbni.med.umich.edu; [9]) based on UniGenes (version 9).  This 
resulted in the analysis of 17215 gene-transcripts out of the 54613 commonly obtained 
using the Human Genome U133 Plus 2.0 CDF provided by Affymetrix. All genes were 
analyzed using a Gaussian linear regression (N (µ, ı2) where µ is the mean and ı2 is 
the variance) including the best hybridization and best labeling spike, the age, and sex. 
The inference criterion used for comparing the models is their ability to predict the 
observed data, i.e. models are compared directly through their minimized minus log-
likelihood. When the numbers of parameters in models differ, they are penalized by 
adding the number of estimated parameters, a form of the Akaike information criterion 
(AIC) [10]. For each gene, a model containing the relevant covariates (E(y) = Hyb. 
Spike + Lab. Spike + Age + Sex) was fitted in order to obtain a reference AIC. Then a 
model containing the group was fitted (E (y) = Hyb. Spike + Lab. Spike + Age + Sex + 
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Grp). The gene under consideration was found to be differentially expressed if the AIC 
of this second model was smaller when compared to the AIC of the model not 
containing the group effect. The genes analyzed and fold changes were loaded into 
GenMapp (version 2.1, build 20080507) and MAPPFinder (version 2.0, build 20041218) 
software packages to evaluate the transcripts in relation to known biological processes. 
The gene database version “Hs-Std_20070817” and the Mapps version 
“Hs_Contributed_20080619” were used for both programs. Only gene-transcripts with 
either their average intensities for the control and patient groups above 500 or average 
intensities for one of these groups above 1000 (background signal criteria) and a 10 
percent fold change were used to obtain a ranked list of pathways with differentially 
expressed genes.  
 
Quantification of reactive oxygen species 
Reactive oxygen species (ROS) levels were measured in four patient (P54, P194, P382 
and P504) and three control fibroblast cultures by dihydroethidine (DHE) oxidation as 
described previously [11]. All cell lines were cultured in parallel. Similarly to the 
microarray data, the ROS data were analyzed using a Gaussian linear regression 
including the day, medium, group, and medium-group interactions if required. As 
previously, the Akaike Information Criteria (AIC) was used to compare models without 
and with the group effect. The model with the smallest AIC was selected as the model 
best fitting the observed data. 
 
Histology and apoptosis in liver and brain 
Histological and immunohistochemical analysis was performed on formalin fixed 
paraffin embedded sections (4ȝm) of liver and brain of patients (P30, P382 and P504) 
and controls. Anonymous control liver (n=3) and brain (n=3) sections (age 15 or older) 
were used for comparison. Subsequent sections were used for HE staining and the 
detection of apoptosis using immunohistochemistry (IHC) with rabbit-anti cleaved 
caspase 3 primary antibody (Cell Signalling, Danvers, MA, USA). IHC was performed 
according to the manufacturer’s protocol. In short, endogenous peroxidase was blocked 
by incubation with 0.3% H2O2 in methanol for 20 minutes, tissue antigenicity was 
recovered using heat-based retrieval (10mM citrate buffer, pH 6, 95°C, 10 min), 
sections were blocked with 4% normal swine serum (DAKO) in phosphate buffered 
saline containing 1% BSA and 0.1% tween (PBT) and incubated overnight with 1:100 
primary antibody in 5% foetal calve serum in PBT. After washing, 1:1000 biotin-
conjugated swine anti-rabbit secondary antibody (DAKO) in PBT was applied for 30 
minutes, followed by 30 minutes of Vectastain ABC reagent (Vector Laboratories, 
Burlingame, CA, USA). 3’3-diaminobenzidine (DAB, DAKO) was applied as a color 
substrate and hematoxylin for nuclear counterstaining. Sections were dehydrated in a 
graded ethanol solution and xylene, subsequently enclosed with Entellan (Merck) and 
evaluated with a Nikon Eclipse E800 microscope. Pictures were taken with a Nikon 
Digital Camera DXM 1200F and analyzed using the Lucia G version 4.81 (Laboratory 
Imaging) software. Cleaved caspase 3 positive (apoptotic) cells were counted in six 
random pictures and expressed as percentage of all cells.  
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Results 
 
In total, eleven patients with POLG1 mutations were included in the study (table 3.1). 
Three patients were homozygous for p.A467T, five patients were compound 
heterozygous for this mutation and another mutation, two patients were compound 
heterozygote for other mutations and one patient had an autosomal dominant mutation 
(P423). Eight patients presented with neurological problems, five patients suffered from 
impaired liver function and three patients had chronic PEO and/or ptosis. Four patients 
died within their first years of life, one patient (P504) was diagnosed incidentally after 
death of valproic acid (VPA) treatment of post traumatic epileptic seizures and one 
patient (P30) experienced clinical symptoms for a prolonged time but deceased after 
VPA treatment. Based on these data, no obvious genotype-phenotype association 
could be observed. 
 
Muscle mtDNA and morphology  
In total, four out of eight patients showed either reduced mtDNA copy number (P509) or 
the presence of multiple deletions in skeletal muscle (P38, P423 and P477, table 3.1). 
Normal values were observed in the younger patients ageing 0 to 23 years. In three out 
of eight patients the activity of one or more OXPHOS complexes was decreased in 
muscle biopsies (table 3.1). Seven out of eight patients showed morphologic 
abnormalities in muscle. Four patients showed myopathic changes with ragged red 
fibers and multiple cytochrome c oxidase negative muscle fibers (patients P38, P194, 
P253 and P509; figure 3.1A-C). Another three patients (P497, P382 and P504) 
exhibited a striped positive staining of the muscle fibers in the trichrome stain in the 
absence of ragged red fibers. One patient (P54) did not show any changes of the 
muscle morphology. Ultrastructural changes were observed in all five patients (P194, 
P253, P497, P504 and P509) evaluated on electron microscopy with aberrant shape, 
size and distribution of the mitochondria. The mitochondria appeared elongated in 
shape or rounded with tubular cristae. Mitochondria were frequently aggregated and 
localized in the subsarcolemmal and A-band areas. One in five patients showed 
mitochondria with paracristalline inclusions (patient P253; figure 3.1D). 
 
Muscle gene expression analysis 
Gene expression levels of 17,215 transcripts were measured in skeletal muscle 
samples of six POLG1 patients and twelve age matched controls (table 3.2). 
Transcripts of 3,718 genes passed the background signal criteria. The expression of 
1,193 transcripts was significantly different between controls and POLG1 patients 
(Appendix). Of the differentially expressed genes, 247 transcripts were increased and 
946 were decreased, respectively. These results indicated mostly small (fold change < 
1.5) gene expression changes. QPCR confirmed nine out of ten microarray results 
(data not shown).  
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Figure 3.1. Histology and apoptosis in tissues of POLG1 patients. Muscle biopsy: Modified Gomori 
trichrome (A), NADH (B) and cytochrome c oxidase (C) stain (400x) and electron microscopy (D). 
Clustered apoptotic cells in the brain of patient P30 (E), which are absent in controls (F) and the 
summarized results of apoptosis detection in liver of patients (P) and controls (C) (G). Bars in E and F 
are 100 µm. Arrows in panel D indicate paracristalline inclusions. 
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Table 3.2. Patients and controls for gene expression analysis. 
Patient code Sex Age at biopsy Control code Sex Age at biopsy 
Age group: young    
P194 F 0 C11 M 0 
P509 F 3 C12 M 1 
   C13 M 9 
   C14 M 2 
   C15 F 5 
   C16 M 2 
Age group: middle    
P38 M 36 C3 F 34 
P54 F 29 C5 F 17 
   C7 F 22 
   C9 M 25 
Age group: old    
P423 F 68 C4 F 64 
P477 F 50 C8 M 53 
Overview of patients and controls used for the microarray gene expression analysis. P = patient, C = 
control, M = male, F = female; * Age groups: young (0 – 10 years old), middle (11 – 49 years old), old (t 
50 years old) 
 
Pathway analysis, using MAPPFinder, showed ten significantly altered pathways 
(p<0.05; table 3.3). In patient cells, the electron transport chain showed higher gene 
expression levels for 75% of its differentially expressed transcripts, whereas uncoupling 
protein 2 (UCP2) transcripts were decreased. In contrast, the expression of almost all 
differentially expressed genes in the fatty acid beta oxidation pathway was decreased 
(table 3.3). Transcripts of carnitine palmitoyltransferase 1 (CPT1) B, which is the rate-
limiting step in beta oxidation, were decreased. This indicated reduced fatty acid 
catabolism.  In the triglyceride synthesis pathway, the expression of most changed 
genes was decreased (table 3.3). Gene expression levels of NAD+ dependent enzymes 
SIRT2 and poly-(ADP-ribose) polymerase 1 (PARP1) were decreased (both fold 
change 0.79).  Based on the observed changes, we performed an additional QPCR for 
SIRT1 and UCP3, which had intensity levels in the background range of the microarray 
analysis. In the QPCR analysis, both were significantly decreased with fold changes 
0.74 and 0.43, respectively. POLG1 itself also showed intensity levels in the 
background range.  
 
Overall, oxidative stress or apoptosis pathways were not significantly altered in muscle 
of POLG1 patients. Nevertheless, in the oxidative stress pathway, superoxide 
dismutase 1 (SOD1) and glutathione peroxidase 4 (GPX4) gene expression levels were 
changed significantly with fold changes 0.91 and 1.46, respectively. Many genes in the 
apoptosis pathway did not reach significance due to low signal intensities. However, for 
the expression of 31 genes there was a tendency to be increased (n=16) or decreased 
(n=15) with an inconclusive effect on the total pathway. There were no significant 
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changes in the expression level of genes involved in mitochondrial biogenesis - 
peroxisome proliferator-activated receptor gamma coactivator 1-alpha/beta (PGC1-Įȕ), 
nuclear respiratory factor 1 (NRF-1) and mitochondrial transcription factor A (TFAM). 
Only minor changes were observed in the expression of genes involved in 
mitochondrial fusion and fission (OPA1 fold change 0.81 and MFN2 fold change 0.83). 
 
Table 3.3.  MAPPFinder results grouped into related categories. 
MAPP Name Changed Up Down Measured On MAPP P-value 
Metabolism and energy production      
Electron Transport Chain 20 15 5 97 105 0.000 
Triglyceride Synthesis 9 2 7 23 24 0.000 
Fatty Acid Beta Oxidation Meta 7 1 6 32 32 0.020 
       
Transcription/translation       
mRNA processing Reactome 29 10 19 119 127 0.000 
Translation Factors 12 1 11 42 50 0.000 
RNA transcription Reactome 9 2 7 36 40 0.008 
       
Others       
IL-9 NetPath 20 6 0 6 23 24 0.012 
Nucleotide Metabolism 4 1 3 16 17 0.043 
Circadian Exercise 8 1 7 46 48 0.046 
Striated Muscle Contraction 7 1 6 38 38 0.048 
Number of differentially expressed genes in the significantly changed (p<0.05) pathways according to 
MAPPFinder. 
 
Increased ROS levels in POLG1 patient fibroblasts 
Reactive oxygen species (ROS) levels were significantly increased in fibroblasts of 
patients P54, P194 and P382 (136% (confidence interval (c.i.) 114-163), 117% (c.i. 
104-133) and 251% (c.i. 213-295) of controls, respectively), but not of patient P504 
(112% of controls (c.i. 96-130)).  
 
Histology and apoptosis in liver and brain 
Histology of liver specimens of three investigated patients (P504, P382 and P30) 
showed a microvesicular steatosis with marked fibrosis, ductular proliferation and 
cholestasis as described before [12]. Hepatocyte mitochondria of patient P509 
appeared aberrant in shape and size and often contained crystalloid inclusions. Post 
mortem examination of the brain of patient P504, exhibited typical Alpers-Huttenlocher 
like changes with ischemia and gliosis of the occipital cortex combined with spongiosis 
and gliosis of cortical and deep gray matter regions with a subtle and generalized 
decrease of neuronal numbers. The brain of patient P30 on the other hand did not 
exhibit changes of the occipital cortex. In this patient a degeneration with decrease of 
neuronal numbers and gliosis at all levels of the corticospinal tracts was observed, 
compatible with a phenotype of Friedreichs ataxia. Immunohistochemistry identified a 
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higher percentage of cleaved caspase 3 positive cells in liver of two (2/3) POLG1 
patients compared with three controls (figure 3.1G). In POLG1 brain sections, a few 
apoptotic hot spots could be seen (figure 3.1E), which were not present in control brain 
sections (figure 3.1F). 
 
 
Discussion 
 
This study provides the first comprehensive characterization of molecular genetic, 
biochemical and morphological processes in human POLG1 patients.  
 
Muscle abnormalities in POLG1 patients 
This study revealed variable muscle aberrations in virtually all POLG1 patients 
investigated. All patients tested showed ultrastructural changes on electron microscopy, 
which is in this study the most sensitive test. Other aberrations were related to the 
mtDNA (multiple deletions or decreased copy number), the activity of OXPHOS 
enzymes or were morphological changes. The three adult POLG1 patients over 35 
years old, for which mtDNA rearrangements could be analyzed, showed multiple 
deletions. Decreased activity of respiratory chain enzymes was observed in three out of 
eight patients. The presence of multiple deletions, mtDNA depletion or decreased 
OXPHOS function is suggestive for defects in the mtDNA maintenance and POLG1, 
but the absence of these features does not exclude mtDNA maintenance or POLG1 
defects, especially in young patients (P30 and P54 [13]). Nevertheless, because 
muscle biopsies will not always be available and based on clinical manifestations 
POLG1 sequencing can be the first step, especially if an urgent diagnosis is required 
for treatment.  
 
Changes in tissues of POLG1 patients 
Metabolic switch in skeletal muscle 
Transcription of genes in the beta oxidation pathway was significantly decreased. This 
might be explained by increased NADH levels as previously observed in fibroblasts 
from patients with isolated mitochondrial complex I (CI) deficiency [14]. Three of the 
patients in this study indeed showed a decreased OXPHOS function. Decreased 
OXPHOS-derived ATP production can stimulate glycolysis. This is associated with 
higher lactate production, inhibition of carnitine palmitoyltransferase 1 (CPT1) and thus 
also beta oxidation [15] (figure 3.2). Excess NADH in the cytosol can be oxidized by 
lactate dehydrogenase. Increased lactate levels are therefore often measured in 
patients with mitochondrial disease, including POLG1 patients [16]. In this study, six out 
of nine patients showed increased lactate levels in serum. The increased transcription 
of the OXPHOS complexes could be a rescue attempt to process excess NADH and 
supply the cell of sufficient energy. This is supported by the decreased transcription of 
UCP2 and UCP3 leading to increased coupling of proton pumping and ATP production. 
The expected higher levels of point mutations and deletions in the mtDNA associated 
with defect pol Ȗ [5] will only allow for increased quantity but not quality of the OXPHOS 
subunits when their transcription is increased. Therefore, the compensatory mechanism 
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might only partially be effective in tissues in which the OXPHOS system is not 
maximally used (e.g. fibroblasts), but would not meet the energy demand of highly 
active tissues such as muscle, liver and brain, leading to disease symptoms.  
In this study, no significant effect was detected on mitochondrial or mtDNA biogenesis 
and its key regulator PGC1-Į, even though two patients showed decreased mtDNA 
copy number. However, SIRT1 transcripts were decreased. SIRT1 normally stimulates 
mitochondrial biogenesis and fatty acid ȕ oxidation through post-translational activation 
of PGC1-Į by deacetylation [17]. The NAD+/NADH ratio has been shown to regulate 
transcription of the SIRT1 gene [17], emphasizing additional cellular consequences of 
disturbed NADH metabolism.  
 
 
Figure 3.2. Pathophysiological processes in POLG1 patients. Processes differentially expressed in 
POLG1patients: decreased beta oxidation, increased expression of OXPHOS subunits and decreased 
expression of uncoupling proteins. These changes suggest increased glycolysis, oxidative stress and 
apoptosis. 
 
Mitochondrial fusion and fission 
Only two genes associated with mitochondrial fusion and fission (OPA1 and MFN2) 
showed minor gene expression changes. Recent literature states that mitochondrial 
fusion is essential for the equilibration of nuclear-encoded mitochondrial proteins over 
all organelles but leads to clonal expansion of mitochondrial deletion mutants with 
replicative advantage. Therefore, fusion is normally coupled to fission which enables 
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selective degradation of damaged mitochondria with decreased membrane potential by 
mitophagy [18]. The gene expression analysis does not provide convincing evidence for 
a role of mitochondrial fission and fusion in POLG1 pathology. However, given the post-
translational regulation of these processes [19], this should still be investigated on the 
protein level when patient material is available. 
 
Increased ROS levels in fibroblast cultures 
The involvement of oxidative stress in POLG1 pathology is controversial. The overall 
oxidative stress pathway expression was not significantly changed, but particular genes 
such as SOD1 and GPX4 transcripts showed altered expression levels. Also UCP3 
expression was decreased. In the setting of doxorubicin-induced heart failure in rats, 
compensatory down-regulation of myocardial UCP2 and UCP3 lead to increased 
mitochondrial ROS production [20]. ROS levels were measured in fibroblast cultures of 
four patients and found to be increased in three (P54, P194 and P382) of them 
compared with controls, but not in patient P504. Increased ROS levels in OXPHOS 
disease are usually believed to originate from complex I or III sites. However, only 
fibroblasts of P194 showed a significant biochemical defect (data not shown). The 
method used cannot distinguish the exact cellular localization of hydroethidine oxidation 
[11], thus, another explanation for increased ROS levels could be the activation of 
alpha-ketoglutarate dehydrogenase in the tricarboxylic acid cycle. This enzyme can be 
stimulated to produce ROS by increased NADH levels [21]. The fact that one patient 
with and another patient without oxidative stress are both homozygous for the p.A467T 
mutation implies that it is not only the POLG defect that triggers ROS production. The 
patients may differ in the mtDNA defects resulting from the POLG1 mutations, but we 
could not test this, because no muscle was left for one of the patients (P504). On the 
other hand, other genetic (protective or exacerbating) factors could be involved in 
controlling ROS levels. Altogether, the current results correspond with the unclear and 
controversial involvement of ROS in POLG1 pathogenesis today. 
Different transgenic mouse models are discordant on the presence [22] or absence [23] 
of increased oxidative stress due to pol Ȗ defects. Furthermore, increased oxidative 
protein damage in the heart of these mice could be reduced by cardial mCAT 
overexpression, leading to attenuated cardiomyopathy [22]. Our results in human 
patients indicated that oxidative stress probably plays a role in part, but not all, of the 
POLG1 patients. Divergent results in the different mouse models and patients could 
possibly be related to alternative effects of different POLG1 mutations, mtDNA defects 
or different genetic backgrounds (i.e. antioxidant expression levels). 
 
Apoptosis in liver and brain 
The expression of only few apoptosis-related genes was significantly changed in 
muscle. Nevertheless, multiple other apoptosis genes showed a trend towards altered 
expression. Therefore, the presence of apoptotic cells in liver and brain, the most 
severely affected tissues in POLG1 patients, was assessed. In the liver, apoptosis was 
distributed relatively evenly across the section and two out of three patients showed a 
more than twofold increase of apoptotic cells compared with controls. Different from the 
liver, there were only a few clusters of apoptotic cells in the brain of patients but not of 
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controls. In agreement, results from transgenic POLG mice showed the induction of 
apoptosis in the duodenum, liver, testis, thymus and skeletal muscle by measuring 
caspase 3 cleavage and TUNEL staining [23]. Strikingly, the two patients with 
increased liver apoptosis (P30 and P382) also showed increased oxidative stress in 
fibroblasts cultures, whereas both were not seen in the third patient (P504). This may 
suggest that apoptosis, possibly associated with increased ROS levels, contributes to 
POLG1 related pathology (P30 and P382). However, the acute effect of trauma or 
drugs (e.g. VPA treatment) seems a much stronger trigger of acute organ failure in a 
previously disease-free individual (P504).  
 
 
Conclusions  
 
Even though muscle, liver and brain material of POLG1 patients is scarce, this study 
elucidated a number of processes involved in POLG1 pathogenesis. The heterogeneity 
in clinical presentation is reflected in the variable morphological, molecular and 
biochemical findings that were obtained. Increased oxidative stress and increased 
apoptosis appear to be related to the severity of the phenotype although trauma and/or 
drugs can shortcut this pathological route and lead to acute organ failure. In the future, 
measuring oxidative damage and apoptosis in liver and brain of additional patients is 
necessary to establish the link between ROS levels and apoptosis induction. 
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Abstract 
 
Defective complex I (CI) is the most common type of oxidative phosphorylation disease, 
with an incidence of 1 in 5,000 live births. Here, whole genome expression profiling of 
fibroblasts from CI deficient patients was performed to gain insight into the cell 
pathological mechanism. Our results suggest that patient fibroblasts responded to 
oxidative stress by Nrf2-mediated induction of the glutathione antioxidant system and 
Gadd45-mediated activation of the DNA damage response pathway. Furthermore, the 
observed reduced expression of selenoproteins, might explain the disturbed calcium 
homeostasis previously described for the patient fibroblasts and might be linked to 
endoplasmic reticulum stress. These results suggest that both glutathione and 
selenium metabolism are potentially therapeutic targets in CI deficiency. 
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Introduction 
 
Mitochondria produce most of the cellular ATP through the process of oxidative 
phosphorylation (OXPHOS). The OXPHOS system is comprised of four multisubunit 
electron transport chain (ETC) complexes (Complex I-IV) and the F0/F1-ATP-synthase 
(Complex V). Complex I (CI) is the largest of the OXPHOS complexes and one of the 
entry points of electrons into the ETC. CI deficiency is the most frequently encountered 
defect in mitochondrial energy metabolism [1] and is associated with e.g. Leigh 
disease, Leber hereditary optic neuropathy (LHON), fatal infantile acidosis, neonatal 
cardiomyopathy with lactic acidosis, leucodystrophy with macrocephaly and 
hepatopathy with renal tubulopathy [2, 3]. Although children usually have a normal 
prenatal development, symptoms start occurring during their first year of life after which 
the disease deteriorates rapidly and may become fatal [4]. 
Disease-causing mutations have been described in both the mitochondrial DNA 
(mtDNA)-encoded (ND1 to ND6, and ND4L genes) and nuclear DNA-encoded 
structural CI subunits (e.g. NDUFS1, NDUFS2, NDUFS4, NDUFS7, NDUFS8) and CI 
assembly factors (e.g.  B17.2L, NDUFA12L, C20ORF7) [5-26]. The cellular 
consequences of CI deficiency have been extensively studied in patient fibroblasts. CI 
deficiency leads to a slightly depolarized mitochondrial membrane potential [27], 
increased reactive oxygen species (ROS) levels [28], increased NAD(P)H levels [29], 
changes in mitochondrial morphology [30] and disturbed calcium homeostasis [31, 32]. 
However, increased ROS production and mitochondrial fragmentation was not always 
detectable [33]. A first study investigating transcriptional responses in CI deficient 
fibroblasts cultured with glucose and galactose using a mitochondria-targeted 
microarray detected the induction of metallothioneins and heat shock proteins and the 
decreased expression of mtDNA-encoded transcripts [34]. To get an unbiased overview 
of the underlying pathological processes (not restricted to mitochondria) in CI 
deficiency, we performed whole genome gene expression and additional pathway 
analysis in fibroblasts of a homogeneous group of CI deficient patients with a defect in 
one of the nuclear encoded structural subunits. The CI deficiency might not stress the 
cell to such an extent that relevant disease-associated gene expression changes can 
be picked up. Therefore, fibroblasts were deprived of glucose to stimulate energy 
production through oxidative phosphorylation. In galactose medium, the flow of 
galactose to glucose-1-phosphate is very slow which obliges cells to obtain ATP from 
mitochondrial oxidation of pyruvate and glutamine [35]. 
 
 
Material and methods 
 
Fibroblast cell lines 
Fibroblasts were derived from skin biopsies of five patients homozygous or compound 
heterozygous for nuclear complex I mutations and five controls. The groups were 
matched for age and sex. All patients have been described previously (#8807 see [26], 
#7898 see [24], #5175 see [15], #6613 see [30], #8382 see [25]). Table 4.1 provides an 
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overview of the subjects and physiological parameters in the patient cell lines [4, 28, 
29, 32]. The age- and sex-matched control group consisted of four male subjects, ages 
6 months (mo), 1 year (y) 7mo, 1y 6mo, 3y 6mo respectively and one female subject of 
1y 11mo. 
Fibroblasts were routinely cultured in medium 199 (Gibco, Paisley, UK) supplemented 
with 10% fetal calf serum and penicillin/streptomycin (respectively 100U/ml and 100 
µg/ml). To stimulate energy production by oxidative phosphorylation, fibroblasts were 
cultured in galactose medium for 48 hours. Galactose medium consisted of DMEM 
without glucose, without pyruvate and with 4 mM L-glutamine (Invitrogen, Paisley, UK), 
5.5 mM D-galactose (Sigma, Zwijndrecht, Netherlands), 1 mM uridine (Acros, Geel, 
BE), 10% dialyzed fetal calf serum (Invitrogen) and penicillin/streptomycin, Glucose 
medium was identical to galactose medium except that D-glucose was present at 5.5 
mM instead of galactose. The stability of the mtDNA was preserved during the course 
of the experiment in all cell lines under both conditions as no mtDNA deletions or 
group/treatment specific differences in mtDNA copy number (supplementary table 4.1) 
could be detected. 
 
Microarray procedure 
Total RNA was isolated using the TRIzol reagent (Invitrogen) and purified with the 
RNeasy clean-up kit (Qiagen, Hilden, DE). RNA quantity and purity were determined 
spectrophotometrically using the Nanodrop ND-1000 (Nanodrop Technologies, 
Wilmington, DE, USA). RNA integrity was assessed by determining the RNA 28S/18S 
ratio using the Bioanalyser 2100 (Agilent Technologies, Santa Clara, CA, USA). 
Fibroblast RNA (150 ng) was reverse transcribed into cDNA and amplified in a two-
round amplification reaction according to the manufacturer’s protocol (Affymetrix, Santa 
Clara, CA, USA). A mixture of cDNA and added hybridization controls was hybridized 
on Affymetrix HG-U133 Plus 2.0 chips, followed by staining and washing steps in the 
GeneChip fluidics station 400 (Affymetrix) according to the manufacturer’s procedures. 
To assess the raw probe signal intensities, chips were scanned using the GeneChip 
scanner 3000 (Affymetrix). 
 
Microarray data analysis 
Images of the Human Genome U133 Plus 2.0 arrays were quantified with GCOS 
software (Affymetrix). The microarray data reported in this manuscript have been 
deposited in NCBI Gene expression omnibus (GEO), accession number GSE27041. 
The chip description file (CDF) used for the analysis was an update created and freely 
distributed by the microarray lab of the university of Michigan 
(http://brainarray.mbni.med.umich.edu; [36]) based on Ensembl (version 10). A more 
detailed description of this analysis is shown in the supplementary data. Briefly, the 
genes were analyzed using Gaussian linear regression including the hybridization and 
labeling spikes, age, sex, passage, mtDNA copy number, and medium. The inference 
criterion used for comparing the models is their ability to predict the observed data, i.e. 
models are compared directly through their minimized minus log-likelihood. When the 
numbers of parameters in models differ, they are penalized by adding the number of 
estimated parameters, a form of the Akaike information criterion (AIC) [37]. For each 
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gene, the group was then added to the model. Then, the group-medium interaction was 
also added to the model. The gene under consideration was found to be differentially 
expressed if the AIC of either of these two models decreased compared to the model 
containing no group effect at all. The genes analyzed and fold changes were loaded 
into the Pathvisio (version 2.0.8) [38] software package to evaluate the transcripts in 
relation to known biological processes. The gene database version 
“Hs_Derby_20090509” was used. Only gene-transcripts with either their average 
intensities for the control and patient groups above 150 or average intensities for one of 
these groups above 300 and a 10 percent up or down regulation fold change were used 
to obtain a ranked list of pathways with differentially expressed genes. Pathvisio 
software was used to select the pathways with a Z score larger than 1.96 and thus 
containing relatively high numbers of differentially expressed genes. 
 
Quantitative PCR 
Differentially expressed genes were validated by real-time quantitative PCR (QPCR) 
with the same RNA samples used for the microarrays. Primers were designed using the 
NCBI Primer-BLAST tool (NCBI home page; http://www.ncbi.nlm.nih.gov/). cDNA was 
prepared from 1 ȝg of RNA in a standard reverse transcriptase reaction. PCR was 
performed in a 7900HT Fast Real-Time PCR System (Applied Biosystems, Foster City, 
CA, USA) using SensiMixPlus SYBR (Quantace, Finchley, UK). Cycling conditions 
were: an initial step of 2 minutes at 50qC, activation of the polymerase at 95qC for 10 
minutes, and 40 cycles of 15 seconds at 95qC followed by 1 minute at 60qC. The TATA-
box binding protein (TBP) gene was used as an internal reference. Genes for which 
QPCR was performed and the primers used for amplification are listed in 
supplementary table 4.2. Results were analyzed using Gaussian linear regression, 
similar to the microarray analysis. The housekeeping gene (TBP), age, sex, passage, 
mtDNA copy number, RNA integrity number (RIN) and medium were included during 
the analysis. The AIC was used to assess whether there was a difference between the 
controls and patients (group effect). All statistical analyses presented were performed 
using the freely available program R [39] and the publicly available library 'growth' [40]. 
 
Western blot analysis 
Protein expression was monitored by Western blot analysis of 12% SDS-PAGE gels 
loaded with 40 µg of whole cell extract. The following primary antibodies were used: 
Complex I (NDUFA9; Mitosciences, Oregon, USA), HMOX1 (Abcam, Cambridge, UK), 
GCLM (Sigma), GSR (Santa Cruz, Heidelberg, DE), and TrxR1 (Santa Cruz). Complex 
II (70kDa Fp; Mitosciences) was used as a loading control. Secondary antibodies used 
were polyclonal goat anti-mouse IgG/HRP (Dako, DK) and immunoPure goat anti-rabbit 
IgG/Peroxidase (Pierce Biotechnology, Rockford, IL, USA). Detection of the signal was 
performed using ECL Western Blotting Substrate (Thermo Scientific, Amsterdam, NL) 
following the manufacturer’s instructions. 
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Results 
 
Global gene expression profiles of fibroblast cell lines from five CI deficient patients 
with a mutation in a nuclear CI gene were characterized in glucose and galactose 
medium to identify processes involved in pathogenesis, novel biomarkers for CI 
deficiency and potential future targets for therapeutic interventions. In order to gain 
insight into the changes in essential cellular processes rather than single genes, genes 
were clustered based on cellular function and analyzed by pathway analysis using 
Pathvisio software [38]. 
 
Gene expression analysis 
In total, disease state, culture condition and their interaction significantly altered the 
expression of 3,279 genes by more than 10 percent. The disease state induced fold 
changes between 0.08 and 6.89 (of which 79% between 0.66 and 1.5 (10-50% 
change)) in the glucose condition and between 0.08 and 12.18 (69% between 0.66 and 
1.5) in the galactose condition. Furthermore, the different culture conditions caused 
gene expression changes of 0.32 to 2.91 (90% between 0.66 and 1.5) and 0.11 to 
29.74 fold (46% between 0.66 and 1.5) in controls and patients respectively. Pathway 
analysis was performed to identify processes that were altered due to the cumulative 
effect of differentially expressed genes (table 4.2, supplementary table 4.3). The sum of 
the differentially expressed genes in a pathway can lead to increased expression, 
decreased expression or a miscellaneous effect (both inhibition and stimulation), which 
is indicated for each pathway.  
 
Changes due to culture condition only 
The metabolic switch due to glucose deprivation of the cells in galactose medium 
changed the expression of 2,888 genes. This included genes with a larger/smaller fold 
change or an opposite fold change in patients compared with controls. If only genes 
were included that showed the same effect on galactose compared with glucose for 
both groups, 1,304 genes were changed and these could be mapped to the pathways 
cholesterol biosynthesis (increased in galactose), proteasome degradation 
(miscellaneous effect) and prostaglandin synthesis and regulation (increased in 
galactose) (figure 4.1B).  
 
Changes due to complex I deficiency 
Between patients and controls, 1,407 and 2,335 genes were significantly changed in 
glucose and galactose, respectively, with an overlap of 1,199 genes. Pathways that 
showed a significant change only in the normal glucose condition included the pentose 
phosphate pathway (increased in patients), heme biosynthesis (decreased in patients), 
alanine and aspartate metabolism (increased in patients), urea cycle and metabolism of 
amino groups (increased in patients) and ganglio spingolipid metabolism (decreased in 
patients). Furthermore, some pathways were significantly altered in both normal 
glucose and galactose condition: senescence and autophagy (miscellaneous effect), 
selenium (decreased in patients), mismatch repair (decreased in patients) and 
nucleotide metabolism (increased in patients) (figure 4.1A). 
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Table 4.2. Pathway analysis results 
 
 
patients vs 
controls 
glucose 
patients vs 
controls 
galactose 
galactose vs 
glucose 
identical in 
patients and 
controls 
galactose vs 
glucose 
different in 
patients and 
controls 
Pathway %
 
ch
an
ge
d 
Z 
sc
or
e 
%
 
ch
an
ge
d 
Z 
sc
or
e 
%
 
ch
an
ge
d 
Z 
sc
or
e 
%
 
ch
an
ge
d 
Z 
sc
or
e 
Changes due to culture condition only       
Cholesterol Biosynthesis 14.29 0.53 14.29 -0.32 57.14 5.92 0.00 -1.34 
Proteasome Degradation 13.33 0.85 25.00 1.53 18.33 2.20 15.00 0.89 
Prostaglandin Synthesis and 
Regulation 13.33 0.60 20.00 0.36 23.33 2.47 6.67 -0.81 
Changes due to disease, notable in normal condition     
Pentose Phosphate Pathway 57.14 4.15 42.86 1.76 28.57 1.65 14.29 0.24 
Heme Biosynthesis 44.44 3.43 33.33 1.25 22.22 1.24 0.00 -1.08 
Alanine and aspartate 
metabolism 33.33 2.69 33.33 1.44 25.00 1.75 8.33 -0.33 
Urea cycle and metabolism of 
amino groups 26.32 2.36 31.58 1.61 31.58 3.17 10.53 -0.12 
Ganglio Sphingolipid Metabolism 26.67 2.14 33.33 1.61 33.33 3.04 6.67 -0.57 
Adipogenesis 15.70 2.10 23.14 1.65 11.57 0.62 12.40 0.36 
Changes due to disease, notable in normal and selective condition    
Senescence and Autophagy 22.58 4.07 27.96 2.68 15.05 1.68 13.98 0.80 
Selenium 17.57 2.17 29.73 2.78 9.46 -0.13 17.57 1.70 
Mismatch repair 33.33 2.32 44.44 2.12 11.11 0.12 22.22 1.03 
Nucleotide Metabolism 27.78 2.51 38.89 2.39 22.22 1.75 22.22 1.45 
Changes due to disease that interact with culture condition     
Oxidative Stress 22.22 2.11 48.15 4.20 14.81 0.85 37.04 4.22 
Selenium metabolism/ 
Selenoproteins 28.13 3.41 40.63 3.45 15.63 1.08 28.13 3.00 
TGF Beta Signaling Pathway 19.23 2.22 34.62 3.26 11.54 0.39 26.92 3.56 
Translation Factors 21.43 2.46 26.19 1.48 19.05 1.99 21.43 2.07 
Changes due to interaction disease-culture condition only     
Cell cycle 14.12 1.26 32.94 3.78 10.59 0.21 24.71 3.92 
G1 to S cell cycle control 12.31 0.61 27.69 2.17 9.23 -0.19 21.54 2.61 
Androgen Receptor Signaling 
Pathway 8.41 -0.57 25.23 2.12 6.54 -1.19 21.50 3.35 
Glutathione metabolism 6.25 -0.51 37.50 2.10 0.00 -1.33 37.50 3.30 
Keap1-Nrf2 7.69 -0.28 46.15 2.72 15.38 0.66 38.46 3.08 
DNA damage response 11.94 0.52 31.34 3.00 11.94 0.56 23.88 3.26 
Glycogen Metabolism 11.43 0.27 31.43 2.17 14.29 0.87 25.71 2.69 
TGF-beta Receptor Signaling 
Pathway 10.27 0.09 22.60 1.64 10.96 0.43 17.12 2.24 
Id Signaling Pathway 6.12 -0.92 22.45 0.91 10.20 0.07 20.41 2.01 
TNF-alpha/NF-kB Signaling 
Pathway 8.00 -0.93 20.00 0.88 8.57 -0.61 16.00 1.98 
Every pathway counts at least 7 genes measured by the microarray. A Z score of more than 1.96 
indicates that a pathway is significantly changed (shown in bold). 
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Figure 4.1. Pathways significantly different (A) in controls and patients and (B) in glucose and 
galactose conditions. Pathways in the box are changed in both culture conditions (A) or groups (B). 
Pathways above and below the box are only changed in the indicated condition (A) or group (B). Arrows 
indicate increased or decreased expression; for pathways without arrow, the direction of the change is 
not clear. 
 
Changes due to disease and interacting with the culture condition 
There were 1,584 genes that differed between patients and controls in the glucose 
and/or galactose culture condition, but for which patients showed a different response 
to the galactose condition compared with the controls. A different response could be a 
response to galactose in only the patients or the controls, a quantitative difference or an 
opposite effect. When considering these genes, part of them were altered as a result of 
the CI deficiency, but additionally showed an interaction between this deficiency and 
the culture condition. Altered pathways included oxidative stress (increased in patients 
and further increased in galactose medium), selenium metabolism and selenoproteins 
(decreased in patients and further decreased in galactose medium), the TGF beta 
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signaling pathway (miscellaneous effect) and translation factors (decreased in 
patients). The remainder of the genes was only altered in patient cells relative to control 
cells on galactose medium but not in glucose medium. This last group of genes was 
mapped to pathways involved in cell cycle progression (decreased in patients), 
oxidative stress (increased in patients; Keap1-NRF2, glutathione metabolism, DNA 
damage response) and signaling (miscellaneous effect; androgen receptor, TGF beta 
receptor, Id, TNF alpha/NF-țB). A general overview of all significantly changed 
pathways is shown in figure 4.1. 
 
QPCR and western blot validation of microarray data 
From the pathway analysis, representative genes with fold changes of more than fifty 
percent were selected and validated by QPCR (table 4.3). For all except one gene (C-
MYC), the QPCR method detected a difference between patients and controls 
comparable with the microarray analysis. Furthermore, to correlate gene expression 
and protein levels, western blot analysis was performed for proteins selected from the 
genes with relatively high gene expression fold changes in significantly altered 
pathways for patients versus controls in galactose medium. Significantly increased 
expression was confirmed for HMOX and GCLC, a similar trend in protein expression 
was observed for TXNRD1 but no change was detected for GSR (figure 4.2). 
Additionally, western blot analysis also revealed that complex I deficiency in the cell 
lines was accompanied by reduced protein levels of complex I (figure 4.2). 
 
 
Discussion  
 
During the last decade, studies have generated extensive knowledge on the 
pathogenesis of CI deficiency [4, 28, 29, 32]. In spite of these advances in 
physiological, biochemical and genetic insights, the total picture is far from complete. In 
the present study, gene expression analysis was performed for a more general 
overview of the processes involved in CI deficiency in fibroblasts. According to recent 
models of complex I assembly, the selected patients all had mutations in structural CI 
subunits of the dehydrogenase and hydrogenase modules of the hydrophilic peripheral 
arm of complex I protruding in the matrix. These modules are involved in oxidation of 
NADH to NAD+ and electron transfer to ubiquinone [41] and mutations in their proteins 
disturb these fluxes, leading to CI deficiency. Therefore, we consider these patients as 
a group with a common pathophysiological basis, making them suitable for genome-
wide gene expression approaches. 
Differential expression of a number of genes and proteins in relevant pathways was 
validated and related to available physiological and biochemical data. 
 
 
Legend Table 4.3. Genes in italics did not show an interaction between disease effect and medium 
effect with QPCR analysis (in contrast to microarray analysis) but are still able to distinguish patients 
from controls in both culture media. 
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Table 4.3. Selected genes for the QPCR signature 
 Disease effect Medium effect 
Gene symbol Glucose condition 
Galactose 
condition Controls Patients 
 Array QPCR Array QPCR Array QPCR Array QPCR 
Keap1-Nrf2 
NRF2  0.77 1.30 1.42 0.82 0.77 1.25 1.42 
KEAP1  0.77 1.28 1.27   1.68 1.58 
Oxidative stress 
CYBA  0.56 0.63 0.56  0.62 0.63 0.62 
FOS 0.44 0.48 1.55 2.10 0.62  2.19 2.85 
HMOX1   7.23 17.58   9.76 28.95 
Glutathione metabolism 
GSR   1.96 2.46   2.31 3.23 
IDH1   1.50 1.79  1.27 1.88 2.61 
GCLC   1.90 1.82   2.38 2.66 
GCLM   1.94 2.67   1.91 2.81 
Selenium metabolism/Selenoproteins 
SELK   2.14 2.30   2.01 2.36 
SEPP1 0.38 0.33 0.21 0.33 0.59 0.39 0.32 0.39 
Pentose phosphate pathway 
PGD   1.75 1.55   2.10 2.36 
DNA damage response 
GADD45A  1.86 2.25 3.20   1.89 2.08 
GADD45B 1.71 3.56 3.40 3.56  1.81 1.84 1.81 
TNFRSF10B   2.05 1.69   2.12 2.11 
C-MYC   1.90   1.78 1.75 1.78 
Cell cycle - anaphase regulation 
ESPL1   0.60 0.35 1.69 2.04   
CDC20  0.48 0.38 0.48 2.55    
Nucleotide metabolism 
PRPS1 1.77 1.79  0.59   0.50 0.29 
Glycogen metabolism 
GBE1 0.87  1.43 1.74   1.63 1.70 
Senescence and autophagy 
ING1  0.71 1.60    1.91 1.69 
TGF Beta signaling pathway 
LTBP1 1.70  0.60 0.23  1.97 0.44 0.54 
TGIF   1.46 1.65   1.71 2.60 
Adipogenesis 
RORA  1.49 1.86 2.59   1.84 2.41 
DDIT3   2.61 2.50  1.65 2.24 3.46 
LMNA   0.45 0.44   0.45 0.46 
ADFP  0.66 1.41    1.95 1.84 
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Figure 4.2. Western blot validation of mRNA results. (A) Original western blot results and (B) a 
graphical representation of differences in protein levels for complex I (CI), HMOX, GSR, GCLM and 
TXNRD1 between controls (white bars) and patients (grey bars) fibroblasts cultured with galactose 
medium, normalized for the expression in controls (* p < 0.05 patients versus controls galactose). 
Complex II (CII) was used as a reference. In panel C, microarray, QPCR and western blot results for 
these genes in patients versus controls in galactose medium were compared. 
 
Experimental set-up 
To be able to examine the consequences of CI deficiency in fibroblasts (which are 
mainly glycolytic), cell lines were challenged to use their OXPHOS system for energy 
production by culturing in galactose medium in the absence of glucose [33, 34]. Our 
analytical model corrected for a number of potential ‘noise’ factors (biological e.g. age, 
sex and passage; technical e.g. chip effect), in contrast to a previous study [34]. The 
approach differed further from this study [34] by type and scope of the array (Affymetrix 
GeneCHIPS versus home-made two-color cDNA microarrays with selected 
mitochondria-related genes). The current study provides a well-controlled and more 
complete picture of the molecular processes in fibroblasts of CI patients. These 
differences can explain why only eleven genes showing differential expression in the 
previous study could be confirmed [34] (supplementary table 4.4). Unfortunately, nine 
additional genes could not be analyzed due to the use of the more accurate updated 
probe set definitions [36] and thirteen genes had low signal intensities, which made 
comparison impossible. However, the eleven confirmed results included multiple 
metallothionein transcripts, which were key elements in the previous study [34].   
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General gene expression analysis results 
Linear regression analysis showed significantly altered expression of in total 3,279 
genes due to disease, culture medium or a combination of both. As expected, gene 
expression differences were the highest when comparing patient and control cells 
cultured in galactose medium and when comparing the glucose and galactose condition 
in patient fibroblasts. Both the number of differentially expressed genes and the 
expression difference were higher. In control cells, less than 10% of the differentially 
expressed genes showed fold changes of more than 50% in galactose compared with 
glucose indicating that control cells were better capable of handling the galactose 
challenge. The altered expression of a number of genes was validated by QPCR and 
all of these, except for one gene (C-MYC), showed a response similar to the microarray 
thus confirming the overall reliability of the microarray data. Furthermore, for two genes, 
increased gene expression was accompanied by increased protein expression, 
validating the biological relevance of the detected differences in gene and pathway 
expression. 
 
Differentially expressed processes 
To identify processes that were altered due to the cumulative effect of differentially 
expressed genes in such a process, pathway analysis was performed. Pathways that 
were only changed in patient versus control fibroblasts both cultured in the presence of 
glucose were mainly involved in metabolism and included in most cases only a small 
number of genes with limited fold changes. This suggests that under glycolytic 
conditions, fibroblasts can adapt relatively easily to alternative energy sources. 
Therefore, we focused on processes that were changed due to the combination of 
disease and galactose culturing when the cells are forced to use their oxidative 
phosphorylation system. 
 
Oxidative stress 
Although the oxidative stress pathway was significantly changed when comparing 
patient and control cells on glucose, the difference was more significant (higher Z 
score) and more genes were involved on galactose medium. This is consistent with the 
observation of increased ROS levels in the CI deficient fibroblasts (table 4.1; [4, 28]). 
Furthermore, in an independent study with fibroblasts from OXPHOS (including CI 
deficient) patients, we observed higher ROS levels when fibroblasts (including controls) 
were cultured with galactose compared with glucose (manuscript in preparation). 
Transcripts of genes involved in glutathione homeostasis were increased, but 
transcription of the other antioxidant enzymes, catalase and superoxide dismutase 
(mitochondrial and extracellular), was decreased. Although enzyme activity 
measurements should confirm these results, this suggests that the glutathione 
antioxidant system is the main defense mechanism counterbalancing increased ROS 
production in CI fibroblasts. Additionally, the induction of the DNA damage response 
through increased expression of GADD45A and GADD45B could further emphasize 
cellular stress. Gadd45-mediated growth arrest [42] might explain why fibroblasts of CI 
deficient patients proliferate at a slower rate than healthy control fibroblasts.  
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A number of redox-sensitive genes that were significantly changed in this study 
(HMOX1, CAT and SOD3) were not reported in a previous study [34], most likely due to 
a different analytical approach. However, the induction of a number of metallothionein 
genes was detected in both studies (supplementary table 4.4). Metallothioneins are 
considered potent antioxidants of which the expression is induced by ROS, heavy 
metals and other forms of cellular stress [34]. Another study with different genetically 
characterized CI deficient patient fibroblast cell lines (NDUFV1 p.W51X + p.T423M and 
NDUFA1 p.R37S + G8R) did not detect differences in catalase and glutathione 
reductase protein expression and only one of the three patient cell lines showed the 
induction of mitochondrial superoxide dismutase protein [33]. This could be explained 
by the fact that, in contrast to our cell lines (table 4.1; [4, 28]), their cell lines did not 
show increased ROS production, explaining the lack of increased antioxidant defense. 
It also suggests that the CI mutations of these patients might have different 
consequences than the ones studied here. 
 
 
Figure 4.3. Activation of the KEAP1-NRF2 pathway in patient fibroblasts cultured with galactose. 
Fold changes of the significantly changed genes (patients versus control cultured with galactose) are 
shown in bold italics. 
 
KEAP1-NRF2-glutathione 
One of the most obvious differentially expressed pathways was the KEAP1-NRF2 
pathway, leading to the activation of a large number of genes involved in glutathione 
homeostasis and the thioredoxin and peroxiredoxin antioxidant defense (figure 4.3). 
ROS-mediated modification of cysteine (Cys) residues in Keap1 is known to result in 
diminished binding of Nrf2, leading to decreased Nrf2 degradation, its translocation to 
the nucleus and transcription of genes containing the antioxidant response element 
(ARE) in their promoter region [43, 44]. Activation of NRF2 signaling was described 
previously in fibroblasts of patients with a mutation in the mitochondrial ATP6 gene [45]. 
Consistent with a lack of NRF2 signaling, glutathione levels in patient fibroblasts were 
not significantly different from controls in de glucose situation (table 4.1; [29]). However, 
reduced glutathione (GSH) levels of cell lines 7898 and 5175 were at the lower limit of 
control values and oxidized glutathione (GSSG) levels were at the higher limit of control 
values for cell line 6613 [29]. It has been suggested previously that antioxidants present 
in the culture medium may quench ROS [46], which might make up-regulation of the 
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antioxidants unnecessary. With the induction of glutathione homeostasis genes, it can 
be expected that glutathione levels are increased in the galactose situation to buffer the 
additional free radicals and prevent oxidative damage. Up-regulation of GCLC was 
confirmed at the protein level. 
 
Selenium and selenoproteins 
Pathway analysis revealed significant differences in the expression of the selenium 
(metabolism) and selenoprotein genes in control and patient fibroblasts. Although some 
overlap exists between these pathways and the oxidative stress pathway, the functions 
of many of the selenoproteins are unknown [47]. Selenoproteins are a group of proteins 
that contain selenocystein as an integral part of their polypeptide chain and include 
different protein families such as the thioredoxin reductases (TXNRDs) and glutathione 
peroxidases (GPXs), and a number of alphabetically annotated selenoproteins (SelK, 
SelM, SelN…) [47, 48]. While some classes are definitely involved in antioxidant 
pathways (GPXs) and redox pathways (TXNRDs), others have been implicated to play 
a role in calcium homeostasis (SelN) [47]. Recently, it was shown that association of 
SelN with the ryanodine receptor was necessary to control release of calcium from 
intracellular endoplasmic reticulum stores [49]. Thus, a decrease of SEPN1 transcripts, 
might correlate with the decreased calcium fluxes measured in the studied patient cell 
lines (table 4.1; [31, 32]). If confirmed this might provide a new lead in the pathogenesis 
of CI deficiency. In HepG2 cells, SelK was induced by endoplasmic reticulum stress 
and protected the cells from stress induced apoptosis [50]. The increased mRNA 
expression of TXNRD1 and SelK, opposed to the decreased expression of multiple 
other selenoproteins, might suggest the preferential expression of selenoproteins 
involved in stress reduction in oxidative CI deficient patient fibroblasts. The expression 
of selenoproteins is depending on the cellular selenium status [51]. Selenium deficiency 
has been shown to induce the expression of Nrf2 target genes [51, 52], providing a link 
between the observed induction of the Keap1-Nrf2 pathway and the decreased 
expression of selenoproteins. Therefore, monitoring and adjusting selenium levels 
might be beneficial for patients with complex I deficiency. Dietary selenium has been 
supplemented for the treatment or prevention of cancer [53] and Alzheimer’s disease 
[54]. This study emphasizes the relevance of testing the applicability and efficiency of 
selenium supplementation also for CI deficiency, which should be tested first in vitro 
and in animal models and later in clinical trials. 
 
 
Conclusion 
 
The gene expression analysis supports the changes in oxidative stress levels 
previously measured in fibroblasts of CI deficient patients. It was shown that the cells 
adapt to and protect themselves against a higher oxidative state through transcriptional 
regulation of the NRF2 pathway. Additionally, altered expression of selenoproteins 
provided a new way to explain diminished calcium fluxes in the CI deficient fibroblasts. 
Altogether, the glutathione and selenium pathways might be considered as (new) 
targets for future therapeutic interventions. Extending our approach to other CI deficient 
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patient groups with functionally different defects (assembly factor or mtDNA defects 
affecting the CI proton translocation) in different genes will elucidate if the mechanisms 
identified are common to all complex I patients or if heterogeneity of pathophysiological 
processes exist . 
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Abstract 
 
Oxidative phosphorylation (OXPHOS) disorders are often associated with increased 
oxidative stress and antioxidant therapy is frequently given as treatment. However, the 
role of oxidative stress in OXPHOS disorders or patients is far from clear and 
consequently the preventive or therapeutic effect of antioxidants is highly anecdotic. 
Therefore, we performed a systematic study of a panel of oxidative stress parameters 
(ROS levels, damage and defense) in fibroblasts of  twelve well-characterized 
OXPHOS patients with a defect in the POLG1 gene, in the mitochondrial DNA 
(mtDNA)-encoded tRNA-Leu gene (3243A>G or 3302A>G) and in one of the mtDNA-
encoded NADH dehydrogenase complex I (CI) subunits. All except two cell lines (one 
POLG1 and one tRNA-Leu) showed increased ROS levels compared with controls, but 
only four (two CI and two tRNA-Leu) cell lines provided evidence for increased 
oxidative protein damage. The absence of a correlation between ROS levels and 
oxidative protein damage implies differences in damage prevention or correction. This 
was investigated by gene expression studies, which showed adaptive and 
compensating changes involving antioxidants and the unfolded protein response, 
especially in the POLG1 group. This study indicated that patient fibroblasts enable the 
identification of patients that potentially benefit from antioxidant therapy. Furthermore, 
the fibroblast model can also be used to search for and test novel, more specific 
antioxidants or explore ways to stimulate compensatory mechanisms. 
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Introduction 
 
Oxidative phosphorylation (OXPHOS) disorders are the most common group of 
inherited metabolic disorders characterized by a primary dysfunction of the OXPHOS 
system. The clinical and biochemical heterogeneity of OXPHOS disorders is partly due 
to the dual (mitochondrial and nuclear DNA) genetic control of mitochondrial energy 
production. Other factors that could explain this heterogeneity are only partly resolved, 
awaiting further insight in the pathophysiological processes. Recently, a number of 
papers have addressed the issue of oxidative stress in OXPHOS disorders (e.g. [1-8]). 
The electron transport chain in the mitochondria is considered the major source of 
reactive oxygen species (ROS), which are by-products of the redox reactions 
necessary to reduce NADH to NAD+ [9]. At low levels, ROS behave as signaling 
molecules [10], but increased levels are damaging for DNA, proteins and lipids as well 
as detrimental for cellular function [11-14]. Therefore, cells are well equipped with 
antioxidant systems to control ROS levels. Oxidative stress occurs when the balance 
between pro-oxidants (ROS) and antioxidants is disturbed and antioxidants are no 
longer able to maintain normal physiological ROS levels. 
 
Increased ROS production has been described in patients with clinically, biochemically 
[4, 15, 16] and/or genetically [17-19] diagnosed OXPHOS disorders, in cybrid models 
[6-8] and in cell lines where the respiratory chain was inhibited by chemicals [20]. The 
antioxidant status of tissues or cell cultures from OXPHOS patients [1, 5, 6, 16, 19, 21] 
was investigated with variable and sometimes contradictory results. Only few studies 
report the total picture of oxidative stress in these patients, including ROS production, 
antioxidant defense and the eventual oxidative damage [6, 19, 22]. The goal of this 
study was to investigate the role of oxidative stress in three different genetically 
characterized OXPHOS disorders: patients with mutations in the POLG1 gene, patients 
with a tRNA leucine (tRNA-Leu) mutation in the mtDNA (3243A>G and 3302A>G) 
causing mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes 
(MELAS) and patients with a mutation in one of the mtDNA encoded complex I 
subunits. Complex I deficiency and tRNA-Leu mutations have been associated with 
increased oxidative stress previously [19, 23], although not all studies could confirm this 
[24]. Importantly, different parameters have been characterized to determine oxidative 
stress, including increased probe oxidation [23] combined with antioxidant expression 
[24] and increased oxidative damage, or combinations of the three [19]. For POLG1 
mutations, a couple of studies were performed in transgenic mice, but again with 
conflicting conclusions: transgenic mouse models carrying the D257A mutation in the 
exonuclease domain of pol Ȗ did not increase oxidative stress [25, 26] whereas 
transgenic mice with cardiac-targeted human mutant Y955C pol Ȗ, affecting the 
polymerase domain, did [27].  
 
Our study aimed at investigating parameters including ROS levels, ROS detoxification 
(glutathione levels, antioxidant gene expression) and oxidative damage (protein 
carbonyls) in patient-derived fibroblasts as a model system. Because the genetic defect 
might not stress the cells to such an extent that relevant disease-associated changes 
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can be picked up, fibroblasts were deprived of glucose to stimulate energy production 
through oxidative phosphorylation. Nevertheless, our main focus is on changes due to 
the genetic defect and not the difference between the two culture conditions. This 
model will help to resolve the underlying adaptive mechanisms, identify the subgroup of 
patients that will most likely benefit from antioxidant treatments and test the efficacy of 
new targeted candidate antioxidants. 
 
 
Materials and methods 
 
Patient fibroblast cell lines 
Fibroblasts were derived from skin biopsies of five patients with a POLG1 mutation, 
four with a tRNA-Leu (m.3243A>G or m.3302A>G) MELAS mutation, three with a 
mutation in an mtDNA encoded complex I subunit, and three controls (table 5.1). 
Fibroblasts were routinely cultured in Dulbecco’s modified Eagle medium (DMEM; 
Gibco, Paisley, UK) supplemented with 10% fetal bovine serum, 0.2 mM uridine (Acros, 
Geel, BE), penicillin and streptomycin. To stimulate energy production by oxidative 
phosphorylation, fibroblasts were cultured for 72 hours without glucose in de presence 
of galactose. Galactose medium consisted of DMEM without glucose supplemented 
with 5.5mM galactose (Sigma, Zwijndrecht, Netherlands), 20% FBS, 0.2 mM uridine, 
penicillin and streptomycin [28]. Measurements were performed in primary cell cultures 
between passage 7 and 20. Except for the quantification of reactive oxygen species, 
cultures from the same cell line and condition were pooled and the cell pellet was 
divided for the different assays. 
 
Quantification of reactive oxygen species  
Reactive oxygen species (ROS) levels were measured as described previously [23]. In 
short, fibroblasts were incubated in HEPES-Tris medium (132 mM NaCl, 4.2 mM KCl, 1 
mM CaCl2, 1 mM MgCl2, 10 mM HEPES and 5.5 mM D-glucose or galactose, pH 7.4), 
containing 10 ȝM hydroethidine (HEt; Molecular Probes, Paisley, UK) for 10 minutes at 
37qC. The reaction was stopped by thorough washing of the cells with PBS. Culture 
dishes were mounted in an incubation chamber placed on the stage of an inverted 
microscope (Axiovert 200M, Carl Zeiss, Jena, DE) equiped with a Zeiss 40x/1.3 NA 
fluor objective. The cells were excited at 490 nm using a monochromator (Polychrome 
IV, TILL Photonics, Gräfelfing, DE). Fluorescence emission light was directed by a 
525DRLP dichroic mirror filter (Omega) onto a CoolSNAP HQ monochrome CCD-
camera (Roper Scientific, Vianen, NL) with an acquisition time of 100 ms. Hardware 
was controlled with Metafluor 6.0 software (Universal Imaging Corporation, 
Downingtown, PA, USA). Processing and analysis of fluorescence images was 
performed with MetaMorph 6.1 (Universal Imaging Corporation). All cell lines were 
examined on at least two but possibly up to four different days. In total, at least 50 cells 
(range 52-407) were analyzed on each day for each cell line and condition, resulting in 
a total of at least 150 cells (range 156-568) analyzed for each cell line and condition. 
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Table 5.1. Patient characteristics for primary fibroblast cell lines. 
Cell line Sex 
Age at 
biopsy 
(years) 
Groupa Mutation(s)b OXPHOS complex activityc 
2862S F 24 POLG p.467A>T HOM CI 67, CII 125, CIII 108, CIV 87, CS 93 
06E0703 F 16 POLG p.467A>T HOM CI 54, CII 141, CIII 79, CIV 84, CS 71 
00E0741 F <1 POLG p.227R>P + p.467A>T 
CI 34, CII 76,CIII 31, CIV 50, 
CS 227 
3591 M 8 POLG p.305S>R + p.467A>T 
CI 50, CII 86, CIII 57, CIV 89, 
CS 142 
05E0536 F 1 POLG p.467A>T + p.957A>P CI 63, CII 81, CIV 57, CS 150 
      
2400 M 27 tRNA-Leu m.3243A>G (80%) CI 43, CII 86, CIII 67, CIV 80, CS 125 
1933 M 27 tRNA-Leu m.3243A>G (90%) CI 50, CII 84, CIII 60, CIV 79, CS 117 
2830 F 19 tRNA-Leu m.3243A>G (83%) CI 57, CII 86, CIII 77, CIV 60, CS 100 
1330 M 34 tRNA-Leu m.3302A>G (50%) CI 62, CII 100, CIII 79, CIV 83, CS 108 
      
3765 M 5 CI ND1, m.3890G>A (80%) 
CI 34, CII 69, CIII 72, CIV 114, 
CS 160 
2181 M 3 CI ND5, m.13042G>A (86%) 
CI 50, CII 90, CIII 59, CIV 70, 
CS 110 
1682 F 4 CI ND5, m.13511A>T (60%) 
CI 52, CII 94, CIII 91, CIV 115, 
CS 105 
      
C0388   Control - n.a. 
C0407   Control - n.a. 
C2244   Control - n.a. 
a Patient cell lines are grouped according to their genetic defect: polymerase gamma mutations (POLG), 
mtDNA tRNA leucine mutation with MELAS phenotype (MELAS) and mtDNA complex I subunit 
mutation (CI). b Mutations are given at the protein level for POLG and at the mtDNA level for MELAS 
and CI, the mutation percentage of the mtDNA mutations is given between ( ). cThe activities of the 
different OXPHOS complexes is expressed as the percentage of a control population, normalized to 
citrate synthase (CS) activity. CI=complex I, CII=complex II, CIII=complex III, CIV=complex IV. n.a. = 
not applicable. 
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Preparation of lysates for glutathione measurements and protein carbonyls 
Cell pellets were resuspended in ice-cold extraction buffer (0.1% Triton X-100 and 
0.6% sulfosalicylic acid in 0.1M potassium phosphate buffer with 5mM EDTA disodium 
salt, pH 7.5) and homogenized with a Teflon pestle. After sonication and 2 freeze-thaw 
cycles, the suspension was centrifuged for 4 min at 3000g (4 degrees) and the 
supernatant was stored at -70 degrees until further use. Protein concentrations were 
determined using the Bio-Rad Protein Assay. 
 
Glutathione measurement 
Total glutathione (reduced (GSH) + oxidized (GSSG)) was measured in the cell lysates 
as described in [29]. In short, freshly prepared 5,5’-dithio-bis(2-nitrobenzoic acid) 
(Sigma) and glutathione reductase (Sigma) solutions were mixed and added to the cell 
lysates (40ȝg protein in 20 microliter). After 30s, NADPH (Sigma) was added and the 
rate of change in absorbance at 412nm was proportional to the concentration of total 
GSH ([GSH] + 2 x [GSSG]) in the sample. The concentration of total GSH was deduced 
from the regression curve generated from several standards of GSH. Data were 
analyzed using the univariate analysis of variance in the SPSS software package. 
 
Protein carbonyl detection 
To detect oxidative modifications of proteins, the OxyblotTM Protein Oxidation Detection 
kit (Millipore, Amsterdam, NL) was used. After derivatization of the carbonyl groups in 
the cell lysates with di-nitrophenylhydrazone, oxidatively modified proteins were 
detected by immunoblotting according to the manufacturer’s protocol in two replicates. 
Results were normalized to beta-actin protein levels in different lanes of the same gels. 
 
Oxidative stress related gene expression 
The expression levels of genes involved in oxidative stress and inflammation were 
measured using the OxyGenesTM microarrays (Probiox SA, Liege, BE) [30]. RNA was 
isolated from cell pellets with the High Pure RNA Isolation kit (Roche, Woerden, NL). 
RNA quantity and purity were determined spectrophotometrically using the Nanodrop 
ND-1000 (Nanodrop Technologies, Wilmington, DE, USA) and RNA integrity was 
assessed by determining the RNA 28S/18S ratio using the Bioanalyser 2100 (Agilent 
Technologies, Santa Clara, CA, USA). 2 ȝg of RNA was reverse transcribed into cDNA 
according to the 3DNA Array 900 protocol (Genisphere, Hatfield, PA, USA). Next, 
cDNA was hybridized on the OxyGenesTM slides overnight, followed by washing steps 
and hybridization of CyTM3-labeled 3DNA capture reagent according to the 
manufacturer’s procedures (Genisphere). To assess the raw probe signal intensities, 
slides were scanned using the LS Reloaded laser scanner (Tecan, Männedorf, CH) 
with gain settings 160, 180 and 200 and analyzed using Array-Pro analyzer software 
(MediaCybernetics, Bethesda, USA) or scanned using the Agilent High-Resolution 
Microarray Scanner (Agilent Technologies, Amstelveen, NL) and analyzed using 
Feature Extraction 10.7 software (Agilent Technologies). 
 
 
 
Oxidative stress in OXPHOS disorders | 5 
 
 
99
 
Data analysis 
The data were analyzed using multivariate Gaussian linear regression including a one 
(protein carbonyls and Oxygenes™) or two level (ROS levels) random effect to take 
into account the dependence among observations from the same subject (all assays) 
and the dependence among the different measurement days (ROS levels). For the 
ROS level analysis, the medium (glucose and galactose) and the group (control, 
complex I, tRNA-Leu and POLG) were included during the analysis, as well as 
interactions among these when required. For the protein carbonyl analysis, the 
reference protein (beta-actin), concentration, day, gel number, medium and group were 
included. The inference criterion used for comparing the models reflects their ability to 
predict the observed data, i.e. models are compared directly through their minimized 
minus log-likelihood. When the numbers of parameters in models differ, they are 
penalized by adding the number of estimated parameters, a form of the Akaike 
information criterion (AIC) [31]. First, all cell lines were analyzed together and then 
each one was also considered separately. In each case, the relevant group differences 
were reported if the model with the smallest AIC contained any combination of one or 
more groups. 
For the Oxygenes™ analysis, one of the 30 housekeeping genes, the pooled sample, 
the background intensity, the scanner used, the medium and group were included 
during the analysis as well as interactions among these when required. Similarly to the 
ROS levels and protein carbonyl analysis, the AIC was used to assess whether there 
was a group effect. First, each gene was analyzed for all cell lines in the patient groups 
together and then the analysis was also repeated for all genes but considering each 
cell line separately. In each analysis, the relevant group differences were reported if the 
model with the smallest AIC contained any combination of one or more groups. 
Importantly, the reported fold changes are estimated values by the models, taking into 
account both the effect of the mutation and the medium. 
 
 
Results 
 
Increased ROS levels in most of the patient cell lines 
ROS levels, quantified by the oxidation rate of hydroethidine (HEt), were assessed in 
the control and patient cell lines under glucose and galactose conditions (table 5.2). 
Unlike the estimated fold changes for the patient group differences, analysis of 
individual cell lines and controls did not always estimate a medium effect, i.e. a different 
fold change for the glucose and galactose condition, due to low power. In these cases, 
the estimated fold changes represent the difference between the specific patient and 
control fibroblasts regardless of the medium. 
Except for two cell lines, one POLG1 mutant (06E0703; p.467A>T homozygote) and 
one tRNA-Leu mutant (1330; m.3302A>G), all other cell lines showed increased HEt 
oxidation compared with control cell lines in glucose and galactose medium. HEt 
oxidation was highest in the CI group, although one of the POLG1 cell lines (05E0536; 
p.467A>T + p.957A>P) presented with the highest HEt oxidation rate. Although the 
main focus was on changes due to the mutation and not the differences between 
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culture conditions, six cell lines showed a larger fold change for HEt oxidation (versus 
controls) in galactose compared with glucose. Galactose medium also induced a 1.53 
fold increase in HEt oxidation in controls (table 5.2).  
 
Table 5.2. ROS levels as measured by HEt oxidation.  
Cell line  Glucose mean (C.I.) Galactose mean (C.I.) 
Average control 1.00 1.53 (1.49-1.57) 
(3 cell lines)   
   
Average POLG 1.47 (1.12-1.82) 1.71 (1.34-2.18) 
2862S 1.36 (1.14-1.63) 1.96 (1.65-2.34) 
06E0703 1.12 (0.96-1.30) 
00E0741 1.18 (1.04-1.33) 
3591 1.51 (1.35-1.70) 
05E0536 2.51 (2.13-2.95) 4.80 (4.08-5.65) 
   
Average tRNA-Leu 1.48 (1.14-1.83) 1.72 (1.35-2.19) 
2400 1.45 (1.28-1.64) 
1933 1.30 (1.12-1.51) 1.92 (1.65-2.23) 
2830 1.74 (1.46-2.08) 2.52 (2.10-3.03) 
1330 1.10 (0.96-1.25) 
   
Average CI 1.87 (1.47-2.27) 2.28 (1.73-3.01) 
3765 1.61 (1.37-1.90) 2.38 (2.01-2.83) 
2181 2.31 (1.98-2.69) 
1682 1.36 (1.20-1.54) 
HEt oxidation expressed as fold change compared with control in the respective culture medium. Values 
are estimated fold changes for patients versus controls provided by the model, taking into account both 
the effect of the mutation and the medium. Values for the patient groups and the individual cell lines 
were estimated in separate analyses. If the fold change was not significantly different for a cell line 
between both media, the fold change of the best fitting model was estimated for glucose and galactose 
together. Values in bold differ significantly from control in the respective medium or glucose and 
galactose together. # versus control glucose, only applies for the patient groups comparison. 
 
Oxidative damage 
The levels of protein carbonyls, an index for oxidative protein damage, were 
significantly elevated in three patient cell lines cultured with glucose and galactose: 
tRNA-Leu cell lines 2400 (80% m.3243A>G) and 1933 (90% m.3243A>G) and CI cell 
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line 3765 (80% m.3890G>A). CI cell line 1682 (60% m.13511A>T) only showed 
increased levels of protein carbonyls compared with controls when cultured with 
galactose medium (table 5.3). 
 
Table 5.3. Oxidative protein damage (protein carbonyls). 
Cell line Glucose mean (C.I.) Galactose mean (C.I.) 
Average control 1.00 
(3 cell lines)   
Average POLG 1.07 (0.94-1.21) 
2862S 1.07 (0.76-1.50) 
06E0703 0.93 (0.81-1.08) 
00E0741 1.14 (0.96-1.35) 
3591 1.15 (0.92-1.43) 
05E0536 0.92 (0.73-1.66) 
   
Average tRNA-Leu 1.30 (1.13-1.48) 
2400 1.25 (1.06-1.47) 
1933 1.56 (1.29-1.89) 
2830 1.26 (0.90-1.77) 
1330 1.14 (0.94-1.39) 
   
Average CI 1.22 (1.06-1.41) 
3765 1.36 (1.07-1.74) 
2181 1.08 (0.96-1.22) 
1682 1.12 (0.76-1.65) 2.22 (1.79-2.75) 
Protein carbonyls as measured using the Oxyblot assay, expressed as fold change compared with 
control in the respective culture medium. Values are estimated fold changes for patients versus controls 
provided by the model, taking into account both the effect of the mutation and the medium. Values for 
the patient groups and the individual cell lines were estimated in separate analyses. If the fold change 
was not significantly different for a cell line or group between both media (due to less power compared 
with the analysis of the groups), the fold change of the best fitting model was estimated for glucose and 
galactose together. Values in bold differ significantly from control. 
 
Stress-related gene expression and antioxidant defense 
To examine ROS-related gene expression changes, the transcription levels of stress-
related genes were determined using OxyGenes™ microarrays. Of the 165 genes on 
the microarray, 38 genes showed more than 20% difference in expression above the 
background level in at least one of the groups and one of the culture media. Of these 
38 genes, 10 were altered due to the genetic defect only, as their expression was not 
influenced by the culture medium in controls and patients (table 5.4). Therefore these 
were considered specific for the genetic defects and included, amongst others, heat 
shock protein (HSPA1A), oxidative stress related (SOD1, PON2, MT1M) and 
inflammatory (ICAM1, IL2RG, TNFRSF1B) genes. The expression of the remaining 28 
genes was altered due to both the culture medium and genetic defect (supplementary 
table 5.1). The POLG group showed the highest number of differentially expressed 
genes compared with controls, both in glucose and galactose medium. The galactose 
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medium induced larger expression changes of 17 stress-related genes in the POLG 
group (supplementary table 5.1). In contrast, the tRNA-Leu and CI groups showed less 
differentially expressed genes, both in glucose and galactose (supplementary table 
5.1).  A closer examination of the gene expression changes of classical antioxidant 
genes in the individual cell lines (table 5.5) revealed an inconsistent picture. On the one 
hand, genes could behave comparable in multiple cell lines of one or more patient 
groups in one or both culture conditions (e.g. GSR in POLG glucose and galactose, 
GPX1 in tRNA-Leu galactose, SOD1 in tRNA-Leu and CI galactose). Whereas, on the 
other hand, their expression changed differently, either up or down, in cell lines of the 
same group in one or both culture conditions (e.g. GPX1 in POLG glucose and 
galactose, SOD1 in tRNA-Leu and CI glucose) (table 5.5). 
 
Table 5.4. Stress-related gene expression changes due to disease without medium effect. 
Gene FC CI vs control 
FC POLG 
vs control 
FC tRNA-Leu 
vs control 
FC All 
vs control 
HSPA1A    3.39 (2.80-4.09) 
ICAM1  1.58 (1.33-1.87)   
IGFBP3  1.40 (1.35-1.45)   
IL2RG 0.68 (0.56-0.82) 1.27 (1.03-1.56) 0.68 (0.56-0.82)  
MT1M  2.36 (2.07-2.69)   
PON2    0.58 (0.38-0.89) 
SIRT1  2.60 (1.36-4.96)   
SOD1  1.99 (1.71-2.31)   
SOS2  1.38 (1.27-1.50)   
TNFRSF1B 0.67 (0.59-0.76)    
Fold changes of stress-related genes in patients versus controls as measured by the OxyGenes™ 
microarrays. Fold changes were the same for glucose and galactose medium. Values are estimated fold 
changes for patient groups versus controls provided by the model, taking into account both the effect of 
the mutation and the medium. If the fold change was not significantly different for all patient groups, the 
fold change of the best fitting model was estimated for three groups together and provided in the  ‘All vs 
control’ column. Only significant results are shown. 
 
Total glutathione levels were measured to evaluate the oxidative status of the cell lines 
(figure 5.1). Univariate analysis of variance did not detect any significant difference 
between the groups or culture conditions. As can be appreciated from figure 5.1, there 
was a large variation between cell lines of patients within one group. Eight patient cell 
lines showed total glutathione values below the control range in the glucose situation. 
Additionally, the total glutathione levels in galactose were increased compared with the 
glucose levels in seven of these same cell lines, making them similar to control levels in 
galactose. On the contrary a decrease or no change at all was observed in the control 
cell lines or the remaining patient cell lines.  
 
Correlations between different parameters 
To search for correlations between the different parameters (ROS levels, oxidative 
protein damage, total GSH levels and classic antioxidant gene expression) and 
between these parameters and sex and age, a correlation matrix was created 
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(supplementary table 5.2). Statistical significant correlations (p value < 0.05) were only 
detected between ROS levels and CAT expression fold changes (Pearson’s r -0.508) 
and protein carbonyl levels and GPX1 expression fold changes (Pearson’s r 0.454).  
 
 
Discussion 
 
The goal of this study was to characterize different oxidative stress parameters in three 
groups of patients with a genetically characterized mitochondrial disorder caused by 
mutations either in the POLG1 gene or in mtDNA encoded complex I and tRNA leucine 
genes. Fibroblast cells predominantly use glycolysis for energy production when 
cultured with high glucose availability [24, 32, 33]. Hence, cell lines were forced to 
derive ATP from OXPHOS using glucose-free galactose medium [34]. An overview of 
the results is shown in table 5.6. 
 
Table 5.5. Antioxidant gene expression for each cell line. 
Gene CAT  SOD1  GSR  GPX1 
Cell line glu gal  glu gal  glu gal  glu gal 
POLG            
2862S  1.37  2.35 19.05   2.42  0.77 2.50 
06E0703  1.36     1.21    
00E0741 1.29      1.22   1.51 0.58 
3591        1.46    
05E0536          0.73 
            
tRNA-Leu            
2400    14.35 0.64  1.75    0.54 
1933           0.67 
2830    0.56   2.64   0.42 
1330          0.75 0.51 
            
CI            
3765  1.40          
2181    4.11 0.54   1.17   0.79 
1682    0.61      1.29 
Fold changes are given relative to the average control (glucose or galactose). Values are estimated fold 
changes for patients versus controls provided by the model, taking into account both the effect of the 
mutation and the medium. If the fold change was not significantly different for a cell line between both 
media, the fold change of the best fitting model was estimated for glucose and galactose together. 
Blanc cells indicate no (<10% change) or a non-significant difference compared with controls. 
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Oxidative stress in patients with mutations in mtDNA encoded complex I subunits 
The fibroblast cell lines with mutations in mtDNA encoded complex I subunits 
presented the highest ROS levels, accompanied with most oxidative protein damage 
(2/3 cell lines) and only few changes in antioxidant gene expression (table 5.6). 
Interestingly, the CI cell line with the highest ROS levels was the cell line without 
oxidative damage, indicating adaptation to or compensation of the defect. The other 
two cell lines seemed less capable to adapt to or compensate for increased ROS 
levels, resulting in oxidative stress and damage. Possible consequences of extensive 
oxidative stress are cell cycle arrest, senescence and apoptosis [35].  Increased ROS 
levels have been detected previously in cells or tissues of patients with a genetically 
(nuclear [23] or mitochondrial DNA [16]) and/or functionally [4] characterized CI 
deficiency. The finding is not surprising as CI is one of the major ROS sources in 
mitochondria [36].  Luo et al observed increased lipid peroxidation in fibroblasts of 
patients with CI deficiency [37], but this was not detected in another study by Verkaart 
et al [15]. The only publication reporting on oxidative protein damage in CI deficiency 
involved cybrids carrying the 3460, 11778 and 14484 Leber mutations showing 
increased protein carbonylation [38]. This nicely supports our results. In contrast to the 
lymphoblast cell lines  from biochemically characterized CI deficient patients with 
predominantly (5/6 cell lines) homoplasmic mtDNA mutations [16], we did not detect 
consistently increased expression of SOD, CAT, GPX and GST in our patients with a 
genetic defect in mtDNA CI genes [16]. However, in their study, increased expression 
of the genes in the presence of elevated ROS levels was not correlated with increased 
expression of the corresponding proteins and they actually measured lower antioxidant 
activity of these enzymes, except for SOD1. In spite of the inconsistency between RNA 
and protein data, they concluded, mainly based on the enzyme data, that ROS levels 
and alteration of ROS scavenging enzymes were good parameters to assign 
antioxidant therapy. However, oxidative damage parameters were not examined, which 
in our study seemed to be an appropriate biomarker to estimate the eventual 
consequences of increased ROS levels in fibroblasts. 
 
Oxidative stress in patients with mutations in tRNA leucine genes 
All three cell lines with the m.3243A>G mutation (80-90% heteroplasmy) experienced 
increased ROS levels, whereas the cell line with the m.3302A>G mutation (60%) did 
not (table 5.6). In this study with primary patient fibroblast cell lines, the lack of 
increased ROS levels in the m.3302A>G cell line is likely due to the lower mutation 
percentage but a different molecular mechanism compared with the m. 3243A>G tRNA-
Leu mutation cannot be excluded [39]. The m.3302A>G and m.3243A>G tRNA-Leu 
mutations have been shown to increase superoxide production in homoplasmic cybrid 
models with deficiencies of OXPHOS complexes I, III, IV and V [40], whereas in our 
group complex I deficiency was most prominent, and in muscle of patients with the 
m.3243A>G mutation [19]. Oxidative protein damage was observed in two m.3243A>G 
cell lines. Again, the cell line with the highest ROS levels did not show oxidative 
damage in galactose. For the tRNA-Leu patients, only few studies previously reported 
on oxidative damage. One study detected increased protein carbonylation in muscle 
biopsies [19] while two other studies did not observe increased oxidative damage in 
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cybrids carrying the homoplasmic 3243A>G [6, 39] or 3302A>G [39] mutations. There 
have been no reports on oxidative stress/damage in mutant tRNA-Leu fibroblasts so 
far. 
 
 
 
Figure 5.1. Total glutathione (GSH+GSSG) levels. 
 
 
Our results differ partly from previous studies on antioxidant enzymes in MELAS 
patients, reporting increased gene expression and activities of SOD, CAT and GPX, 
although studies are difficult to compare due to differences in cell types, mutation load 
and analytical approaches [5, 6, 41]. In one study, the mutation load was considerably 
lower (<45% heteroplasmy) than in our fibroblasts, and myoblast cultures were used 
[5]. This might indicate that antioxidant defenses are triggered at lower ROS levels in 
muscle-derived cells, compared with fibroblasts, to prevent accumulation of oxidative 
damage in post-mitotic tissues; however, ROS levels, which could support this 
hypothesis, were not determined in the myoblast cultures. Therefore, it is not certain 
that the gene expression changes resulted from increased ROS production related to 
the mtDNA mutations. A second study did not quantify their immunohistochemical 
results in muscle [41], making it difficult to judge and compare the results. Finally, a 
third study used homoplasmic mutation load and cybrid models [6] instead of primary 
patient material. Although there is a possible interference of the nuclear cancer 
background here, the increased expression of antioxidant genes nicely correlates with 
the lack of oxidative damage. Altogether, all studies point to increased ROS production, 
whether or not compensated by antioxidant defenses. These studies emphasize the 
importance of standardization and examining different aspects of oxidative stress to be 
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able to compare the results of different studies, especially if heterogeneous patient 
populations or different model systems with different adaptive capacities are being 
used. 
 
Oxidative stress in patients with mutations in the POLG1 gene 
All except one POLG1 cell line showed increased ROS levels. POLG1 cell line 
06E0703 has the same mutation as cell line 2862S, while only the latter showed 
increased ROS levels (table 5.6). This suggests that other factors in addition to or apart 
from the primary genetic defect(s) play a role in ROS levels in the POLG group (and 
possibly also in the other groups). This might involve intrinsic individual differences in 
ROS scavenging capacity due to e.g. genetic polymorphisms or environmental factors 
[42]. It may also be related to the random effect of pol Ȗ on mtDNA stability and point 
mutations leading to many, random low level heteroplasmy mutations in contrast to the 
high heteroplasmic CI and tRNA-Leu mutations. Even though the POLG and tRNA-Leu 
group experienced similar ROS levels, the former group seemed less vulnerable to 
accumulate oxidative protein damage in fibroblasts. As suggested by the multiple gene 
expression changes, this is possibly correlated with an  adaptive activation of the 
antioxidant or repair systems associated with increased endogenous ROS levels in our 
patient lines [43]. No human cells or tissues with POLG1 mutations have been 
evaluated for oxidative stress parameters so far. In POLG mutator mice with 
proofreading deficient D268A polymerase resulting in the random accumulation of 
mtDNA mutations, no or only mildly increased ROS production and no oxidative 
damage could be detected in several tissues (liver, heart, muscle) by two groups [25, 
26]. Contrastingly, a third group examining the same mice, did observe increased 
oxidative protein damage in the heart which could be attenuated by overexpression of 
mitochondrial catalase [44]. Additionally, in transgenic mice with cardiac-targeted 
human mutant Y955C pol Ȗ, affecting the polymerase domain, increased oxidative DNA 
damage associated with decreased mtDNA copy number was observed [27]. In 
concordance with the latter publications, the current study implies that ROS levels are 
increased in most POLG1 patients and therefore their antioxidant levels and oxidative 
damage markers should be followed up to supplement them with antioxidants when 
their endogeneous system starts failing. 
 
Increased ROS levels in the majority of primary fibroblasts of OXPHOS patients 
One of the general observations in this study is that ROS levels were increased in most 
patient-derived cell lines, both when cultured with glucose and galactose medium (table 
5.6). The moderate increase in ROS levels in control fibroblasts due to the replacement 
of glucose by galactose might reflect increased basal OXPHOS-related ROS 
production due to the switch from glycolysis to OXPHOS for energy production. Our 
results indicated that ROS levels could already be increased by quite moderate 
OXPHOS deficiencies (e.g. CI activity lower than 70% of the average control activity), 
as shown for most fibroblasts in this study, e.g. due to disturbed electron fluxes in the 
mutated complexes. In support of this theory, increased superoxide production was 
measured in fibroblasts of patients with a mutation in a nuclear DNA-encoded CI gene 
and residual CI activities up to 75% of controls [23]. A drawback is that the method 
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applied cannot distinguish the exact site(s) of HEt oxidation and that the exact 
mechanism therefore remains speculative [23]. Other proteins that might influence the 
measured ROS levels are alpha-ketoglutarate dehydrogenase in the tricarboxylic acid 
cycle [45, 46] and NADPH oxidases (NOX) [47], all suggested to be influenced by the 
redox status of cells [48]. Therefore, genetically defined OXPHOS deficiencies might 
not only increase ROS levels by electron leakage at the OXPHOS complexes but also 
by altering the NAD+/NADH ratio.  
 
Adaptive processes in fibroblasts of OXPHOS patients 
Most cell lines showed increased ROS levels but no increased oxidative protein 
damage. Stress-induced adaptive gene expression changes, especially in the POLG1 
cell lines, might account for these findings. The existence of such a delicate balance is 
supported by the presence of oxidative damage in one CI mutant fibroblast cell line in 
galactose but not glucose medium, associated with higher ROS levels.  The increased 
expression of stress-inducible HSPA1A, DNAJB1 and HSF2 in the glucose and/or 
galactose condition in patient cell lines pointed to a stress condition induced by the 
genetic defect. Heat shock proteins function as chaperones for correct folding of other 
proteins. The induction of these genes indicates activation of the unfolded protein 
response and possibly increased endoplasmic reticulum stress. Defects in protein 
synthesis have been associated with the 3243A>G mutation previously [49]. The 
activation of the unfolded protein response in the patients of this study might be related 
to prevention or repair of oxidative protein damage. Other compensatory mechanisms 
such as protein regeneration and muscle regeneration have also been observed in 
muscle biopsies of m.3243A>G mutation carriers [19]. However, repair and 
regenerative processes are highly energy demanding. Therefore, probably also the 
remaining energy capacity of a defect OXPHOS system plays a role in the faith of cells. 
Recently, exercise training has been shown to be beneficial for improving oxidative 
metabolism in muscle [50] and to induce antioxidant-related adaptations, enhancing the 
ability to cope with oxidative stress [51]. Thus, possibly also the physical activity or 
training of patients plays a role in how well their antioxidant systems will be able to 
cope with or adapt to the increased ROS levels caused by their genetic defect. 
 
A consistent correlation was observed between classic antioxidant genes and the other 
oxidative stress parameters. ROS levels were inversely correlated with CAT expression 
and protein carbonyl levels were correlated with GPX1 gene expression. Superoxide 
has been shown previously to inhibit catalase directly [52], whereas GPX1 was crucial 
for protection against protein oxidation in mice [53], both of which might explain the 
observed correlations. Therefore, the expression of these genes might serve as 
biological biomarkers, although this remains to be confirmed in a larger patient cohort. 
 
  
10
8 
Ta
bl
e 
5.
6.
 S
um
m
ar
iz
in
g 
ov
er
vi
ew
 o
f o
xi
da
tiv
e 
st
re
ss
 p
ar
am
et
er
s 
fo
r e
ac
h 
ce
ll 
lin
e.
 
C
el
l l
in
e 
M
ut
at
io
n 
O
XP
H
O
S 
co
m
pl
ex
es
 
C
ul
tu
re
 
R
O
S 
le
ve
ls
 
O
xi
da
tiv
e 
da
m
ag
e 
A
nt
io
xi
da
nt
 re
sp
on
se
 
B
en
ef
it 
fr
om
 a
nt
io
xi
da
nt
 
th
er
ap
y?
* 
P
O
LG
 
 
 
 
 
 
 
 
28
62
S
 
p.
46
7A
>T
 H
O
M
 
 
gl
u 
Ĺ 
 
Ĺ 
S
O
D
1,
 Ļ
 G
P
X
1 
Fo
llo
w
-u
p 
en
do
ge
no
us
 
pr
ot
ec
tio
n 
ga
l 
ĹĹ
 
 
Ĺ 
C
A
T,
 Ĺ
Ĺ 
S
O
D
1,
 Ĺ
 G
S
R
, Ĺ
 G
P
X
1 
06
E
07
03
 
p.
46
7A
>T
 H
O
M
 
 
gl
u 
 
 
Ĺ 
G
S
R
 
N
o 
ga
l 
 
 
Ĺ 
C
A
T,
 Ĺ
 G
S
R
 
00
E
07
41
 
p.
22
7R
>P
 
p.
46
7A
>T
 
Ļ 
gl
u 
Ĺ 
 
Ĺ 
C
A
T,
 Ĺ
 G
S
R
, Ĺ
 G
P
X
1 
Fo
llo
w
-u
p 
en
do
ge
no
us
 
pr
ot
ec
tio
n 
ga
l 
Ĺ 
 
Ļ 
G
P
X
1 
35
91
 
p.
30
5S
>R
 
p.
46
7A
>T
 
 
gl
u 
Ĺ 
 
 
Fo
llo
w
-u
p 
en
do
ge
no
us
 
pr
ot
ec
tio
n 
ga
l 
Ĺ 
 
Ĺ 
G
S
R
 
05
E
05
36
 
p.
46
7A
>T
 
p.
95
7A
>P
 
 
gl
u 
ĹĹ
 
 
Ļ 
G
P
X
1 
P
ro
ba
bl
y 
ga
l 
ĹĹ
Ĺ 
 
Ļ 
G
P
X
1 
 tR
N
A
-L
eu
 
 
 
 
 
 
 
 
24
00
 
80
%
 
m
.3
24
3A
>G
 
Ļ 
gl
u 
Ĺ 
Ĺ 
ĹĹ
 S
O
D
1,
 Ĺ
 G
S
R
 
Y
es
 
ga
l 
Ĺ 
Ĺ 
Ļ 
S
O
D
1,
 Ļ
 G
P
X
1 
19
33
 
90
%
 
m
.3
24
3A
>G
 
 
gl
u 
Ĺ 
Ĺ 
 
Y
es
 
ga
l 
ĹĹ
 
Ĺ 
Ļ 
G
P
X
1 
28
30
 
83
%
 
m
.3
24
3A
>G
 
 
gl
u 
Ĺ 
 
Ļ 
S
O
D
1 
P
ro
ba
bl
y 
ga
l 
ĹĹ
 
 
Ļ 
S
O
D
1,
 Ĺ
 G
S
R
, Ļ
 G
P
X
1 
13
30
 
60
%
 
m
.3
30
2A
>G
 
 
gl
u 
 
 
Ļ 
G
P
X
1 
N
o 
ga
l 
 
 
Ļ 
G
P
X
1 
  
 
 
 
 
 
 
 
  
10
9 
C
el
l l
in
e 
M
ut
at
io
n 
O
XP
H
O
S 
co
m
pl
ex
es
 
C
ul
tu
re
 
R
O
S 
le
ve
ls
 
O
xi
da
tiv
e 
da
m
ag
e 
A
nt
io
xi
da
nt
 re
sp
on
se
 
B
en
ef
it 
fr
om
 a
nt
io
xi
da
nt
 
th
er
ap
y?
* 
C
I 
37
65
 
80
%
 
m
.3
89
0G
>A
 
Ļ 
gl
u 
Ĺ 
Ĺ 
 
Y
es
 
ga
l 
ĹĹ
 
Ĺ 
Ĺ 
C
A
T 
21
81
 
86
%
 
m
.1
30
42
G
>A
 
 
gl
u 
ĹĹ
 
 
Ĺ 
S
O
D
1 
P
ro
ba
bl
y 
ga
l 
ĹĹ
 
 
Ļ 
S
O
D
1,
 Ĺ
 G
S
R
, Ļ
 G
P
X
1 
16
82
 
60
%
 
m
.1
35
11
A
>T
 
 
gl
u 
Ĺ 
 
Ļ 
S
O
D
1 
Y
es
 
ga
l 
Ĺ 
Ĺ 
Ļ 
S
O
D
1,
 Ĺ
 G
P
X
1 
* b
as
ed
 o
n 
th
e 
co
m
bi
na
tio
n 
of
 R
O
S
 le
ve
ls
, o
xi
da
tiv
e 
da
m
ag
e 
an
d 
an
tio
xi
da
nt
 g
en
e 
ex
pr
es
si
on
 in
 fi
br
ob
la
st
s 
  
11
0 
Conclusions 
 
In this study using fibroblasts of patients with different genetically characterized 
OXPHOS disease, it was shown that in the majority ROS was increased and could lead 
to oxidative damage in different OXPHOS disorders, although not in every patient-
derived fibroblast. This has to be determined individually. Whether this also applies to 
more clinically relevant tissues, like brain and muscle of those patients, is not clear, but 
is not unlikely given data from literature involving other tissues [19, 54, 55] and mouse 
studies [27, 56] illustrating that fibroblasts are not the most sensitive system. Therefore, 
patient-derived fibroblasts can be used to identify patients with increased risk for 
oxidative damage, who will most likely benefit from boosting their antioxidant defense 
and energy capacity (training), possibly leading to patient-tailored prevention and 
antioxidant therapy in the future. Nevertheless, even in these patients, efficacy and 
toxicity of antioxidant supplementation should be evaluated carefully as side-effects can 
occur [57]. 
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Supplementary table 5.2. Correlation matrix  
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ROS levels        
Protein carbonyl level -0.158       
Total GSH level -0.093 -0.032      
CAT expression FC -0.508 -0.197 -0.005     
SOD1 expression FC -0.001 -0.050 0.246 0.227    
GSR expression FC 0.258 -0.170 -0.120 -0.160 0.400   
GPX1 expression FC 0.225 0.454 0.046 -0.177 0.327 0.234  
 
Correlation matrix for ROS levels, protein carbonyl levels, total GSH levels and fold changes of classic 
antioxidant genes. The Pearson correlation values produced by SPSS are shown; significant 
correlations are depicted in bold. 
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Mitochondrial enchephalomyopathies are a clinically and genetically highly 
heterogeneous group of diseases. They are also referred to as oxidative 
phosphorylation (OXPHOS) disorders, because of the causative role of deficiencies of 
the OXPHOS system in the pathology of most cases. The pathophysiology of these 
disorders is only partly understood and efficient therapies are not available for the vast 
majority of patients. The aims of this thesis were: 
1. to facilitate diagnostics of mtDNA-based OXPHOS disorders by determining the non-
pathogenic variation of mtDNA in the general population; 
2. to gain knowledge on primary and secondary biological processes involved in 
OXPHOS disorders which have an impact on prognosis and therapy;  
3. to explore the extent to which different pathogenic mtDNA and nuclear DNA 
mutations induce oxidative stress and the consequences of this in a cell line model.  
The general discussion elaborates on the most significant findings and models and puts 
them in a broader perspective of strategies to unravel pathophysiology and evaluate 
therapy. 
 
 
Mitochondrial DNA: evolution and disease 
 
The mitochondrial DNA (mtDNA) codes for 13 subunits of complex I, III, IV and V of the 
OXPHOS chain and 22 tRNAs and 2 rRNAs necessary for mRNA translation. 
Therefore, it is not surprising that mtDNA mutations or variants can affect OXPHOS 
function. Some variants cause disease themselves but others only influence the risk of 
developing disease or affect the course of the disease (so-called risk factors and 
modifiers). There are also neutral variants that do not have disease-related 
consequences. An additional factor in determining the effect of variants is the multi-
copy nature of the mtDNA with a threshold of expression for heteroplasmic pathogenic 
mtDNA mutations. In order to understand the presence and the consequences of 
mtDNA variants, it is necessary to understand how mtDNA variants arise, how they are 
maintained and why some variants are tolerated whereas others are not. 
 
According to the endosymbiotic hypothesis, eukaryotic mitochondria evolved from 
endocytosed aerobic bacteria more than 1 billion years ago, when oxygen entered the 
atmosphere. During eukaryotic evolution, most (but not all) of the bacterial genome 
encoded genes have been transferred to the nuclear genome, leading to the present 
dual genetic control of the OXPHOS system [1]. Interestingly, the number of transferred 
genes differs between eukaryotic species as exemplified in table 6.1. Although in 
vertebrates there is an almost invariant gene content, other species show considerable 
mtDNA plasticity, mostly attributable to differences in the number of tRNA genes [2]. 
This suggests some form of stabilization in more evolved species and a flexibility of 
eukaryotic mitochondria regarding their ability to import tRNAs from the cytoplasm. 
Even though the number of protein coding genes is rather stable, loss of ATP8 was 
shown in five evolutionary-distant fast-evolving taxa (Nematoda, Rotifera, 
Chaetognatha, Platyhelminthes and Bivalvia). This might indicate that ATP8 is 
 12
0 
‘dispensable’ in the mtDNA [2] and might also have consequences for the tolerance of 
variation within this gene. 
 
Table 6.1. Genes encoded by the mtDNA in eukaryotic species. 
Species Number of mtDNA genes Number of protein coding genes 
H. sapiens (human) 37 13 
M. musculus (mouse) 37 13 
G. gallus (chicken) 37 13 
D. rerio (zebra fish) 37 13 
D. melanogaster (fruit fly) 37 13 
P. megacephalus (frog) 35 11 
C. elegans (worm) 36 12 
S. cephaloptera (worm) 13 11 
A. aurita (jelly fish) 19 15 
M. occidentalis (mite) 53 21 
S. cerevisiae (yeast) 46 19 
A. thaliana (plant) 131 117 
According to NCBI Genome. 
 
The mtDNA has a higher mutation rate compared to the nuclear DNA. Presumably due 
to the proximity of the mtDNA to the electron transport chain, a major ROS production 
site, and the lack of protective histones, the mtDNA is more prone to oxidative damage 
[3, 4]. Although originally it was suggested that mitochondria have no or only a limited 
DNA repair capacity [5], efficient base excision repair in mitochondria was detected 
afterwards [6, 7]. Furthermore, mitochondrial dynamics, characterized by mitochondrial 
fusion and fission, has been shown to be important for mitochondrial genomic stability 
through intramitochondrial exchange of mutant mtDNA and stimulation of autophagy of 
damaged mitochondria [8].  However, the uniparental (maternal) inheritance, the 
mitochondrial bottleneck (random unbalanced partitioning of the cytoplasm during 
gamete formation) and possibly low recombination, lead to accumulation of mutations 
that escape the repair machinery [9] even though their original goal might be the 
maintenance of mitochondrial genomic integrity [10]. This is not necessarily negative, 
as the genetic variation is the driving force of evolution, providing a species the 
possibility to adapt to environmental changes. For example, there is evidence of natural 
selection on mtDNA variants by temperature [11, 12]. When the human population 
started expanding and migrated from tropical Africa to more northern and colder 
climates, variants that decrease coupling efficiency and ATP production but increase 
heat production would be advantageous for survival [11, 12]. A correlation between two 
non-synonymous mtDNA variants in ND3 and ATP6 and temperature has been 
described recently [11]. Additional evidence for an adaptive role of ancient mtDNA 
polymorphisms comes from the presence of the same mtDNA variant on different 
mtDNA haplogroup backgrounds [13]. Contrastingly, the same beneficial ancient 
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mtDNA adaptations might be correlated with complex bioenergetic disorders related to 
the sedentary life-style and increasing age of the human population today (e.g. obesity, 
diabetes, cardiovascular disease) [12, 14]. Obviously, pathogenic mutations are under 
strong negative selection to prevent fixation of the mutation in the population. No 
advantage for disease-causing mtDNA mutations has been observed at the population 
level [14]. Altogether, after ages of evolution, the human mtDNA sequence will consist 
of conserved positions, which are identical among most species, and variable positions. 
Mutation of conserved positions will probably be associated with (in utero) mortality and 
disease (pathogenic mutations) while mutation of variable positions will have minor 
consequences and will be detected more frequently in the human population.  
 
To study the strength and consequences of natural/purifying selection on mtDNA 
variation, offspring of the so-called mtDNA mutator mouse was studied [15]. The 
mutator mice accumulate high levels of mtDNA mutations randomly across their mtDNA 
due to their proofreading deficient polymerase gamma [15, 16]. However, already after 
a few generations, a strong selection against non-synonymous changes in protein 
coding was reported. The strongest selection was observed in genes with high 
sequence conservation (COX1, COX2). Similar results were obtained for selective 
forces on the human mtDNA when resequencing the mitochondrial genome of 730 
subjects (chapter 2). In agreement with the presumed evolutionary dispensability, also 
in this study ATP8 was among the genes with most tolerated variation. Until recently, 
the study of mtDNA and nuclear DNA variants on a large scale by PCR, DHPLC 
analysis and/or Sanger sequencing was laborious and time-consuming. Now, the use 
of next generation whole genome sequencing leads to high throughput analysis of 
whole genomes and will lead to a detailed map of both genomes. This map will consist 
of positions that are targeted by tolerated polymorphisms (occurring in healthy 
individuals) or pathogenic mutations (in diseased but not healthy individuals) or 
positions that never show variation. The latter situation probably points to mutations 
that are not compatible with life and will never be detected. Detailed and complete 
knowledge on tolerance and natural selection in large numbers of individuals will 
provide valuable information for evaluating the pathogenicity of DNA variants in patients 
and their families. Furthermore, as mitochondria have been implicated to play a role in 
a plethora of diseases (e.g. diabetes, Alzheimer’s disease and cancer), the significance 
of mtDNA variation in these pathologies can also be judged more adequately. In 
addition to in silico predictions, functional assays can be applied for those pathogenic 
variants leading to enzyme deficiencies. Cytosolic hybrids (cybrids) carrying the mutant 
mtDNA in a cancer nuclear background (e.g. osteosarcoma) can be used for this 
purpose [17-19]. However, this approach does not apply to variants with subtle defects 
with no measurable effect on enzyme activities. 
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Models to study pathophysiology and/or test compounds: 
suitability/applicability  
 
When disease-causing mutations are identified, the pathogenic mechanism has to be 
unraveled in order to investigate potential therapeutic strategies. There will be no single 
model able to deal with all follow-up investigations and high-throughput analyses in cell 
lines and simple model organisms will be complemented with studies in more laborious 
mammalian models. The same applies for intervention studies. Several potential 
models exist, including human (post-mitotic tissue), human primary cell culture, rodents 
and small animals (e.g. Caenorhabditis elegans [worm], Drosophila melanogaster [fruit 
fly], Danio rerio [zebrafish]). Each of the models has its own advantages, 
disadvantages and applications (figure 6.1). 
 
 
Figure 6.1. Different models to study inherited disorders with characteristics and applications. 
 
For pathophysiological studies, affected tissues from patients would allow the most 
relevant and specific disease processes to be identified. However, for diseases 
affecting non-dividing tissues (e.g. brain), the availability and amount of material is 
limited. In chapter 3, we circumvented this by studying morphological, genetic (mtDNA) 
and gene expression changes in muscle of POLG1 patients to unravel biological 
processes involved in POLG1 pathogenesis. Gene expression analysis in muscle 
hinted towards a possible association of ROS production and apoptosis with patient 
phenotypes, which was subsequently confirmed in liver and brain of part of the patients. 
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This study demonstrates how only mildly sub-pathologically affected but better 
available tissues (such as muscle) can be the surrogate tissue for the identification of 
pathological processes in more severely affected tissues (such as brain and liver).  
 
Due to the limited availability of post-mitotic patient material, primary cell cultures of 
dividing patient tissues (e.g. fibroblasts) are often used to study pathophysiology and to 
test therapies in vitro [20, 21]. Although this model type allows for high-throughput in 
vitro screening assays, the complex in vivo interactions and physiological conditions 
are not comparable with in vitro conditions and often the consequences of the primary 
defect are less outspoken, especially in the case of OXPHOS disorders [22], where e.g. 
fibroblast can switch from oxidative to glycolytic energy production. Furthermore, it is 
important to check the genetic and biochemical stability of the cell lines over time in 
case they are used as tester panels for compound screening. A panel of fibroblasts cell 
lines of complex I deficient patients was characterized for this purpose (chapter 4). The 
primary goal was to characterize a complex I deficient cell culture system that could be 
used for high-throughput screening of small compounds for beneficial effects on 
complex I activity and energy production. The use of fibroblasts was complicated by the 
mainly (~70%) glycolytic energy production in fibroblasts under standard (glucose) 
culture conditions [23]. To induce OXPHOS-derived (oxidative) energy production, and 
thus stress the primary OXPHOS defect, fibroblast cell lines were cultured in glucose-
lacking galactose-containing medium in the presence of glutamine (an essential amino 
acid for cell growth [24]). Although in HeLa cells, it has been shown that ATP 
production in galactose medium occurs mainly (98%) through glutaminolysis [25], 
others did not detect a glutamine dependency of fibroblasts in glucose and galactose 
medium [26]. Nevertheless, possible energy production through other non-glytolytic 
pathways has to be kept in mind.  Only minor gene expression changes and no signs of 
mtDNA instability (large scale rearrangements and copy number) were detected, 
suggesting that cultured complex I deficient fibroblasts have an inherent genetic 
stability. This makes these parameters less suitable for testing interventions, but they 
can be used to check stability of the model in time. Other parameters such as 
biochemical indicators (e.g. posttranslational modification of pyruvate dehydrogenase), 
mitochondrial morphology, mitochondrial membrane potential and calcium fluxes [27-
29] have been tested as well and are better indicators to test the effect of adding 
compounds to the cell culture medium (B. Wieringa and P. Willems, personal 
communication). The primary patient cell cultures are not only suitable for manipulating 
the primary defect of complex I deficiency, they can also be used to explore secondary 
manifestations of OXPHOS deficiency, like for example oxidative stress, which is 
considered a major contributing factor to OXPHOS pathology.  By an in-depth analysis 
of the level of oxidative stress in different genetically characterized OXPHOS patients, 
we were able to identify patients with increased ROS levels and evaluate their risk for 
acquiring oxidative damage in relevant tissues (chapter 5). This information gives an 
indication which patients will be more likely to benefit from antioxidant therapy.  
However, biological processes or responses identified by in vitro assays should be 
carefully translated to the patients. Especially when screening compounds or drugs, 
one must keep in mind that the in vitro results do not always correlate with in vivo 
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effects. Validation of candidate compounds in animal models is necessary to examine 
their pharmacokinetic and toxic properties before going into clinical trials. For some 
compounds already on the market, like ROS-scavenger or stimulators of mitochondrial 
biogenesis, the toxic properties have been established, but the positive effect should be 
carefully judged. This may be difficult as the patients are often unique and grouping is 
not possible, implying that drug administration is based on individual evaluation and not 
on a group effect. For better insight in this, mice models are often used because of the 
high homology between the human and murine genes but also due to the similar 
phenotypes they develop. For example, mice expressing mutant proofreading deficient 
D257A polymerase gamma [16, 30] and mice with complex I deficiency by knocking out 
(KO) or mutating complex I subunit NDUFS4 [31, 32] have been created. The POLG 
mutator mice presented with increased accumulation of mtDNA mutations and 
deletions and premature ageing-related phenotypes (e.g. reduced fertility, heart 
enlargement, sarcopenia, hearing loss) [16, 30]. Some of these features also occur as 
a phenotype in POLG1 patients [33]. NDUFS4-KO mice manifested a lethal phenotype, 
similar to the Leigh-like symptoms in human patients carrying NDUFS4 mutations [31]. 
Heterozygous dominant-negative mutant NDUFS4 mice were viable and also 
presented with biochemical changes similar to human Leigh patients [32]. 
Nevertheless, it is obvious that strain specific differences exist and that it is not possible 
to make a mouse for each complex human phenotype.  The main disadvantages of 
mouse or other higher organism models are the high costs and the laborious and time-
consuming nature of the experiments. In finding a balance between a high-throughput 
analysis and matching phenotypes, small animal models come into sight. These 
vertebrate (D. rerio) or invertebrate animals (D. melanogaster, C. elegans) usually have 
a rapid development, are easy to manipulate genetically and can be phenotyped in a 
high-throughput fashion. Mutants are often available and compounds can be 
administered by adding directly to the food, medium or water, making these models 
suitable for the study of pathophysiology as well as compound screening. Their main 
disadvantage is their evolutionary distance to humans and the fact that not all of these 
small organisms contain the organs that are affected in human disease. In the end, 
there is not a single model optimal for every application. Therefore, the most 
appropriate mode of action would be to use the models interdependently in a 
continuum, exploiting all of their individual advantages (figure 6.1).  
 
 
Pathological processes in genetically characterized OXPHOS disorders 
 
The clinical symptoms/syndromes associated with OXPHOS dysfunction and their ages 
of onset are extremely variable. There is often no clear genotype:phenotype correlation 
[34]. One may say that the step from gene to phenotype is too big and ‘genomes speak 
biochemistry, not phenotypes’ [35] but even that is not always straightforward in case of 
OXPHOS disorders. Patients with exactly the same mutation(s) can have different 
biochemistry results in muscle [36], which challenges the concept of monogenic 
disorders and suggests that in mitochondrial disorders genetic complexity is the rule. 
During the last decades, the molecular basis of OXPHOS pathology has been 
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intensively studied. This research has been primarily focused on genetically 
characterized OXPHOS patients. However, it should be emphasized that half of the 
patients with a diagnostic OXPHOS deficiency do not have a genetic diagnosis yet [37]. 
Therefore, family studies using linkage analysis and/or next generation or exome 
sequencing are applied to identify new genes associated with mitochondrial function or 
reveal new OXPHOS-related functions for a previously known gene. In rare cases, this 
approach can lead from a genetic mutation directly to therapy (e.g. CoQ10 
supplementation for patients with CABC1 [38] or ETFDH [39] mutation). However, most 
often, the molecular consequences of a novel mutation are not so straightforward and 
primary and secondary consequences have to be unraveled to identify targets for 
therapeutic interventions. 
 
The primary consequence of an OXPHOS disorder is generally considered to be the 
inability of mitochondria to supply sufficient ATP to meet cellular needs, which often 
becomes manifest when large amounts of energy are required, for example in case of 
an infection [40]. However, different gene defects lead to OXPHOS deficiency and 
disease in different ways. There are mutations in the protein-coding genes of the 
OXPHOS system itself, in genes coding for OXPHOS system assembly factors, in 
genes responsible for the replication and maintenance of the mtDNA and in genes 
more indirectly related to OXPHOS function. Furthermore, the negative effect on 
tissues or organs relates also to their dependence on OXPHOS instead of glycolysis for 
energy supply and the residual capacity they have.  A summary of common processes 
in OXPHOS patients, partly identified and described in this thesis, is presented in figure 
6.2.  Interventions directed at these processes should be beneficial for the larger group 
of patients. 
 
Bioenergetics 
Increased lactate levels in POLG1 patients (chapter 3) and in OXPHOS patients in 
general [41], indicate a metabolic switch from OXPHOS to glycolysis derived ATP 
production and pyruvate to lactate oxidation for NAD+ regeneration. Increased 
concentrations of lactate and tricarboxylic acid cycle intermediates are frequently 
encountered in patients with OXPHOS disease [42, 43] as a measure of disturbed 
bioenergetics. Reinecke et al recently reviewed the limited literature on RNA 
expression changes of metabolic genes in a variety of disease phenotypes and models 
for OXPHOS deficiency [44]. Even though a disturbance of energy metabolism genes is 
most often apparent in OXPHOS patients [40], expression changes of the genes 
involved in the different studies are highly diverse and inconsistent [44]. This is a further 
reflection of the extreme heterogeneic pathogenicity of the disorders, illustrating that 
multiple pathways and processes are playing a role. Characterization of gene 
expression changes, contributing to disease manifestation and progression, at the 
individual level is important to obtain more insight in personal consequences of and 
adaptations to OXPHOS deficiency. 
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Figure 6.2. Pathophysiological processes involved in OXPHOS disease. 
 
Mitochondrial ATP production is essential for transport of key metabolites across 
membranes. Cellular ionic calcium is an important second messenger, regulating many 
cellular processes with variable spatial and temporal dynamics [45]. Calcium 
homeostasis, which is normally maintained within a very narrow range around ~100 nM 
[45], has often been shown to be aberrant in mitochondrial diseases [46-48]. Impaired 
sequestration of calcium in intracellular calcium stores (mitochondria, 
sarcoplasmic/endoplasmic reticulum) can be secondary to ATP depletion [28] and ROS 
[49] due to their effect on the ATP-dependent Ca2+ pumps. Calcium has been shown to 
be a physiological stimulator of mitochondrial OXPHOS function, although at high 
concentration it changes to a pathological enhancer of ROS production [50]. Other 
potential pathological effects following deregulated calcium homeostasis are the 
opening of mitochondrial permeability transition pore, resulting in cytochrome c release 
and apoptosis [50]. Recently, the protein responsible for mitochondrial calcium 
pumping, the mitochondrial calcium uniporter (MCU), was identified and characterized 
[51, 52]. Future studies are necessary to establish the exact mechanism and the 
regulation of mitochondrial calcium transport by MCU.   
 
OXPHOS defects are also associated with changes in the mitochondrial membrane 
potential [53, 54]. Altered mitochondrial membrane potential influences mitochondrial 
dynamics (fission and fusion) [55]. Depolarized mitochondria are not able to fuse with 
the network after fission and are targeted for autophagy/mitophagy [56]. This 
bioenergetic quality control mechanism has to monitor that dysfunctional mitochondria 
are selectively removed from the mitochondrial network. Increased stimulation or 
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activation of  autophagy has been described for mtDNA point mutations [57] and 
deletions [58] before and are expected to apply also for other OXPHOS disorders with 
altered mitochondrial membrane potential. The processes mentioned above are 
generally reported in OXPHOS disorders. Nevertheless, specific gene mutations can 
lead to more specific metabolic consequences such as reduced flavine adenine 
dinucleotide (FAD) binding due to ACAD9 mutation [59], (secondary) CoQ10 deficiency 
due to ETFDH deficiency associated with ETFDH mutation [39] or mutation of CABC1, 
involved in CoQ10 synthesis [38].  
 
Oxidative stress and apoptosis 
ROS production 
ROS production has predominantly been considered a secondary factor following 
dysfunction of one of the OXPHOS complexes (especially complex I or III [60, 61]) or 
changes in the mitochondrial membrane potential [62, 63]. Fibroblasts of patients with a 
POLG1, mitochondrial tRNA Leu or mtDNA encoded complex I subunit mutation 
showed increased ROS production with a moderate OXPHOS deficiency (chapter 5). 
This could indicate that moderately decreased (lower than 65% activity of average 
control) OXPHOS function already increases ROS levels. In support of this theory, at 
least for complex I deficiency, increased superoxide production was measured in 
fibroblasts of patients with a mutation in a nuclear DNA-encoded CI gene and residual 
CI activities up to 75% of control [61]. However, the methods applied (HEt oxidation) do 
not distinguish the exact site(s) of ROS production [61] and therefore, other proteins 
might be responsible for the increased ROS levels measured. Genetic OXPHOS 
defects have been associated with a shift in the intramitochondrial NAD+/NADH ratio 
towards NADH [44, 64]. This can stimulate ROS production (superoxide and H2O2) by 
alpha-ketoglutarate dehydrogenase in the tricarboxylic acid cycle [65, 66]. The NADPH 
oxidases (NOX) are another class of proteins that mainly function in ROS production 
[67] and have also been suggested to be regulated by the redox status of cells [68]. 
Therefore, ROS should also be considered as a pathological process in genetically 
characterized OXPHOS patients without diagnostic OXPHOS deficiency in fibroblasts.  
One therapeutic strategy that is often applied is antioxidant supplementation to 
scavenge increased ROS. However, up to now, the efficacy of such therapy has been 
highly anecdotic as patients have not been carefully evaluated for amount and origin of 
ROS production. The most recent evidence of a positive therapeutic effect of 
antioxidants for mitochondrial disease comes from a small double-blind cross-over 
study involving 27 mitochondrial patients and 42 controls showing that a 30-day 
supplementation with a cysteine donor reduced exercise-induced oxidative damage 
levels in blood [69]. The cell culture models established in this thesis (chapter 4 and 5) 
enable detailed analysis of the ROS factor in the pathology observed and could be 
used to measure the (beneficial) effects of soluble cell permeable antioxidant 
compounds by simply adding them to the cell culture and monitoring the characterized 
parameters. Future addition of measurements related to cellular repair capacity to this 
pipeline would be relevant since repair is highly energy dependent. These studies might 
reveal differences in oxidative damage in cell lines with similar ROS levels and 
antioxidant defenses and ways to prevent and treat them. Nevertheless, although 
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difficult in a small and diverse patient group as this, the effect of antioxidant therapy 
should be evaluated critically as existing evidence also suggests a harmful effect, i.e. 
increased mortality, of particular antioxidant supplementation in the general population 
[70]. Our cell culture model can actually help in selecting patients to enroll in such an 
evaluation study. 
 
Antioxidant defense 
ROS have also a central physiological signaling character, inducing antioxidant 
pathways. This was observed by the induction of the Nrf2-Keap1 pathway (chapter 4) 
and the changed gene expression of classic antioxidant genes (SOD1, GPX1, GSR; 
chapter 5) in fibroblasts with increased ROS levels. The Nrf2-Keap1 pathway is one of 
the major redox-sensitive signaling systems in the cell and acts as a molecular sensor 
of disturbances in cellular homeostasis [71]. Activation of Nrf2 signaling was described 
previously in fibroblasts of patients with a mutation in the mitochondrial ATP6 gene [72], 
indicating a potential general therapeutic relevance for OXPHOS diseases. The Nrf2-
Keap1 pathway has been mentioned before as a therapeutic target for neurovascular 
protection in stroke [73] and has been shown to ameliorate neurodegenerative 
phenotypes in a Drosophila model of Parkinson’s disease [74]. However, care should 
be taken when stimulating this pathway since deregulation of the Nrf2-Keap1 system 
has been implicated in carcinogenesis [75]. The consequences of modulating Nrf2, but 
preferentially also of more specific downstream targets can be evaluated using the cell 
culture models described in this thesis before translating it to animal models and 
eventually human patients. 
 
Whereas the effectiveness of activation of the antioxidant system against the 
accumulation of oxidative damage has been shown in chapter 5, increasing antioxidant 
defenses can be detrimental for other cellular functions. This was shown by the 
preferential expression of selenoproteins involved in (oxidative) stress reduction 
(thioredoxins, SelK) which probably led to decreased expression of multiple other 
selenoproteins (chapter 4). Some of these proteins have been associated with the 
control of calcium fluxes (e.g. SelN, SelK, SelM) [76-78]. The decreased gene 
expression of these proteins in our analysis provides a new hypothesis for the 
decreased calcium fluxes measured previously in the studied patient cell lines [28, 29]. 
In these studies, decreased endoplasmic reticulum (ER) calcium content and slower 
calcium removal from the cytosol were observed [28]. Apart from the hypothesized role 
of decreased ATP delivery [28], the associations of SelN [77] and SelK [78] with the ER 
membrane and its receptors point to a contribution of selenoproteins to the disturbed 
calcium homeostasis. Furthermore, the expression of selenoproteins is dependent on 
the cellular selenium status [79] and therefore, monitoring and adjusting selenium 
levels might eventually prove to be a new therapeutic lead for CI deficient patients. The 
beneficial effect of selenium has also been reported for mtDNA defects [48] and 
therefore, this pathway is probably implicated in OXPHOS defects in more general. 
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Apoptosis 
The process of programmed cell death, or apoptosis, plays an important role in the 
regulation of normal cell populations and focal apoptosis is involved in many normal 
embryonic processes such as the development of organs and digits [80]. However, 
when apoptosis is triggered abnormally in post-mitotic tissues, the functionality of those 
tissues might become compromised. When antioxidant systems fail and cellular 
(oxidative) damage is beyond repair, apoptosis is often triggered. This was observed in 
liver and brain, the most affected tissues, of patients with POLG1 mutations (chapter 
3). Therefore, loss of non-replaceable cells by apoptosis can be regarded as a marker 
of disease severity and/or progression in POLG1 pathogenesis and possibly in other 
OXPHOS diseases [81]. 
 
 
Therapeutic considerations 
 
As a consequence of the extreme clinical, biochemical and genetic diversity in patients, 
it is unlikely that one single therapy could treat all OXPHOS diseases [82]. The current 
rationale is that slightly increasing compromised OXPHOS activity above a certain 
threshold may already be beneficial, even if you stimulate a dysfunctional system. 
Stimulation of mitochondrial biogenesis by for example controlled exercise training is 
currently suggested as a general approach in patients with OXPHOS disease [83]. 
Although the initial feeling might be that rest is better for an already compromised 
muscle, controlled training has been shown to induce muscle regeneration in patients 
with mtDNA disease from satellite cells with generally lower mutation levels, to 
maximize muscle function and to prevent disuse atrophy [83, 84]. Nevertheless, 
additional, more specific treatments will be required for patients in a form of 
‘personalized medicine’. Pathological processes should be characterized in each 
OXPHOS patient, leading to a patient profile that indicates which treatment(s) best 
suit(s) that patient. For example, antioxidants should only be administered to patients 
that really suffer from oxidative damage and would therefore benefit from this kind of 
therapy. Additionally, when drugs are administered to patients, it should be proven that 
the drug reaches the affected tissue(s). For most organs (liver, muscle), this usually 
does not seem to be a problem, but when the brain is involved, the capacity of a drug to 
penetrate the blood brain barrier must be considered. Exogenous antioxidants of 
varying chemical structures have been investigated, but most of them poorly cross the 
blood brain barrier [85]. In this thesis, a standardized and extensive cell line panel has 
been developed for fast and large-scale screening of compounds (new chemical 
substances as well as known nutritional supplements) with therapeutic potential in 
OXPHOS disorders. Default parameters have been documented extensively to 
evaluate the effect of the candidate compounds reliably and in detail. Furthermore, 
monitoring the amount of oxidative (protein) damage and/or apoptosis have been 
pointed out as valuable markers in OXPHOS pathology and can possibly also be 
considered to assess the effect of compounds on disease outcome. 
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Therapeutic approaches 
 
Current therapy approaches are based on specific treatment of particular mitochondrial 
diseases, treatment of symptoms of mitochondrial disease, (prevention by) exercise 
therapy and inhibition of ROS damage and prevention of germline transmission as 
explained below. Specific treatments include CoQ10 replacement therapy for patients 
with CABC1 [38] or ETFDH [39] mutation, L-arginine supplementation in MELAS 
patients [86, 87] and peritoneal dialysis or allogeneic hematopoietic stem cell 
transplantation in patients with TYMP mutations and mitochondrial 
neurogastrointestinal encephalomyopathy [MNGIE] [88]. Furthermore, more than a 
decade ago, riboflavin supplementation has been shown to be beneficial for certain 
patients with complex I deficiency by Scholte et al [89], while recently the genetic basis 
for this finding (ACAD9 mutation) has been elucidated in these patients [59]. Although 
not proven, it is striking that untreated patients with ACAD9 mutations die at young age 
of cardiomyopathies [90, 91].  
 
Symptomatic therapy 
Current symptomatic pharmacological therapy includes, amongst others, sodium 
bicarbonate and dichloroacetate for lactic acidosis, anticonvulsants for epileptic 
seizures and beta blockers for cardiomyopathy [84, 92]. Despite that the effectiveness 
is not clear for most compounds, various treatment cocktails of vitamins and cofactors 
(e.g. riboflavin, thiamine, folic acid, L-carnitine, creatine monohydrate and idebenone) 
are administrated to patients with OXPHOS disease because they are presumed 
harmless [93]. Non-pharmacological treatment options include organ transplantation 
(e.g. kidney or heart with single organ involvement), corrective ptosis surgery, 
gastrostomy and deep brain stimulation [84].  
 
Prevention of transmission 
Instead of treating the disease itself, one might also choose for the prevention of 
mtDNA disease segregation in families. A number of approaches currently available are 
prenatal diagnosis using chorionic villus sampling, preimplantation genetic diagnosis 
(PGD), or nuclear transfer, which is still in the experimental phase [94]. Prenatal 
diagnosis (PND) is applicable for nuclear gene defects. For mtDNA disease this is not 
reliable, as the clinical severity of the phenotype after birth cannot reliably be predicted 
for most mtDNA mutations, based on the mutation percentage in chorionic villus [95]. At 
present, PGD is the better alternative for carriers of heteroplasmic mtDNA mutations 
[95]. In PGD, embryos are generated by in vitro fertilization and tested for the 
mitochondrial DNA mutations. Only the embryos with low or undetectable amounts of 
mutant DNA are transferred to the uterus, which unlike PND, avoids the dilemma of 
pregnancy termination. Although it cannot guarantee that a child will be unaffected, 
PGD aims at reducing the risk of having an affected child [95]. Because of this 
suboptimal testing, a number of ethical questions have arisen on the selection of 
embryos, the setting of safe margins for mtDNA mutations and the wishes of the 
parents [96]. In the future, nuclear transfer might be promising. This involves the fusion 
of a nucleus from a fertilized oocyte with an enucleated donor oocyte. Although recent 
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studies have shown the feasibility hereof in apes in vivo [97] and in humans in vitro [94, 
98], the technique is still experimental, implies many unknowns (e.g. the effect on 
nucleo-mitochondrial interactions) and brings about even more ethical issues [99]. 
 
Gene therapy 
In the last decade, a number of approaches in gene therapy, especially for long-term 
treatment of mtDNA related OXPHOS disorders, have been explored [93]. One strategy 
focuses on introducing a wild type copy of the mutated mitochondrial gene into the 
nucleus, translating the protein in the cytosol and importing normal copies of the protein 
into the mitochondria (allotopic expression). Although elegant, this method involves 
some obstacles to overcome. The protein has to be targeted to the mitochondria (by 
adding a targeting signal), imported into the mitochondria and assembled into a multi-
subunit complex. In addition, translation in the cytosol requires the use of the standard 
genetic code instead of the mitochondrial code [100]. Some successes have been 
reported with the NARP m.T8993G mutation in ATP6, the LHON mutations m.G3460A 
and m.G11778A in ND1 and ND4 respectively and the MERRF m.A8344G mutation in 
tRNALys [101-103]. Allotopic expression of the wild type genes in cybrid cell lines or 
patient fibroblasts carrying the (nearly, >95%) homoplasmic mutations (partially) 
rescued the biochemical defect [101-103]. Another promising long-term therapy is to 
selectively inhibit replication of mutant mtDNA molecules (antigenomic therapy). The 
challenge is to find an agent that discriminates between wild type and mutant mtDNA, 
that can be imported into the mitochondria and binds the mutant mtDNA irreversibly to 
prevent its release when natural replication is occurring [100]. In vitro experiments with 
peptide nucleic acids showed their ability to selectively inhibit replication of the 
m.A8344G MERRF mutant mtDNA [104]. However, problems related with the import of 
the antigenomic molecules into the mitochondria still have to be resolved [100]. So far, 
these approaches have only been tested in vitro. Due to the current lack of pathogenic 
heteroplasmic mtDNA mouse models, further development and translation to human 
patients will not be for the near future [105]. 
 
Even though few OXPHOS disorders can be treated because of a specific metabolic 
defect inherent to a certain mutation, most cannot. The phenotypic diversity of patients 
with the same genetic defect and the genetic heterogeneity of patients with the same 
syndrome or symptoms emphasize that therapy is better not based on the patients’ 
phenotype and/or genotype but on the molecular pathways, some of which are 
described in this thesis that are triggered or changed in the patients’ tissues. Therefore, 
the future strategy would be to systematically monitor key pathways in tissues of 
OXPHOS patients, irrespective of their genetic or biochemical diagnosis, and from this 
build a personal therapy plan to optimize the treatment effect and reduce the amount of 
ineffective medication. 
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Mitochondrial disorders are often fatal multisystem disorders or syndromes, associated 
with abnormalities of the terminal component of mitochondrial energy metabolism, i.e. 
oxidative phosphorylation (OXPHOS). These diseases mainly manifest in tissues with 
high energy demands such as the heart, brain, liver and muscle and are further referred 
to as OXPHOS disorders. It is estimated that OXPHOS disorders affect about 1 in 5000 
individuals. The OXPHOS system is responsible for cellular aerobic energy production 
and its subunits are encoded by over 80 genes of which 37 are located in the 
mitochondrial DNA (mtDNA). However, more than 1000 nuclear DNA (nDNA) genes 
are involved OXPHOS function, assembly and maintenance. Accordingly, mutations in 
the mtDNA or nDNA genes encoding structural OXPHOS elements or nDNA encoded 
factors involved in the maintenance or assembly often lead to OXPHOS disorders. The 
extreme genetic and phenotypic heterogeneity and the lack of consistent genotype-
phenotype correlations complicate genetic testing of these disorders. Moreover, the 
underlying pathological mechanisms of these diseases are only partly understood and 
there is a lack of efficient therapies. The aim of this thesis is to create and evaluate 
models and approaches to facilitate diagnostics of mtDNA-based OXPHOS disorders, 
study OXPHOS pathophysiology and as a consequence identify new potential targets 
for therapeutic interventions. In that respect, mitochondrial DNA resequencing chips 
(chapter 2), microarray gene expression profiling (chapter 3 and 4) and a set of 
oxidative stress markers (chapter 5) have been applied to obtain new information on 
the distribution of mtDNA variation in the general population and pathological and/or 
adaptive processes involved in OXPHOS disease, respectively. Chapter 6 discusses 
the validity and relevance of the different models for the study of OXPHOS disorders. 
 
Evaluating pathogenicity of new unclassified variants identified in patients with 
symptoms related to OXPHOS disorders is not straightforward. Improved insight in the 
presence, tolerance, negative selection and consequences of mtDNA variation in the 
human population will give valuable information for the diagnostic classification of these 
mtDNA variants. In chapter 2, the mtDNA of 730 subjects was resequenced and 
compared with the revised reference sequence. The locations of non-pathogenic 
variants identified in this study and known pathogenic mtDNA mutations were 
evaluated in terms of functional importance and conservation. For the non-pathogenic 
variation, there was a preferential selection against variants in protein coding genes 
with high sequence conservation. Also for tRNA genes, neutral variants and pathogenic 
mutations showed differences in functional location (loop or stem) and sequence or 
base pair conservation. Thus, evaluating the conservation and functional importance of 
a newly identified variant remain the most important parameters. It can be expected 
that this approach combined with the data generated by next generation sequencing 
will lead to a detailed map of all variants ever detected, both for the mitochondrial and 
nuclear DNA. 
 
When a genetic diagnosis for an OXPHOS disorder is established, the pathogenic 
process has to be unraveled in order to determine cause and mechanism of the 
disease symptoms for proper prognosis and to explore potential therapeutic strategies. 
For pathophysiological studies, affected tissues from patients would allow the most 
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relevant and specific disease processes to be identified. However, for diseases 
affecting non-dividing tissues (e.g. brain), the availability and amount of material is 
obviously limited. Therefore, model systems such as other patient derived tissues (e.g. 
muscle biopsies, fibroblasts) can be used. Even though these tissues might be less or 
not affected in OXPHOS patients, they can still provide clues for pathological processes 
in other affected tissues. 
 
To identify new biomarkers or potential therapeutic targets, whole genome gene 
expression profiling and pathway analysis have been applied to explore the underlying 
molecular processes in patients with POLG1 mutations and patients with complex I (CI) 
deficiency, the largest patient groups with mitochondrial disease. DNA polymerase 
gamma (pol Ȗ; POLG1 gene) is the only DNA polymerase involved in maintenance of 
the mtDNA. POLG1 mutations have been reported to cause a broad variety of 
phenotypes involving hepatopathy usually early in life, isolated myopathy in older 
individuals or brain abnormalities at any age. The correlation between genotype and 
phenotype in patients with POLG1 mutations is sometimes tight but more often 
variable. In chapter 3, skeletal muscle from patients with mutations in the POLG1 gene 
was used as a model for pathological changes in liver and brain. The majority of these 
patients exhibited subtle morphological skeletal muscle changes and gene expression 
analysis mainly pointed to an energy metabolism switch (decreased beta oxidation, 
increased coupling of electron transfer and ATP production) and hinted towards 
changes in oxidative stress and apoptosis. The latter increased processes were further 
validated in fibroblast cultures, liver and brain and were shown to be increased in part 
of the patients. Ultimately, this study revealed the involvement of these processes in 
the pathology of at least part of human POLG1 patients for the first time and 
emphasizes the previously described heterogeneity in this patient group, requesting an 
individual-based approach. In chapter 4, primary fibroblast cultures of CI deficient 
patients with a nuclear mutation were used as a model to study pathology. CI 
deficiency is the most frequently encountered defect in mitochondrial energy 
metabolism and is associated with e.g. Leigh and LHON disease, fatal infantile 
acidosis, neonatal cardiomyopathy with lactic acidosis, leucodystrophy with 
macrocephaly and hepatopathy with renal tubulopathy. Although children usually have 
a normal prenatal development, symptoms start occurring during their first year of life 
after which the disease deteriorates rapidly and may become fatal. Because fibroblasts 
primarily (~70%) produce ATP by glycolysis, fibroblasts were experimentally stimulated 
to use OXPHOS (and express the defect) by culturing them without glucose in the 
presence of galactose. Whole genome expression profiling showed that patient 
fibroblasts responded to oxidative stress by Nrf2-mediated induction of the glutathione 
antioxidant system and Gadd45-mediated activation of the DNA damage response 
pathway. Furthermore, the observed reduced expression of selenoproteins could 
explain the disturbed calcium homeostasis previously described for the patient 
fibroblasts and might be linked to endoplasmic reticulum stress. These results indicate 
that both glutathione and selenium metabolism are potentially therapeutic targets in CI 
deficiency.  
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Oxidative stress was observed in both the POLG1 and CI deficiency models (chapter 3 
and 4) and has been implicated to play a role in OXPHOS disorders in literature. 
However, most studies did not report on the full spectrum of ROS levels, ROS 
detoxification (antioxidant status) and oxidative damage. Nevertheless, OXPHOS 
patients are often supplemented with antioxidants, even though their efficacy is highly 
anecdotic. Therefore, a pipe-line for the characterization of ROS levels, stress induced 
(antioxidant) gene expression and oxidative protein damage in fibroblasts was 
established (chapter 5). Using this approach, the level of oxidative stress in fibroblasts 
of three different patient groups (POLG1 patients and patients with mtDNA tRNA-Leu or 
CI mutations) was compared. Whereas almost all cell lines showed increased ROS 
levels compared with wild type fibroblasts, only few concomitantly exhibited increased 
oxidative protein damage. The absence of oxidative damage in the other cell lines 
could partially be explained by increased stress-related (antioxidant) gene expression. 
Even though fibroblasts are better able to adapt to a genetic or biochemical defect than 
severely affected post-mitotic tissues, the current study demonstrated the ability to 
measure altered ROS levels and oxidative damage in these cells. Therefore, the 
fibroblast model provides an indication for the oxidative status of a patient and 
information on which adaptive processes are therapeutically relevant. The 
characterized fibroblasts models in chapter 4 and 5 can also be used for high-
throughput screening of potentially beneficial compounds using the same read-out 
parameter, as used for establishing the pathophysiological processes.  
 
In this thesis, models and methodologies have been developed for the improvement of 
diagnostics, prognostics, understanding and therapy of specific OXPHOS disorders, for 
which the genetic defect was known. Comparable models can be established for other 
OXPHOS disorders as well, applying the same methodologies. However, as discussed 
in chapter 6, no single model system can cover every aspect from the identification of 
pathological processes to the screening of therapeutic compounds. Our in vitro data 
based on patient material should be validated and followed-up in more advanced 
(animal) models before eventually translating them into patient care. 
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Mitochondriële afwijkingen zijn vaak dodelijke afwijkingen of syndromen in meerdere 
organen die geassocieerd zijn met abnormaliteiten van de laatste component van het 
mitochondriële energiemetabolisme, oxidatieve fosforylering (OXPHOS). Deze ziekten 
treffen voornamelijk weefsels met een hoge energiebehoefte zoals het hart, de 
hersenen, de lever en spier. Dezen zullen verder OXPHOS ziekten genoemd worden. 
Naar schatting wordt 1 op 5000 individuen getroffen door een OXPHOS ziekte. Het 
OXPHOS systeem is verantwoordelijk voor de cellulaire aërobe energie productie en 
de afzonderlijke subeenheden worden door meer dan 80 genen gecodeerd waarvan er 
37 gelegen zijn in het mitochondrieel DNA (mtDNA). Er zijn echter meer dan 1000 
genen in het nucleaire DNA (nDNA) betrokken bij OXPHOS functie, assemblage en 
onderhoud. Daarom leiden mutaties in mtDNA of nDNA genen die coderen voor 
structurele OXPHOS elementen of in nDNA gecodeerde factoren betrokken bij 
OXPHOS onderhoud en de assemblage vaak tot OXPHOS ziekten. De extreme 
genetische en fenotypische heterogeniteit en het gebrek aan consistente genotype-
fenotype correlaties maken het genetische testen van deze ziekten complex. Verder 
wordt het onderliggende pathologische mechanisme slechts gedeeltelijk begrepen en is 
er een gebrek aan efficiënte therapieën. Het doel van deze thesis is de creatie en 
evaluatie van modellen en strategieën om de diagnostiek van mtDNA-gebaseerde 
OXPHOS ziekten makkelijker te maken, de pathofysiologie van OXHPOS ziekten te 
bestuderen en bijgevolg nieuwe potentiële doelen voor therapie te identificeren. 
Daarom werden mtDNA resequencing chips  (hoofdstuk 2), microarray genexpressie 
analyse (hoofdstuk 3 en 4) en een set van oxidatieve stress merkers (hoofdstuk 5) 
ingezet om nieuwe informatie te verkrijgen over de verdeling van mtDNA variatie in de 
normale populatie en over de pathologische en/of adaptieve processen betrokken bij 
OXPHOS ziekten. Hoofdstuk 6 bediscussieert de validiteit en de relevantie van de 
verschillende modellen voor het bestuderen van OXPHOS ziekten. 
 
De evaluatie van de pathogeniciteit van nieuwe ongeclassificeerde varianten in 
patiënten met symptomen gerelateerd aan OXPHOS ziekten is niet eenvoudig. Een 
verbeterd inzicht in de aanwezigheid van, de tolerantie van, negatieve selectie tegen en 
de gevolgen van mtDNA variatie in de menselijke populatie zal waardevolle informatie 
verschaffen voor de diagnostische classificatie van deze mtDNA varianten. In 
hoofdstuk 2 werd het mtDNA van 730 individuen geanalyseerd en vergeleken met de 
gereviseerde referentiesequentie. De locatie van niet-pathogene varianten die 
geïdentificeerd werden in deze studie en bekende pathogene mutaties werd 
geëvalueerd met betrekking tot functioneel belang en conservering. Voor de niet-
pathogene variatie was er een preferentiële selectie tegen varianten in eiwitcoderende 
genen met een sterke conservering. Ook voor de tRNA genen toonden de neutrale 
varianten en pathogene mutaties verschillen in functionele locatie (loop of stam) en 
sequentie of basenpaar conservering. Dus, de evaluatie van de conservering en het 
functionele effect van een nieuw geïdentificeerde variant blijven de meest belangrijke 
parameters. Verwacht wordt dat deze aanpak, in combinatie met de data van next 
generation seqeuncing, zal leiden tot een gedetailleerde kaart van alle varianten die 
ooit gedetecteerd werden, zowel voor het mitochondriële als het nucleaire DNA. 
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Wanneer er een genetische diagnose voor een OXPHOS ziekte is, moet het pathogene 
process nog ontrafeld worden om de oorzaak en het mechanisme dat leidt tot de 
symptomen te bepalen zodat de juiste prognose en het onderzoeken van mogelijke 
therapieën mogelijk is. Voor pathofysiologische studies, zouden de aangedane 
weefsels van patiënten toelaten de meest relevante en specifieke processen te 
identificeren. Echter, voor aandoeningen van niet-delende weefsels (bijvoorbeeld 
hersenen) is de beschikbaarheid en hoeveelheid van materiaal beperkt. Daarom 
kunnen modelsystemen zoals andere weefsels (bijvoorbeeld spierbiopsies, 
fibroblasten) van de patiënten gebruikt worden. Hoewel deze weefsels minder of niet 
aangedaan kunnen zijn in OXPHOS patiënten, kunnen ze nog steeds aanwijzingen 
voor pathologische processen in andere aangedane weefsels opleveren. 
 
Genexpressie-analyse van het volledige genoom en process-gebaseerde analyse 
werden toegepast om de onderliggende moleculaire processen in patiënten met 
POLG1 mutaties en patiënten met complex I (CI) deficiëntie te bestuderen en mogelijk 
nieuwe biomerkers of potentiële therapeutische doelwitten te identificeren. DNA 
polymerase gamma (pol Ȗ; POLG1 gen) is het enige DNA polymerase dat betrokken is 
bij het onderhoud van het mtDNA. POLG1 mutaties veroorzaken een brede waaier aan 
fenotypes inclusief hepatopathie op jonge leeftijd, geïsoleerde myopathie in oudere 
individuen en hersenafwijkingen op elke leeftijd. De correlatie tussen genotype en 
fenotype in patiënten met POLG1 mutaties is soms eenduidig maar meestal variabel. In 
hoofdstuk 3 werd skeletspier van patiënten met mutaties in het POLG1 gen gebruikt 
als model voor pathologische veranderingen in lever en hersenen. De meerderheid van 
deze patiënten hadden subtiele morfologische skeletspier veranderingen. 
Genexpressie-analyse wees voornamelijk op een omschakeling van het energie 
metabolisme (vermindere beta oxidatie, versterkte koppeling van elektronentransport 
en ATP productie) en suggereerde veranderingen in oxidatieve stress en apoptose. 
Deze laatste processen werden verder gevalideerd in fibroblastkweken, lever en 
hersenen en bleken verhoogd te zijn in een gedeelte van de patiënten. Uiteindelijk 
heeft deze studie voor het eerst aangetoond dat deze processen betrokken zijn bij de 
pathologie van minstens een gedeelte van de humane POLG1 patiënten. Voorts wordt 
de eerder beschreven heterogeniteit van deze patiëntengroep en de nood aan een 
individuele aanpak nogmaals benadrukt. 
In hoofdstuk 4 werden primaire fibroblast kweken van CI deficiënte patiënten met een 
nucleaire mutatie gebruikt als model om CI pathologie te bestuderen. CI deficiëntie is 
het meeste frequente defect in mitochondrieel energie metabolisme en is geassocieerd 
met bvb. Leigh en LHON ziekte, fatale infantiele acidose, neonatale cardiomyopathie 
met lactaat acidose, leukodystrofie met macrocefalie en hepatopathie met renale 
tubulopathie. Hoewel kinderen meestal een normale prenate ontwikkeling doormaken, 
beginnen de eerste symptomen te verschijnen tijdens hun eerste levensjaar waarna de 
ziekte snel verergert en tot overlijden kan leiden. Omdat fibroblasten voornamelijk 
(~70%) ATP produceren via glycolyse, werden de fibroblasten experimenteel 
gestimuleerd om OXPHOS te gebuiken (en het defect tot expressie te brengen) door 
hen te kweken zonder glucose in aanwezigheid van galactose. Genexpressie-analyse 
van het volledige genoom toonde aan dat patiëntfibroblasten op oxidatieve stress 
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reageerden door Nrf2-gemedieerde inductie van het glutathion antioxidant systeem en 
Gadd45-gemedieerde activatie van de DNA schade respons. Verder kan de ge-
observeerde verminderde expressie van seleno-eiwitten de eerder beschreven 
verstoorde calcium homeostase in deze patiënten fibroblasten verklaren en kan dit ook 
gelinkt zijn aan endoplasmatisch reticulum stress. Deze resultaten tonen aan dat zowel 
glutathion als selenium metabolisme potentiële therapeutische kandidaten zijn bij CI 
deficiëntie. 
Oxidatieve stress werd in beide (POLG1 en CI deficiëntie) modellen geobserveerd en 
wordt ook in de literatuur genoemd als een speler in OXPHOS ziekten. De meeste 
studies rapporteerden echter niet over het volledige spectrum van reactieve zuurstof 
soorten (ROS) niveaus, ROS detoxificatie (antioxidant status) en oxidatieve schade. 
Desalniettemin krijgen OXPHOS patiënten vaak antioxidant supplementen, ook al is 
hun efficiëntie sterk anecdotisch. Daarom werd een pijplijn opgezet voor de 
characterisatie van ROS niveaus, stress geïnduceerde (antioxidant) genexpressie en 
oxidatieve eiwit schade in fibroblasten (hoofdstuk 5). Met deze aanpak werd de mate 
van oxidatieve stress in fibroblasten van drie verschillende patiënten groepen (POLG1 
patiënten en patiënten met mtDNA tRNA-Leu of CI mutaties) vergeleken. Hoewel bijna 
alle cellijnen verhoogde ROS niveaus vertoonden vergeleken met controle fibroblasten, 
waren er slechts enkele met verhoogde oxidatieve eiwitschade. De afwezigheid van 
oxidatieve schade in de andere cellijnen kon gedeeltelijk verklaard worden door 
verhoogde stress-gerelateerde (antioxidant) genexpressie. Ook al zijn fibroblasten 
beter in staat om zich aan te passen aan een genetisch of biochemisch defect dan 
ernstig aangedane post-mitotische weefsel, de huidige studie laat zien dat het mogelijk 
is verhoogde ROS niveaus en oxidatieve schade in de cellen te meten. Daarom geeft 
het fibroblast model een indicatie voor de oxidatieve status van een patiënt en tevens 
ook informatie over welke adaptieve processen mogelijk van therapeutisch belang 
kunnen zijn. De gekarakteriseerde fibroblastmodellen in hoofdstuk 4 en 5 kunnen 
voorts ook gebruikt worden voor het high throughput screenen van potentiële 
therapeutische stoffen, gebruik makend van dezelfde uitleesparameters als voor de 
studie van de pathofysiologische processen. 
   
In deze thesis werden modellen en methods ontwikkeld voor de verbetering van 
diagnose, prognose, het begrip en de therapie van specifieke OXPHOS ziekten 
waarvoor het genetisch defect gekend was. Vergelijkbare modellen kunnen ook 
opgezet worden andere OXPHOS ziekten. Echter, zoals aangehaald in hoofdstuk 6, 
zal geen enkel modelsysteem in staat zijn om elk aspect, van de identificatie van de 
pathologische processen tot de screening van therapeutische stoffen, te omvatten. 
Onze in vitro data, gebaseerd op patiëntenmateriaal, moet daarom ook gevalideerd en 
opgevolgd worden in meer geavanceerde (dier)modellen voordat ze vertaald kan 
worden naar patiëntenzorg. 
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Is het dan eindelijk zover? Ik kan het bijna niet geloven... mijn boekje is klaar! En dat na 
5 jaar die parodoxaal soms traag en soms snel leken om te vliegen. Natuurlijk werd ik 
gedurende deze tijd bijgestaan, geholpen, vermaakt... door een hele hoop mensen die 
ik hieronder wat uitgebreider wil bedanken. Ik zal me voor het grotendeels Nederlandse 
publiek alvast verontschuldigen voor de Vlaamse termen die hieronder wel eens de 
revue zouden kunnen passeren en andersom natuurlijk ook -. 
 
Eerst en vooral wil ik Bert bedanken. Simpelweg, zonder jou zou dit boekje er niet zijn. 
Dank je dat je me de kans gegeven hebt om deze ervaringen op te doen. Als mijn 
promotor, en tevens enige begeleider, zorgde je ervoor dat ik de rode draad in het 
verhaal niet kwijt raakte. Op momenten dat ik wel eens minder gemotiveerd was, wist je 
toch weer de juiste dingen te zeggen. Van jou heb ik verder geleerd dat je in Nederland 
een mail begint met ‘Beste’ en eindigt met ‘Groeten’ (wat in jouw mails – zelfs héle 
korte – zelden tot nooit ontbreekt) in plaats van het Vlaamse ‘Geachte’ en ‘Met 
vriendelijke groet’. Ik vond het ook heel fijn dat ik over alles open met je kon praten, 
zowel de leuke als de minder leuke dingen. 
Volgende in rij is René. Dankjewel dat je mijn co-promotor wilde zijn. Ondanks dat 
Rotterdam en Maastricht ver van elkaar liggen, stond je altijd klaar om te helpen als dat 
mogelijk was. Ik vergeet nooit dat je ons (Auke, jij en ik) als 1 groep, met jou in 
Rotterdam en Auke en ik in Maastricht, voorstelde aan anderen tijdens een symposium 
in Nijmegen. Dat geeft wel aan dat de RoMa-mensen een clubje vormen van 
onderzoekers die graag samenwerken.  
 
In Rotterdam zijn er nog meer mensen die ik graag zou willen bedanken: Kees, Rob en 
Wim. Kees, bedankt voor de vele OXPHOS activiteit metingen en dat je me hebt 
ingewijd in de wondere wereld van de biochemie. Rob, jou ken ik het kortst in 
Rotterdam, maar jouw bijdrage aan het POLG verhaal heeft het echt naar een hoger 
niveau gebracht. En Wim, jammer dat we elkaar al een tijd niet meer gezien hebben, 
maar dankjewel voor mijn eerste ervaring met ROS-kleuringen! 
 
Naast Rotterdam en Maastricht heb ik nog een andere stad in Nederland ontdekt: 
Nijmegen. Jan, Be, Merei, Richard, Peter, Werner, John en alle anderen van het IOP 
Genomics project: dank jullie voor de leuke samenwerking! Ik heb echt genoten van de 
halfjaarlijkse projectmeetings en de discussies die daar plaatsvonden (ook al moesten 
we vanuit Maastricht soms wel héél vroeg vertrekken s’ochtends). Merei en Richard, ik 
denk dat het toch nog een mooi verhaal geworden is, niet? De moeite van de vele uren 
celkweek wel waard. Peter, Werner en John, bedankt voor het helpen met de ROS-
metingen en de hartelijke ontvangst voor de paar weken die ik bij jullie in het lab heb 
doorgebracht. 
 
Hoog tijd om even dichter bij huis te komen. De paranimfen: Florence, als voorganger 
heb ik veel van je geleerd, niet enkel wijsheden over het hele AIO-traject/gebeuren 
maar ook dagdagelijkse gebeurtenissen kwamen op de AIO-kamer vaak aan bod. Na 
een half jaartje afwezigheid, was ik blij dat je er toch weer terug bent zodat ik je kon 
lastig vallen met al mijn vragen over promotie/verdediging/paperassen. Maar uiteraard 
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vind ik het gewoon ook leuk om die gelijkgestemde ziel weer in de buurt te hebben! 
Zullen we eens een keertje gaan dansen? -  Gonda, ik heb iedere keer genoten van 
onze reisjes, terrasjes, filmpjes... Hopelijk hebben we binnenkort weer terug wat meer 
tijd om wat vaker af te spreken (met 2 of met 4 aan tafel ;))! Ook jij heel veel succes 
met je promotietraject. Dank jullie wel dat jullie mijn paranimfen wilden zijn! 
 
De andere (oud)-AIO’s/postdocs: Nicole, jij weet als geen ander dat je met mij geen 
grapjes moet uithalen want voordat je het weet ben je carnavalsprinses bij Klinische 
Genetica -; Bianca, jij zorgde ervoor dat ik snel ingewerkt was in het mito/POLG-
wereldje; Lars, Mr. MSN-afkortingen, net gemist op de kamer maar dat betekent niet 
dat we geen leuke carnaval en pinkpop momenten hebben beleefd; Rudy, heeft mijn 
Vlaamse invloed je wat kunnen voorbereiden op je baan in Leuven?; Ruben, Mr. 
Parafilm-fetisj en ‘Harry Potter with the magic wand’, I will keep the pussies, you can 
stick with the balls -; Rita, I’m glad everything returned to normal in the end, good luck 
finishing your thesis; Mike, Mr. Ochtendhumeur, hopelijk geraak je nog een keertje in 
de Alpen, de vakantie was (afgezien van die gips) echt super, succes in Finland!; Auke, 
Mr. Ochtendhumeur 2, als ik nu van voetbal zou houden, was ik altijd up-to-date met 
jou op de kamer... maar ik hou niet van voetbal!!! -; Abhishek, you were here only 
shortly but I learned a lot about the Indian way of life, for example... Indian people can 
appreciate a joke or two (hundred) -; Minh, you only started your PhD training recently, 
good luck and enjoy life in the Netherlands! With lots of spring rolls and Vietnamese 
noodles -. Allemaal heel erg bedankt! Ze zeggen wel eens, gedeelde smart is halve 
smart en gedeelde vreugde is dubbele vreugde. 
 
Niet te vergeten zijn natuurlijk alle andere mensen van de afdeling, zowel in UNS50 als 
in het 3X/Noordgebouw. Rosy, bedankt voor het regelen van allerlei afspraken, 
papierwerk enzovoort; Patrick, thanks for all the analyses, I know they were not always 
straight-forward; Fons, zonder jouw hulp met de SeqC data was ik nu waarschijnlijk nog 
altijd aan het tellen, dankjewel!; Bieke, Erika en Rik, bedankt voor de hulp bij de 
experimenten en labdingen in het algemeen; Torik, Roselie, Wanwisa, Ellen, Iris, 
Frank, Barbie, Bart, Jo, Jos, Marion, Sabine, Miroslav, Rob, Ton en Marij, ik zal de 
afgelopen jaren wel minstens een keer om hulp gevraagd hebben, dank je voor jullie 
tijd. Robin en Kelly, ik vond het heel leuk om jullie als stagiaires te (mogen) begeleiden. 
Bedankt voor jullie inzet en veel succes met jullie verdere loopbaan! 
Alexandra, ik denk dat ik jouw nummer wel het meest van allemaal heb ingetoetst. Voor 
mijn gevoel wist jij gewoon bijna altijd alle antwoorden op mijn vragen. Heel erg 
bedankt! Chantal, Eveline en Debby, jullie horen eveneens tot het mito-clubje en 
konden ook wel eens door mij gespamd worden. Bedankt voor alle hulp!  
 
Eigenlijk is het al een tijdje geleden dat ik mijn echte AIO-periode heb afgesloten. 
Daarom wil ik toch nog even alle ‘nieuwe’ collega’s bij Clinical Genomics en Maastro 
Lab/Clinic willen bedanken voor hun hulp, kennis, collegialiteit en de kansen die ze mij 
de afgelopen maanden gegeven hebben. 
Alle andere co-auteurs die ik nog niet vermeld heb of mensen die ik onbewust vergeten 
ben: heel erg bedankt, thanks a lot, merci beaucoup! 
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De afgelopen jaren draaiden natuurlijk niet enkel om werk. Op de universiteit waren er 
de koffie pauzes. Antoine, jij bent een aantal jaar mijn koffiemaatje geweest, het zullen 
inderdaad wel ettelijke liters geweest zijn alles tesamen. Veel succes met je opleiding 
en niet te vergeten je onmiskenbare observatievermogen, vooral voor vrouwelijk 
schoon - Maar eerlijk gezegd, zonder Papendal had ik je misschien nooit leren 
kennen. Aanbeland in het Arnhemse zou ik toch ook nog de andere mensen willen 
bedanken die die 3 weekjes (over)leefbaar gemaakt hebben: kamergenootjes Hilde en 
Jelly, Kris, Anneleen en Bart, Olivier, en alle anderen... bedankt voor de leuke avonden! 
Erik, ook jij bedankt voor de leuke BBQ’s, PhD parties, borrels... 
Ik heb verder het privilege gehad om ondergedompeld te worden in de karatewereld. 
Sensei Peter (R.I.P.), sensei Ramon en sensei Tamara, ik heb ZO veel van jullie 
geleerd, karate is zoveel meer dan enkel een gevechtssport, het is een manier van 
leven. Jullie club voelt aan als een hele hechte groep vrienden, bijna als een familie. 
Jullie hadden precies in de gaten wanneer ik even een dipje had en konden dan 
precies de juiste woorden gebruiken om dat weer te overwinnen (ja, motiveren en 
oppeppen is een van jullie sterke punten). Samen met alle andere karateka, waaronder 
Charlotte, Irene, Samefko, Vasken... dank jullie wel voor de hele leuke tijd! 
Naast de karateclub was er nog een ander clubje dat ik niet mag vergeten. Meisjes die 
elkaar kennen van de universiteit. Maar kleine meisjes worden groot! Ann, Kim, Katrien 
en Greet, ik vond het echt leuk dat we zijn blijven afspreken, dank jullie voor de 
gezellige momenten. Ook al is het de laatste tijd wat minder geweest door 
omstandigheden, we moeten dit zeker in ere houden! 
Ine, een zoveelste prettig gestoorde Belg in Maastricht. Ach ja, gek zijn doet geen pijn 
he - Het klikte meteen tussen ons en woorden waren vaak niet nodig om duidelijk te 
maken wat we bedoelden. Ook al woon je nu in Washington, ik hoop dat we regelmatig 
contact zullen blijven houden. Dankjewel voor de leuke tijd! 
Lisanne en Dennis: het is echt wel gezellig dat we van het nieuwjaarsetentje een (twee) 
maandelijks evenement hebben kunnen maken. Dank jullie voor de gekke toestanden 
en niet-voor-publicatie foto’s!  
 
Er zijn twee mensen zonder wie dit hele verhaal niet mogelijk was geweest: mama en 
papa. Bedankt dat jullie me de kans gegeven hebben om te gaan studeren en erna nog 
even te blijven plakken totdat ik op mijn eigen benen kon staan. Ook al begrijpen jullie 
waarschijnlijk niet veel van wat er in dit boekje allemaal staat, ik ben jullie heel erg 
dankbaar voor alle wijsheid die jullie mij tot nog toe hebben bijgebracht en alle steun 
die ik aan jullie gehad heb. Hopelijk zijn jullie even trots op mij als ik ben op jullie! Ben, 
grote kleine broer, ook al kwamen we niet altijd even goed overeen, ik weet dat ik toch 
altijd bij je terecht kon/kan als dat nodig was/is. 
 
Als laatste maar zeker niet de minste, Ben(jamin), je hebt me leren kennen in een (voor 
mij) nogal stressvolle periode waarin ik waarschijnlijk niet altijd even veel tijd voor je 
had. Dankjewel voor je geduld en je steun! Nu meer tijd voor ons. 
 
An 
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Biomedische Wetenschappen aan de Universiteit Hasselt/transnationale Universiteit 
Limburg. In 2005 liep ze korte stages bij het Biomedisch Onderzoeksinstituut van de 
Universiteit Hasselt en de afdeling Gezondheidsrisicoanalyse en Toxicologie van de 
Universiteit Maastricht en behaalde ze haar Bachelor diploma met grote 
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Limburg. Haar afstudeerstage bij het Biomedisch Onderzoeksinstituut situeerde zich 
rond het identificeren van nieuwe diagnostische merkers voor Multiple Sclerose en 
leidde tot het behalen van het Master diploma Biomedische Wetenschappen met 
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ADP  adenosine di-phosphate 
AIC  Akaike information criterion 
ATP  adenosine tri-phosphate 
CAT   catalase 
CI  complex I 
COX   cytochrome C oxidase 
D-loop  displacement loop 
DNA  deoxyribonucleic acid 
EM  electron microscopy 
ETC   electron transport chain 
FAD+/FADH2 flavin adenine dinucleotide 
GSEQ  Genechip Sequence Analysis Software (Affymetrix) 
H2O2  hydrogen peroxide 
IHC  immunohistochemistry 
KSS  Kearns Sayre syndrome 
LHON  Leber hereditery optic neuropathy 
LS  Leigh syndrome 
MDS  mitochondrial depletion syndrome 
MELAS mitochondrial encephalomyopathy, lactic acidosis and stroke-like 
episodes 
MERRF myoclonus epilepsy with ragged red fibers 
MNGIE  mitochondrial neurogastrointestinal encephalomyopathy 
mRNA  messenger ribonucleic acid 
mtDNA  mitochondrial DNA 
NAD+/NADH nicotinamide adenine dinucleotide 
NARP  neuropathy, ataxia and retinitis pigmentosa 
nDNA  nuclear DNA 
O2-·  superoxide 
OH·  hydroxyl radical 
OXPHOS oxidative phosphorylation 
PEO  progressive external ophtalmoplegia 
Pol Ȗ  polymerase gamma 
QPCR   quantitative polymerase chain reaction 
rCRS  revised Cambridge Reference Sequence 
ROS   reactive oxygen species 
RRF  ragged red fibers 
rRNA  ribosomal ribonucleic acid 
SDH  succinate dehydrogenase 
SeqC  Sequence Pilot – module C (JSI) 
SOD   superoxide dismutase 
tRNA  transfer ribosomal ribonucleic acid 
VPA  valproic acid 
WC  Watson-Crick 
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Supplementary table 3.1.  Significantly differentially expressed genes in muscle of POLG1 
patients. 
Ensemble ID fc GeneSymbol Description 
ENSG00000130600 0.37 H19 H19, imprinted maternally expressed transcript (non-protein 
coding) 
ENSG00000165312 0.42 OTUD1 OTU domain containing 1 
ENSG00000175567 0.45 UCP2 Uncoupling protein 2 (mitochondrial, proton carrier) 
ENSG00000124588 0.49 NQO2 NAD(P)H dehydrogenase, quinone 2 
ENSG00000129250 0.49 KIF1C Kinesin family member 1C 
ENSG00000169047 0.53 IRS1 Insulin receptor substrate 1 
ENSG00000198925 0.56 ATG9A ATG9 autophagy related 9 homolog A (S. cerevisiae) 
ENSG00000204574 0.56 ABCF1 ATP-binding cassette, sub-family F (GCN20), member 1 
ENSG00000177731 0.56 FLII Flightless I homolog (Drosophila) 
ENSG00000133454 0.56 MYO18B Myosin XVIIIB 
ENSG00000120709 0.56 FAM53C Family with sequence similarity 53, member C 
ENSG00000197905 0.56 TEAD4 TEA domain family member 4 
ENSG00000114999 0.57 TTL Tubulin tyrosine ligase 
ENSG00000108823 0.57 SGCA Sarcoglycan, alpha (50kDa dystrophin-associated glycoprotein) 
ENSG00000103264 0.57 FBXO31 F-box protein 31 
ENSG00000144868 0.58 TMEM108 Transmembrane protein 108 
ENSG00000164068 0.58 RNF123 Ring finger protein 123 
ENSG00000079999 0.58 KEAP1 Kelch-like ECH-associated protein 1 
ENSG00000204463 0.59 BAT3 HLA-B associated transcript 3 
ENSG00000089693 0.59 MLF2 Myeloid leukemia factor 2 
ENSG00000143321 0.60 HDGF Hepatoma-derived growth factor (high-mobility group protein 1-
like) 
ENSG00000148229 0.60 POLE3 Polymerase (DNA directed), epsilon 3 (p17 subunit) 
ENSG00000106070 0.60 GRB10 Growth factor receptor-bound protein 10 
ENSG00000034152 0.60 MAP2K3 Mitogen-activated protein kinase kinase 3 
ENSG00000123700 0.61 KCNJ2 Potassium inwardly-rectifying channel, subfamily J, member 2 
ENSG00000156804 0.61 FBXO32 F-box protein 32 
ENSG00000102935 0.61 ZNF423 Zinc finger protein 423 
ENSG00000129245 0.62 FXR2 Fragile X mental retardation, autosomal homolog 2 
ENSG00000134644 0.62 PUM1 Pumilio homolog 1 (Drosophila) 
ENSG00000141965 0.62 FEM1A Fem-1 homolog a (C. elegans) 
ENSG00000182446 0.62 NPLOC4 Nuclear protein localization 4 homolog (S. cerevisiae) 
ENSG00000111046 0.63 MYF6 Myogenic factor 6 (herculin) 
ENSG00000165916 0.63 PSMC3 Proteasome (prosome, macropain) 26S subunit, ATPase, 3 
ENSG00000197746 0.63 PSAP Prosaposin 
ENSG00000087191 0.63 PSMC5 Proteasome (prosome, macropain) 26S subunit, ATPase, 5 
ENSG00000186350 0.63 RXRA Retinoid X receptor, alpha 
ENSG00000103994 0.63 ZFP106 Zinc finger protein 106 homolog (mouse) 
ENSG00000189091 0.63 SF3B3 Splicing factor 3b, subunit 3, 130kDa 
ENSG00000136247 0.63 ZDHHC4 Zinc finger, DHHC-type containing 4 
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ENSG00000111276 0.63 CDKN1B Cyclin-dependent kinase inhibitor 1B (p27, Kip1) 
ENSG00000112245 0.64 PTP4A1 Protein tyrosine phosphatase type IVA, member 1 
ENSG00000102572 0.64 STK24 Serine/threonine kinase 24 (STE20 homolog, yeast) 
ENSG00000092607 0.64 TBX15 T-box 15 
ENSG00000122971 0.64 ACADS Acyl-Coenzyme A dehydrogenase, C-2 to C-3 short chain 
ENSG00000130749 0.64 CS007_HUMAN Zinc finger CCCH domain-containing protein C19orf7 
ENSG00000182108 0.64 MYLE_HUMAN Protein MYLE (Dexamethasone-induced protein) 
ENSG00000165795 0.65 NDRG2 NDRG family member 2 
ENSG00000107829 0.65 FBXW4 F-box and WD repeat domain containing 4 
ENSG00000036448 0.65 MYOM2 Myomesin (M-protein) 2, 165kDa 
ENSG00000119242 0.65 CCDC92 Coiled-coil domain containing 92 
ENSG00000145901 0.65 TNIP1 TNFAIP3 interacting protein 1 
ENSG00000198954 0.66 KIAA1279 KIAA1279 
ENSG00000179364 0.66 PACS2 Phosphofurin acidic cluster sorting protein 2 
ENSG00000144579 0.66 CTDSP1 CTD (carboxy-terminal domain, RNA polymerase II, polypeptide 
A) small phosphatase 1 
ENSG00000125827 0.66 TXNDC13 Thioredoxin domain-containing protein 13 precursor 
ENSG00000143761 0.66 ARF1 ADP-ribosylation factor 1 
ENSG00000134590 0.66 FAM127A Family with sequence similarity 127, member A 
ENSG00000107372 0.66 ZFAND5 Zinc finger, AN1-type domain 5 
ENSG00000171497 0.66 PPID Peptidylprolyl isomerase D 
ENSG00000159692 0.67 CTBP1 C-terminal binding protein 1 
ENSG00000138668 0.67 HNRPD Heterogeneous nuclear ribonucleoprotein D0 
ENSG00000169564 0.67 PCBP1 Poly(rC) binding protein 1 
ENSG00000095139 0.67 ARCN1 Archain 1 
ENSG00000084463 0.67 WBP11 WW domain binding protein 11 
ENSG00000107959 0.67 PITRM1 Pitrilysin metallopeptidase 1 
ENSG00000115677 0.67 HDLBP High density lipoprotein binding protein 
ENSG00000099942 0.67 CRKL Crk-like protein 
ENSG00000168575 0.67 SLC20A2 Solute carrier family 20 (phosphate transporter), member 2 
ENSG00000173545 0.67 ZNF622 Zinc finger protein 622 
ENSG00000100714 0.67 MTHFD1 Methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 
1, methenyltetrahydrofolate cyclohydrolase, 
formyltetrahydrofolate synthetase 
ENSG00000101400 0.67 SNTA1 Syntrophin, alpha 1 (dystrophin-associated protein A1, 59kDa, 
acidic component) 
ENSG00000123815 0.67 ADCK4 AarF domain containing kinase 4 
ENSG00000159720 0.67 ATP6V0D1 ATPase, H+ transporting, lysosomal 38kDa, V0 subunit d1 
ENSG00000122884 0.67 P4HA1 Prolyl 4-hydroxylase, alpha polypeptide I 
ENSG00000130957 0.67 FBP2 Fructose-1,6-bisphosphatase 2 
ENSG00000182533 0.67 CAV3 Caveolin 3 
ENSG00000185052 0.68 SLC24A3 Solute carrier family 24 (sodium/potassium/calcium exchanger), 
member 3 
ENSG00000078804 0.68 TP53INP2 Tumor protein p53 inducible nuclear protein 2 
ENSG00000160094 0.68 ZNF362 Zinc finger protein 362 
ENSG00000065675 0.68 PRKCQ Protein kinase C, theta 
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ENSG00000096384 0.68 HSP90AB1 Heat shock protein 90kDa alpha (cytosolic), class B member 1 
ENSG00000104341 0.68 LAPTM4B Lysosomal protein transmembrane 4 beta 
ENSG00000197043 0.68 ANXA6 Annexin A6 
ENSG00000204310 0.68 AGPAT1 1-acylglycerol-3-phosphate O-acyltransferase 1 
(lysophosphatidic acid acyltransferase, alpha) 
ENSG00000004142 0.68 POLDIP2 Polymerase (DNA-directed), delta interacting protein 2 
ENSG00000015676 0.68 NUDCD3 NudC domain containing 3 
ENSG00000082641 0.68 NFE2L1 Nuclear factor (erythroid-derived 2)-like 1 
ENSG00000103319 0.68 EEF2K Eukaryotic elongation factor-2 kinase 
ENSG00000065060 0.68 C6orf107 UHRF1-binding protein 1 
ENSG00000107140 0.68 TESK1 Testis-specific kinase 1 
ENSG00000188636 0.69 LDOC1L Leucine zipper, down-regulated in cancer 1-like 
ENSG00000102974 0.69 CTCF CCCTC-binding factor (zinc finger protein) 
ENSG00000164062 0.69 APEH N-acylaminoacyl-peptide hydrolase 
ENSG00000197321 0.69 SVIL Supervillin 
ENSG00000130764 0.69 LRRC47 Leucine rich repeat containing 47 
ENSG00000167182 0.69 SP2 Sp2 transcription factor 
ENSG00000174243 0.69 DDX23 DEAD (Asp-Glu-Ala-Asp) box polypeptide 23 
ENSG00000177728 0.69 KIAA0195 KIAA0195 
ENSG00000007314 0.69 SCN4A Sodium channel, voltage-gated, type IV, alpha subunit 
ENSG00000185909 0.69 KLHDC8B Kelch domain containing 8B 
ENSG00000159346 0.69 ADIPOR1 Adiponectin receptor 1 
ENSG00000109775 0.69 C4orf20 CDNA FLJ11200 fis, clone PLACE1007725 
ENSG00000125304 0.69 TM9SF2 Transmembrane 9 superfamily member 2 
ENSG00000108639 0.69 SYNGR2 Synaptogyrin 2 
ENSG00000078618 0.69 NRD1 Nardilysin (N-arginine dibasic convertase) 
ENSG00000111481 0.69 COPZ1 Coatomer protein complex, subunit zeta 1 
ENSG00000113141 0.69 IK IK cytokine, down-regulator of HLA II 
ENSG00000114853 0.69 ZBTB47 Zinc finger and BTB domain containing 47 
ENSG00000103502 0.69 CDIPT CDP-diacylglycerol--inositol 3-phosphatidyltransferase 
(phosphatidylinositol synthase) 
ENSG00000158828 0.69 PINK1 PTEN induced putative kinase 1 
ENSG00000105968 0.69 H2AFV H2A histone family, member V 
ENSG00000073969 0.69 NSF N-ethylmaleimide-sensitive factor 
ENSG00000134686 0.69 PHC2 Polyhomeotic homolog 2 (Drosophila) 
ENSG00000136891 0.69 TEX10 Testis expressed 10 
ENSG00000090097 0.70 PCBP4 Poly(rC) binding protein 4 
ENSG00000132471 0.70 WBP2 WW domain binding protein 2 
ENSG00000185000 0.70 DGAT1 Diacylglycerol O-acyltransferase 1 
ENSG00000132383 0.70 RPA1 Replication protein A1, 70kDa 
ENSG00000136451 0.70 VEZF1 Vascular endothelial zinc finger 1 
ENSG00000133606 0.70 MKRN1 Makorin ring finger protein 1 
ENSG00000004487 0.70 AOF2 Flavin-containing amine oxidase domain-containing protein 2 
ENSG00000125534 0.70 C20orf149 Chromosome 20 open reading frame 149 
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ENSG00000135624 0.70 CCT7 Chaperonin containing TCP1, subunit 7 (eta) 
ENSG00000161202 0.70 DVL3 Dishevelled, dsh homolog 3 (Drosophila) 
ENSG00000036257 0.70 CUL3 Cullin 3 
ENSG00000103150 0.70 MLYCD Malonyl-CoA decarboxylase 
ENSG00000120438 0.70 TCP1 T-complex 1 
ENSG00000176087 0.70 SLC35A4 Solute carrier family 35, member A4 
ENSG00000156515 0.70 HK1 Hexokinase 1 
ENSG00000180304 0.70 OAZ2 Ornithine decarboxylase antizyme 2 
ENSG00000144028 0.70 ASCC3L1 Activating signal cointegrator 1 complex subunit 3-like 1 
ENSG00000178764 0.70 ZHX2 Zinc fingers and homeoboxes protein 2  
ENSG00000119335 0.70 SET Protein SET (Phosphatase 2A inhibitor I2PP2A) (I-2PP2A)  
ENSG00000141699 0.70 NP_835227.1 NA 
ENSG00000108270 0.70 AATF Apoptosis antagonizing transcription factor 
ENSG00000047249 0.70 ATP6V1H ATPase, H+ transporting, lysosomal 50/57kDa, V1 subunit H 
ENSG00000138363 0.70 ATIC 5-aminoimidazole-4-carboxamide ribonucleotide 
formyltransferase/IMP cyclohydrolase 
ENSG00000163431 0.70 LMOD1 Leiomodin 1 (smooth muscle) 
ENSG00000204619 0.70 PPP1R11 Protein phosphatase 1, regulatory (inhibitor) subunit 11 
ENSG00000114867 0.70 EIF4G1 Eukaryotic translation initiation factor 4 gamma, 1 
ENSG00000126457 0.71 PRMT1 Protein arginine methyltransferase 1 
ENSG00000006125 0.71 AP2B1 Adaptor-related protein complex 2, beta 1 subunit 
ENSG00000104848 0.71 KCNA7 Potassium voltage-gated channel, shaker-related subfamily, 
member 7 
ENSG00000153827 0.71 TRIP12 Thyroid hormone receptor interactor 12 
ENSG00000136813 0.71 KIAA0368 Proteasome-associated protein ECM29 homolog  
ENSG00000162104 0.71 ADCY9 Adenylate cyclase 9 
ENSG00000124299 0.71 PEPD Peptidase D 
ENSG00000177105 0.71 RHOG Ras homolog gene family, member G (rho G) 
ENSG00000111897 0.71 SERINC1 Serine incorporator 1 
ENSG00000177189 0.71 RPS6KA3 Ribosomal protein S6 kinase, 90kDa, polypeptide 3 
ENSG00000185551 0.71 NR2F2 Nuclear receptor subfamily 2, group F, member 2 
ENSG00000108515 0.71 ENO3 Enolase 3 (beta, muscle) 
ENSG00000012822 0.71 CALCOCO1 Calcium binding and coiled-coil domain 1 
ENSG00000078061 0.71 ARAF A-Raf proto-oncogene serine/threonine-protein kinase 
ENSG00000113048 0.71 MRPS27 Mitochondrial ribosomal protein S27 
ENSG00000198676 0.71 Q7Z4H1_HUMAN HBeAg-binding protein 1 
ENSG00000197451 0.72 HNRPAB Heterogeneous nuclear ribonucleoprotein A/B 
ENSG00000065970 0.72 FOXJ2 Forkhead box J2 
ENSG00000077549 0.72 CAPZB Capping protein (actin filament) muscle Z-line, beta 
ENSG00000115806 0.72 GORASP2 Golgi reassembly stacking protein 2, 55kDa 
ENSG00000122203 0.72 KIAA1191 KIAA1191 
ENSG00000188130 0.72 MAPK12 Mitogen-activated protein kinase 12 
ENSG00000188677 0.72 PARVB Parvin, beta 
ENSG00000198837 0.72 DENND4B DENN/MADD domain containing 4B 
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ENSG00000100632 0.72 ERH Enhancer of rudimentary homolog (Drosophila) 
ENSG00000119950 0.72 MXI1 MAX interactor 1 
ENSG00000114544 0.72 SLC41A3 Solute carrier family 41, member 3 
ENSG00000185883 0.72 ATP6V0C ATPase, H+ transporting, lysosomal 16kDa, V0 subunit c 
ENSG00000104812 0.72 GYS1 Glycogen synthase 1 (muscle) 
ENSG00000100109 0.72 TFIP11 Tuftelin interacting protein 11 
ENSG00000100412 0.72 ACO2 Aconitase 2, mitochondrial 
ENSG00000115657 0.72 ABCB6 ATP-binding cassette, sub-family B (MDR/TAP), member 6 
ENSG00000131462 0.72 TUBG1 Tubulin, gamma 1 
ENSG00000115840 0.72 SLC25A12 Solute carrier family 25 (mitochondrial carrier, Aralar), member 
12 
ENSG00000137073 0.72 UBAP2 Ubiquitin associated protein 2 
ENSG00000167671 0.72 UBXD1 UBX domain-containing protein 1 
ENSG00000022840 0.72 RNF10 Ring finger protein 10 
ENSG00000185651 0.73 UBE2L3 Ubiquitin-conjugating enzyme E2L 3 
ENSG00000102225 0.73 PCTK1 PCTAIRE protein kinase 1 
ENSG00000143365 0.73 LRRN6D Nuclear receptor ROR-gamma 
ENSG00000141646 0.73 SMAD4 SMAD family member 4 
ENSG00000102900 0.73 NUP93 Nucleoporin 93kDa 
ENSG00000140718 0.73 NP_001073901.1 NA 
ENSG00000142186 0.73 SCYL1 SCY1-like 1 (S. cerevisiae) 
ENSG00000179262 0.73 RAD23A RAD23 homolog A (S. cerevisiae) 
ENSG00000187446 0.73 CHP1_HUMAN Calcium-binding protein p22 
ENSG00000011007 0.73 TCEB3 Transcription elongation factor B polypeptide 3  
ENSG00000143621 0.73 ILF2 Interleukin enhancer binding factor 2, 45kDa 
ENSG00000169221 0.73 TBC1D10B TBC1 domain family, member 10B 
ENSG00000139990 0.73 WDR22 WD repeat domain 22 
ENSG00000186204 0.73 CYP4F12 Cytochrome P450, family 4, subfamily F, polypeptide 12 
ENSG00000107404 0.73 DVL1L1 Segment polarity protein dishevelled homolog DVL-1  
ENSG00000111652 0.73 COPS7A COP9 constitutive photomorphogenic homolog subunit 7A 
(Arabidopsis) 
ENSG00000112305 0.73 SMAP1 Small ArfGAP 1 
ENSG00000182500 0.73 TMEM142A Calcium release-activated calcium channel protein 1  
ENSG00000144659 0.73 SLC25A38 Solute carrier family 25, member 38 
ENSG00000099821 0.73 POLRMT Polymerase (RNA) mitochondrial (DNA directed) 
ENSG00000204389 0.73 HSPA1A Heat shock 70 kDa protein 1  
ENSG00000099622 0.73 CIRBP Cold inducible RNA binding protein 
ENSG00000100220 0.73 C22orf28 Chromosome 22 open reading frame 28 
ENSG00000130821 0.73 SLC6A8 Solute carrier family 6 (neurotransmitter transporter, creatine), 
member 8 
ENSG00000100347 0.73 SAMM50 Sorting and assembly machinery component 50 homolog (S. 
cerevisiae) 
ENSG00000111540 0.73 RAB5B RAB5B, member RAS oncogene family 
ENSG00000100242 0.73 UNC84B Unc-84 homolog B (C. elegans) 
ENSG00000170153 0.73 RNF150 Ring finger protein 150 
ENSG00000138814 0.74 PPP3CA Protein phosphatase 3 (formerly 2B), catalytic subunit, alpha 
isoform 
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ENSG00000185721 0.74 DRG1 Developmentally regulated GTP binding protein 1 
ENSG00000132716 0.74 WDR42A WD repeat domain 42A 
ENSG00000167986 0.74 DDB1 Damage-specific DNA binding protein 1, 127kDa 
ENSG00000157020 0.74 SEC13 SEC13 homolog (S. cerevisiae) 
ENSG00000102007 0.74 PLP2 Proteolipid protein 2 (colonic epithelium-enriched) 
ENSG00000077522 0.74 ACTN2 Actinin, alpha 2 
ENSG00000126247 0.74 CAPNS1 Calpain, small subunit 1 
ENSG00000092203 0.74 KIAA0737 Epidermal Langerhans cell protein LCP1 
ENSG00000145945 0.74 FAM50B Family with sequence similarity 50, member B 
ENSG00000006704 0.74 GTF2IRD1 GTF2I repeat domain containing 1 
ENSG00000196230 0.74 TUBB Tubulin beta chain  
ENSG00000159069 0.74 FBXW5 F-box and WD repeat domain containing 5 
ENSG00000197081 0.74 IGF2R Insulin-like growth factor 2 receptor 
ENSG00000155189 0.74 AGPAT5 1-acylglycerol-3-phosphate O-acyltransferase 5 
(lysophosphatidic acid acyltransferase, epsilon) 
ENSG00000181929 0.74 PRKAG1 Protein kinase, AMP-activated, gamma 1 non-catalytic subunit 
ENSG00000062485 0.74 CS Citrate synthase 
ENSG00000179889 0.74 NP_055842.1 NA 
ENSG00000164024 0.74 METAP1 Methionyl aminopeptidase 1 
ENSG00000087365 0.74 SF3B2 Splicing factor 3b, subunit 2, 145kDa 
ENSG00000162413 0.74 KLHL21 Kelch-like 21 (Drosophila) 
ENSG00000129116 0.74 PALLD Palladin, cytoskeletal associated protein 
ENSG00000006757 0.74 PNPLA4 Patatin-like phospholipase domain containing 4 
ENSG00000187555 0.74 USP7 Ubiquitin specific peptidase 7 (herpes virus-associated) 
ENSG00000013455 0.74 ARPC1A Actin related protein 2/3 complex, subunit 1A, 41kDa 
ENSG00000123992 0.74 DNPEP Aspartyl aminopeptidase 
ENSG00000049245 0.74 VAMP3 Vesicle-associated membrane protein 3 (cellubrevin) 
ENSG00000124422 0.74 USP22 Ubiquitin specific peptidase 22 
ENSG00000143870 0.74 PDIA6 Protein disulfide isomerase family A, member 6 
ENSG00000184007 0.75 PTP4A2 Protein tyrosine phosphatase type IVA, member 2 
ENSG00000186187 0.75 ZNRF1 Zinc and ring finger 1 
ENSG00000100462 0.75 PRMT5 Protein arginine methyltransferase 5 
ENSG00000168610 0.75 STAT3 Signal transducer and activator of transcription 3 (acute-phase 
response factor) 
ENSG00000166974 0.75 MAPRE2 Microtubule-associated protein, RP/EB family, member 2 
ENSG00000079246 0.75 XRCC5 X-ray repair complementing defective repair in Chinese 
hamster cells 5 (double-strand-break rejoining) 
ENSG00000013374 0.75 NUB1 Negative regulator of ubiquitin-like proteins 1 
ENSG00000124214 0.75 STAU1 Staufen, RNA binding protein, homolog 1 (Drosophila) 
ENSG00000197170 0.75 PSMD12 Proteasome (prosome, macropain) 26S subunit, non-ATPase, 
12 
ENSG00000110025 0.75 SNX15 Sorting nexin 15 
ENSG00000166685 0.75 COG1 Component of oligomeric golgi complex 1 
ENSG00000135424 0.75 ITGA7 Integrin alpha-7 precursor  
ENSG00000183386 0.75 FHL3 Four and a half LIM domains 3 
ENSG00000095637 0.75 SORBS1 Sorbin and SH3 domain containing 1 
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ENSG00000175806 0.75 MSRA Methionine sulfoxide reductase A 
ENSG00000169184 0.75  NA 
ENSG00000180900 0.75 SCRIB Scribbled homolog (Drosophila) 
ENSG00000126368 0.75 NR1D1 Nuclear receptor subfamily 1, group D, member 1 
ENSG00000115525 0.75 ST3GAL5 ST3 beta-galactoside alpha-2,3-sialyltransferase 5 
ENSG00000151327 0.75 C14orf24 NA 
ENSG00000146457 0.75 WTAP Wilms' tumor 1-associating protein  
ENSG00000175591 0.75 P2RY2 Purinergic receptor P2Y, G-protein coupled, 2 
ENSG00000166337 0.75 TAF10 TAF10 RNA polymerase II, TATA box binding protein (TBP)-
associated factor, 30kDa 
ENSG00000145990 0.75 GFOD1 Glucose-fructose oxidoreductase domain containing 1 
ENSG00000176171 0.75 BNIP3 BCL2/adenovirus E1B 19kDa interacting protein 3 
ENSG00000163125 0.75 KIAA0460 NA 
ENSG00000163866 0.75 C1orf212 NA 
ENSG00000148498 0.75 PARD3 Par-3 partitioning defective 3 homolog (C. elegans) 
ENSG00000143702 0.75 CEP170 Centrosomal protein 170kDa 
ENSG00000108468 0.75 CBX1 Chromobox homolog 1 (HP1 beta homolog Drosophila ) 
ENSG00000011638 0.75 TMEM159 Transmembrane protein 159 
ENSG00000164054 0.75 NP_057563.3 scotin  
ENSG00000185787 0.75 MORF4L1 Mortality factor 4 like 1 
ENSG00000172731 0.76 LRRC20 Leucine rich repeat containing 20 
ENSG00000188554 0.76 NBR1 neighbor of BRCA1 gene 1  
ENSG00000170296 0.76 GABARAP GABA(A) receptor-associated protein 
ENSG00000170027 0.76 YWHAG Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
activation protein, gamma polypeptide 
ENSG00000185896 0.76 LAMP1 Lysosomal-associated membrane protein 1 
ENSG00000118639 0.76 RNF103 Ring finger protein 103 
ENSG00000171503 0.76 ETFDH Electron-transferring-flavoprotein dehydrogenase 
ENSG00000143457 0.76 GOLPH3L Golgi phosphoprotein 3-like 
ENSG00000111716 0.76 LDHB Lactate dehydrogenase B 
ENSG00000171867 0.76 PRNP Major prion protein precursor 
ENSG00000184678 0.76 HIST2H2BE Histone cluster 2, H2be 
ENSG00000060762 0.76 BRP44L Brain protein 44-like 
ENSG00000115216 0.76 NRBP1 Nuclear receptor binding protein 1 
ENSG00000119953 0.76 SMNDC1 Survival motor neuron domain containing 1 
ENSG00000106105 0.76 GARS Glycyl-tRNA synthetase 
ENSG00000142046 0.76 TMEM91 Transmembrane protein 91 
ENSG00000144043 0.76 TEX261 Testis expressed 261 
ENSG00000117450 0.76 PRDX1 Peroxiredoxin 1 
ENSG00000167987 0.76 VPS37C Vacuolar protein sorting 37 homolog C (S. cerevisiae) 
ENSG00000163159 0.76 VPS72 Vacuolar protein sorting 72 homolog (S. cerevisiae) 
ENSG00000156471 0.76 PTDSS1 Phosphatidylserine synthase 1 
ENSG00000157916 0.76 RER1 RER1 retention in endoplasmic reticulum 1 homolog (S. 
cerevisiae) 
ENSG00000184916 0.76 JAG2 Jagged 2 
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ENSG00000113657 0.76 DPYSL3 Dihydropyrimidinase-like 3 
ENSG00000084090 0.76 STARD7 StAR-related lipid transfer (START) domain containing 7 
ENSG00000099875 0.76 MKNK2 MAP kinase interacting serine/threonine kinase 2 
ENSG00000131507 0.76 NDFIP1 Nedd4 family interacting protein 1 
ENSG00000170745 0.76 KCNS3 Potassium voltage-gated channel, delayed-rectifier, subfamily 
S, member 3 
ENSG00000184489 0.76 PTP4A3 Protein tyrosine phosphatase type IVA, member 3 
ENSG00000135723 0.76 FHOD1 Formin homology 2 domain containing 1 
ENSG00000157881 0.76 PANK4 Pantothenate kinase 4 
ENSG00000168066 0.76 SF1 Splicing factor 1 
ENSG00000174132 0.76 TMEM157 Transmembrane protein 157 precursor  
ENSG00000005243 0.76 COPZ2 Coatomer protein complex, subunit zeta 2 
ENSG00000198355 0.76 PIM3 Pim-3 oncogene 
ENSG00000162980 0.76 ARL5A ADP-ribosylation factor-like 5A 
ENSG00000068383 0.76 INPP5A Inositol polyphosphate-5-phosphatase, 40kDa 
ENSG00000157450 0.76 RNF111 Ring finger protein 111 
ENSG00000100522 0.76 GNPNAT1 Glucosamine-phosphate N-acetyltransferase 1 
ENSG00000115484 0.76 CCT4 Chaperonin containing TCP1, subunit 4 (delta) 
ENSG00000047315 0.76 POLR2B Polymerase (RNA) II (DNA directed) polypeptide B, 140kDa 
ENSG00000130962 0.76 PRRG1 Proline rich Gla (G-carboxyglutamic acid) 1 
ENSG00000148468 0.76 C10orf38 NA 
ENSG00000146007 0.76 ZMAT2 Zinc finger, matrin type 2 
ENSG00000197324 0.77 LRP10 Low density lipoprotein receptor-related protein 10 
ENSG00000145495 0.77 Mar-06 membrane-associated ring finger 
ENSG00000100897 0.77 WDR23 WD repeat domain 23 
ENSG00000103274 0.77 NUBP1 Nucleotide binding protein 1 (MinD homolog, E. coli) 
ENSG00000087111 0.77 PIGS Phosphatidylinositol glycan anchor biosynthesis, class S 
ENSG00000145916 0.77 RMND5B Required for meiotic nuclear division 5 homolog B (S. 
cerevisiae) 
ENSG00000162144 0.77 CYBASC3 Cytochrome b, ascorbate dependent 3 
ENSG00000103342 0.77 GSPT1 G1 to S phase transition 1 
ENSG00000109971 0.77 HSPA8 Heat shock 70kDa protein 8 
ENSG00000116350 0.77 SFRS4 Splicing factor, arginine/serine-rich 4 
ENSG00000142684 0.77 ZNF593 Zinc finger protein 593 
ENSG00000119318 0.77 RAD23B RAD23 homolog B (S. cerevisiae) 
ENSG00000145391 0.77 SETD7 SET domain containing (lysine methyltransferase) 7 
ENSG00000106554 0.77 CHCHD3 Coiled-coil-helix-coiled-coil-helix domain containing 3 
ENSG00000137996 0.77 RTCD1 RNA terminal phosphate cyclase domain 1 
ENSG00000109332 0.77 UBE2D3 Ubiquitin-conjugating enzyme E2D 3 (UBC4/5 homolog, yeast) 
ENSG00000175216 0.77 CKAP5 Cytoskeleton associated protein 5 
ENSG00000140497 0.77 SCAMP2 Secretory carrier membrane protein 2 
ENSG00000084754 0.77 HADHA Hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-
Coenzyme A thiolase/enoyl-Coenzyme A hydratase 
(trifunctional protein), alpha subunit 
ENSG00000132405 0.77 TBC1D14 TBC1 domain family, member 14 
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ENSG00000198786 0.77 MT-ND5 NADH-ubiquinone oxidoreductase chain 5  
ENSG00000149100 0.77 PCID1 B5 receptor  
ENSG00000006695 0.77 COX10 COX10 homolog, cytochrome c oxidase assembly protein, 
heme A: farnesyltransferase (yeast) 
ENSG00000136238 0.77 RAC1 Ras-related C3 botulinum toxin substrate 1 (rho family, small 
GTP binding protein Rac1) 
ENSG00000031698 0.77 SARS Seryl-tRNA synthetase 
ENSG00000179632 0.77 MAF1 MAF1 homolog (S. cerevisiae) 
ENSG00000157306 0.77 THTPA Thiamine triphosphatase 
ENSG00000058600 0.77 POLR3E Polymerase (RNA) III (DNA directed) polypeptide E (80kD) 
ENSG00000152642 0.77 GPD1L Glycerol-3-phosphate dehydrogenase 1-like 
ENSG00000185950 0.77 IRS2 Insulin receptor substrate 2 
ENSG00000160917 0.77 CPSF4 Cleavage and polyadenylation specific factor 4, 30kDa 
ENSG00000100902 0.77 PSMA6 Proteasome (prosome, macropain) subunit, alpha type, 6 
ENSG00000124486 0.77 USP9X Ubiquitin specific peptidase 9, X-linked 
ENSG00000178952 0.77 TUFM Tu translation elongation factor, mitochondrial 
ENSG00000198771 0.77 RCSD1 RCSD domain containing 1 
ENSG00000185262 0.77 FAM100B Family with sequence similarity 100, member B 
ENSG00000196792 0.77 STRN3 Striatin, calmodulin binding protein 3 
ENSG00000101605 0.77 MYOM1 Myomesin 1, 185kDa 
ENSG00000175826 0.77 DULLARD Dullard homolog (Xenopus laevis) 
ENSG00000188021 0.77 UBQLN2 Ubiquilin 2 
ENSG00000170310 0.77 STX8 Syntaxin 8 
ENSG00000170881 0.77 RNF139 Ring finger protein 139 
ENSG00000125821 0.77 HARS2 Histidyl-tRNA synthetase 2, mitochondrial (putative) 
ENSG00000168802 0.77 Q71E72_HUMAN chromosome transmission fidelity factor 8 homolog (S. 
cerevisiae)  
ENSG00000129084 0.78 PSMA1 Proteasome (prosome, macropain) subunit, alpha type, 1 
ENSG00000134775 0.78 FHOD3 Formin homology 2 domain containing 3 
ENSG00000131446 0.78 MGAT1 Mannosyl (alpha-1,3-)-glycoprotein beta-1,2-N-
acetylglucosaminyltransferase 
ENSG00000134014 0.78 ELP3 Elongation protein 3 homolog (S. cerevisiae) 
ENSG00000075568 0.78 TMEM131 Transmembrane protein 131 
ENSG00000162923 0.78 WDR26 WD repeat domain 26 
ENSG00000165704 0.78 HPRT1 Hypoxanthine phosphoribosyltransferase 1 
ENSG00000151240 0.78 DIP2C DIP2 disco-interacting protein 2 homolog C (Drosophila) 
ENSG00000172765 0.78 TMCC1 Transmembrane and coiled-coil domain family 1 
ENSG00000132388 0.78 UBE2G1 Ubiquitin-conjugating enzyme E2G 1 (UBC7 homolog, yeast) 
ENSG00000148834 0.78 GSTO1 Glutathione S-transferase omega 1 
ENSG00000113360 0.78 RNASEN Ribonuclease type III, nuclear 
ENSG00000118564 0.78 FBXL5 F-box and leucine-rich repeat protein 5 
ENSG00000171603 0.78 CLSTN1 Calsyntenin 1 
ENSG00000178537 0.78 SLC25A20 Solute carrier family 25 (carnitine/acylcarnitine translocase), 
member 20 
ENSG00000168216 0.78 LMBRD1 LMBR1 domain containing 1 
ENSG00000168884 0.78 TNIP2 TNFAIP3 interacting protein 2 
ENSG00000111666 0.78 CHPT1 Choline phosphotransferase 1 
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ENSG00000176871 0.78 WSB2 WD repeat and SOCS box-containing 2 
ENSG00000064601 0.78 CTSA Cathepsin A 
ENSG00000146872 0.78 TLK2 Tousled-like kinase 2 
ENSG00000154945 0.78 ANKRD40 Ankyrin repeat domain 40 
ENSG00000180758 0.78 GPR157 G protein-coupled receptor 157 
ENSG00000068120 0.78 COASY Coenzyme A synthase 
ENSG00000090615 0.78 GOLGA3 Golgi autoantigen, golgin subfamily a, 3 
ENSG00000196507 0.78 TCEAL3 Transcription elongation factor A (SII)-like 3 
ENSG00000197157 0.78 SND1 Staphylococcal nuclease and tudor domain containing 1 
ENSG00000136758 0.78 YME1L1 YME1-like 1 (S. cerevisiae) 
ENSG00000158470 0.78 B4GALT5 UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, 
polypeptide 5 
ENSG00000169083 0.78 AR Androgen receptor 
ENSG00000173692 0.78 PSMD1 Proteasome (prosome, macropain) 26S subunit, non-ATPase, 
1 
ENSG00000004776 0.78 HSPB6 Heat shock protein, alpha-crystallin-related, B6 
ENSG00000013583 0.78 HEBP1 Heme binding protein 1 
ENSG00000085377 0.78 PREP Prolyl endopeptidase 
ENSG00000105711 0.78 SCN1B Sodium channel, voltage-gated, type I, beta 
ENSG00000101457 0.78 DNTTIP1 Deoxynucleotidyltransferase, terminal, interacting protein 1 
ENSG00000140350 0.78 ANP32A Acidic (leucine-rich) nuclear phosphoprotein 32 family, member 
A 
ENSG00000110958 0.78 PTGES3 Prostaglandin E synthase 3 (cytosolic) 
ENSG00000054793 0.78 ATP9A ATPase, class II, type 9A 
ENSG00000167674 0.79 NP_001001520.1 hepatoma-derived growth factor-related protein 2 isoform 1  
ENSG00000126945 0.79 HNRPH2 Heterogeneous nuclear ribonucleoprotein H' 
ENSG00000068903 0.79 SIRT2 Sirtuin (silent mating type information regulation 2 homolog) 2 
(S. cerevisiae) 
ENSG00000186298 0.79 PPP1CC Protein phosphatase 1, catalytic subunit, gamma isoform 
ENSG00000061676 0.79 NCKAP1 NCK-associated protein 1 
ENSG00000090621 0.79 PABPC4 Poly(A) binding protein, cytoplasmic 4 (inducible form) 
ENSG00000116871 0.79 RPRC1 arginine/proline rich coiled-coil 1 
ENSG00000150459 0.79 SAP18 Sin3A-associated protein, 18kDa 
ENSG00000130021 0.79 HDHD1A Haloacid dehalogenase-like hydrolase domain containing 1A 
ENSG00000197724 0.79 PHF2 PHD finger protein 2 
ENSG00000088833 0.79 NSFL1C NSFL1 (p97) cofactor (p47) 
ENSG00000148335 0.79 C9orf32 NA 
ENSG00000025800 0.79 KPNA6 Karyopherin alpha-6 
ENSG00000121440 0.79 PDZRN3 PDZ domain containing ring finger 3 
ENSG00000168734 0.79 PKIG Protein kinase (cAMP-dependent, catalytic) inhibitor gamma 
ENSG00000100288 0.79 CPT1B Carnitine palmitoyltransferase 1B (muscle) 
ENSG00000116096 0.79 SPR Sepiapterin reductase (7,8-dihydrobiopterin:NADP+ 
oxidoreductase) 
ENSG00000196455 0.79 PIK3R4 Phosphoinositide-3-kinase, regulatory subunit 4 
ENSG00000204560 0.79 DHX16 DEAH (Asp-Glu-Ala-His) box polypeptide 16 
ENSG00000116521 0.79 SCAMP3 Secretory carrier membrane protein 3 
ENSG00000156026 0.79 CCDC109A Coiled-coil domain containing 109A 
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ENSG00000160967 0.79 CUTL1 NA 
ENSG00000101266 0.79 CSNK2A1 Casein kinase 2, alpha 1 polypeptide 
ENSG00000138629 0.79 UBL7 Ubiquitin-like 7 (bone marrow stromal cell-derived) 
ENSG00000028203 0.79 VEZT Vezatin, adherens junctions transmembrane protein 
ENSG00000108349 0.79 CASC3 Cancer susceptibility candidate 3 
ENSG00000131378 0.79 RFTN1 Raftlin, lipid raft linker 1 
ENSG00000149929 0.79 HIRIP3 HIRA interacting protein 3 
ENSG00000146731 0.79 CCT6A Chaperonin containing TCP1, subunit 6A (zeta 1) 
ENSG00000187715 0.79 KLHDC6 Kelch domain containing 6 
ENSG00000071655 0.79 MBD3 Methyl-CpG binding domain protein 3 
ENSG00000163346 0.79 PBXIP1 Pre-B-cell leukemia homeobox interacting protein 1 
ENSG00000136478 0.79 TEX2 Testis expressed 2 
ENSG00000006831 0.79 ADIPOR2 Adiponectin receptor 2 
ENSG00000147416 0.79 ATP6V1B2 ATPase, H+ transporting, lysosomal 56/58kDa, V1 subunit B2 
ENSG00000155506 0.79 LARP1 La ribonucleoprotein domain family, member 1 
ENSG00000106290 0.79 TAF6 TAF6 RNA polymerase II, TATA box binding protein (TBP)-
associated factor, 80kDa 
ENSG00000071205 0.79 ARHGAP10 Rho GTPase activating protein 10 
ENSG00000121210 0.79 KIAA0922 KIAA0922 
ENSG00000130175 0.79 PRKCSH Protein kinase C substrate 80K-H 
ENSG00000071462 0.79 WBSCR22 Williams Beuren syndrome chromosome region 22 
ENSG00000171206 0.79 TRIM8 Tripartite motif-containing 8 
ENSG00000174684 0.79 B3GNT1 UDP-GlcNAc:betaGal beta-1,3-N-
acetylglucosaminyltransferase 1 
ENSG00000103942 0.79 HOMER2 Homer homolog 2 (Drosophila) 
ENSG00000130165 0.79 ELOF1 Elongation factor 1 homolog (S. cerevisiae) 
ENSG00000116649 0.79 SRM Spermidine synthase 
ENSG00000112276 0.79 BVES Blood vessel epicardial substance 
ENSG00000139405 0.79 C12orf52 Chromosome 12 open reading frame 52 
ENSG00000004848 0.79 ARX Aristaless related homeobox 
ENSG00000143799 0.79 PARP1 Poly (ADP-ribose) polymerase 1 
ENSG00000179041 0.79 RRS1 RRS1 ribosome biogenesis regulator homolog (S. cerevisiae) 
ENSG00000171307 0.79 ZDHHC16 Zinc finger, DHHC-type containing 16 
ENSG00000155463 0.80 OXA1L Oxidase (cytochrome c) assembly 1-like 
ENSG00000142864 0.80 SERBP1 SERPINE1 mRNA binding protein 1 
ENSG00000115685 0.80 PPP1R7 Protein phosphatase 1, regulatory (inhibitor) subunit 7 
ENSG00000079459 0.80 FDFT1 Farnesyl-diphosphate farnesyltransferase 1 
ENSG00000067113 0.80 PPAP2A Phosphatidic acid phosphatase type 2A 
ENSG00000165695 0.80 C9orf98 Chromosome 9 open reading frame 98 
ENSG00000156599 0.80 ZDHHC5 Zinc finger, DHHC-type containing 5 
ENSG00000122068 0.80 FYTTD1 Forty-two-three domain containing 1 
ENSG00000131238 0.80 PPT1 Palmitoyl-protein thioesterase 1 
ENSG00000149218 0.80 ENDOD1 Endonuclease domain containing 1 
ENSG00000054523 0.80 KIF1B Kinesin family member 1B 
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ENSG00000102178 0.80 UBL4A Ubiquitin-like 4A 
ENSG00000149547 0.80 EI24 Etoposide induced 2.4 mRNA 
ENSG00000126581 0.80 BECN1 Beclin 1, autophagy related 
ENSG00000115241 0.80 PPM1G Protein phosphatase 1G (formerly 2C), magnesium-dependent, 
gamma isoform 
ENSG00000069998 0.80 CECR5 Cat eye syndrome chromosome region, candidate 5 
ENSG00000105202 0.80 FBL Fibrillarin 
ENSG00000079332 0.80 SAR1A SAR1 homolog A (S. cerevisiae) 
ENSG00000152795 0.80 HNRPDL Heterogeneous nuclear ribonucleoprotein D-like 
ENSG00000023734 0.80 STRAP Serine/threonine kinase receptor associated protein 
ENSG00000204155 0.80 PARG Poly(ADP-ribose) glycohydrolase  
ENSG00000053254 0.80 CHES1 Checkpoint suppressor 1 
ENSG00000110048 0.80 OSBP Oxysterol binding protein 
ENSG00000111275 0.80 ALDH2 Aldehyde dehydrogenase 2 family (mitochondrial) 
ENSG00000140259 0.80 MFAP1 Microfibrillar-associated protein 1 
ENSG00000174080 0.80 CTSF Cathepsin F 
ENSG00000108039 0.80 XPNPEP1 X-prolyl aminopeptidase (aminopeptidase P) 1, soluble 
ENSG00000187109 0.80 NAP1L1 Nucleosome assembly protein 1-like 1 
ENSG00000148541 0.80 FAM13C1 Protein FAM13C1 
ENSG00000152443 0.80 ZNF776 Zinc finger protein 776 
ENSG00000173933 0.80 RBM4 RNA binding motif protein 4 
ENSG00000143384 0.80 MCL1 Myeloid cell leukemia sequence 1 (BCL2-related) 
ENSG00000138449 0.80 SLC40A1 Solute carrier family 40 (iron-regulated transporter), member 1 
ENSG00000113643 0.80 RARS Arginyl-tRNA synthetase 
ENSG00000077157 0.80 PPP1R12B Protein phosphatase 1, regulatory (inhibitor) subunit 12B 
ENSG00000111332 0.80 H2AFJ H2A histone family, member J isoform 2  
ENSG00000105393 0.80 NP_001028721.1 NA 
ENSG00000143771 0.80 CNIH4 Cornichon homolog 4 (Drosophila) 
ENSG00000183624 0.80 C3orf37 Chromosome 3 open reading frame 37 
ENSG00000112478 0.80 VPS52 Vacuolar protein sorting 52 homolog (S. cerevisiae) 
ENSG00000140543 0.80 DET1 De-etiolated homolog 1 (Arabidopsis) 
ENSG00000109534 0.80 NOLA1 Nucleolar protein family A member 1 
ENSG00000136205 0.80 TNS3 Tensin 3 
ENSG00000147065 0.80 MSN Moesin 
ENSG00000122359 0.80 ANXA11 Annexin A11 
ENSG00000196704 0.80 AMZ2_HUMAN Archaemetzincin-2  
ENSG00000167136 0.80 ENDOG Endonuclease G 
ENSG00000151929 0.80 BAG3 BCL2-associated athanogene 3 
ENSG00000157600 0.80 TMEM164 Transmembrane protein 164 
ENSG00000077348 0.80 EXOSC5 Exosome component 5 
ENSG00000187239 0.80 FNBP1 Formin binding protein 1 
ENSG00000110651 0.80 CD81 CD81 molecule 
ENSG00000119280 0.80 C1orf198 Chromosome 1 open reading frame 198 
ENSG00000166272 0.80 C10orf26 NA 
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ENSG00000097033 0.80 SH3GLB1 SH3-domain GRB2-like endophilin B1 
ENSG00000110046 0.80 NP_055919.1 NA 
ENSG00000119718 0.80 EIF2B2 Eukaryotic translation initiation factor 2B, subunit 2 beta, 39kDa 
ENSG00000089289 0.80 IGBP1 Immunoglobulin (CD79A) binding protein 1 
ENSG00000125835 0.80 SNRPB Small nuclear ribonucleoprotein polypeptides B and B1 
ENSG00000172939 0.81 OXSR1 Oxidative-stress responsive 1 
ENSG00000104872 0.81 NOP17 NA 
ENSG00000114786 0.81 ACY1 Aminoacylase 1 
ENSG00000024422 0.81 EHD2 EH-domain containing 2 
ENSG00000211861 0.81 TRAJ28 T-cell receptor alpha J gene segment  
ENSG00000022277 0.81 C20orf43 Chromosome 20 open reading frame 43 
ENSG00000069275 0.81 NUCKS1 Nuclear ubiquitous casein and cyclin-dependent kinases 
substrate 
ENSG00000088256 0.81 GNA11 Guanine nucleotide-binding protein subunit alpha-11  
ENSG00000106993 0.81 CDC37L1 Cell division cycle 37 homolog (S. cerevisiae)-like 1 
ENSG00000102978 0.81 POLR2C Polymerase (RNA) II (DNA directed) polypeptide C, 33kDa 
ENSG00000067560 0.81 RHOA Ras homolog gene family, member A 
ENSG00000108592 0.81 FTSJ3 FtsJ homolog 3 (E. coli) 
ENSG00000186660 0.81 ZFP91 Zinc finger protein 91 homolog (mouse) 
ENSG00000102226 0.81 USP11 Ubiquitin specific peptidase 11 
ENSG00000135049 0.81 AGTPBP1 ATP/GTP binding protein 1 
ENSG00000113552 0.81 GNPDA1 Glucosamine-6-phosphate deaminase 1 
ENSG00000175203 0.81 DCTN2 Dynactin 2 (p50) 
ENSG00000088543 0.81 C3orf18 Chromosome 3 open reading frame 18 
ENSG00000198836 0.81 OPA1 Optic atrophy 1 (autosomal dominant) 
ENSG00000129691 0.81 ASH2L Ash2 (absent, small, or homeotic)-like (Drosophila) 
ENSG00000137492 0.81 PRKRIR Protein-kinase, interferon-inducible double stranded RNA 
dependent inhibitor, repressor of (P58 repressor) 
ENSG00000135211 0.81 TMEM60 Transmembrane protein 60 
ENSG00000047849 0.81 MAP4 Microtubule-associated protein 4 
ENSG00000198492 0.81 YTHDF2 YTH domain family, member 2 
ENSG00000138107 0.81 ACTR1A ARP1 actin-related protein 1 homolog A, centractin alpha 
(yeast) 
ENSG00000130826 0.81 DKC1 Dyskeratosis congenita 1, dyskerin 
ENSG00000065427 0.81 KARS Lysyl-tRNA synthetase 
ENSG00000057608 0.81 GDI2 GDP dissociation inhibitor 2 
ENSG00000066044 0.81 ELAVL1 ELAV (embryonic lethal, abnormal vision, Drosophila)-like 1 (Hu 
antigen R) 
ENSG00000121073 0.81 SLC35B1 Solute carrier family 35, member B1 
ENSG00000138430 0.81 GTPBP9 Putative GTP-binding protein 9 
ENSG00000102893 0.81 PHKB Phosphorylase kinase, beta 
ENSG00000135452 0.81 TSPAN31 Tetraspanin 31 
ENSG00000141905 0.81 NFIC Nuclear factor I/C (CCAAT-binding transcription factor) 
ENSG00000116954 0.81 RRAGC Ras-related GTP binding C 
ENSG00000070770 0.81 CSNK2A2 Casein kinase 2, alpha prime polypeptide 
ENSG00000156253 0.81 C21orf6 NA 
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ENSG00000115053 0.81 NCL Nucleolin 
ENSG00000089154 0.81 GCN1L1 GCN1 general control of amino-acid synthesis 1-like 1 (yeast) 
ENSG00000147649 0.81 MTDH Metadherin 
ENSG00000073111 0.81 MCM2 Minichromosome maintenance complex component 2 
ENSG00000162735 0.81 PEX19 Peroxisomal biogenesis factor 19 
ENSG00000111144 0.81 LTA4H Leukotriene A4 hydrolase 
ENSG00000115561 0.81 VPS24 Vacuolar protein sorting 24 homolog (S. cerevisiae) 
ENSG00000183576 0.81 SETD3 SET domain containing 3 
ENSG00000184047 0.81 DIABLO Diablo homolog (Drosophila) 
ENSG00000185624 0.81 P4HB Prolyl 4-hydroxylase, beta polypeptide 
ENSG00000116748 0.81 AMPD1 Adenosine monophosphate deaminase 1 (isoform M) 
ENSG00000152700 0.81 SAR1B SAR1 homolog B (S. cerevisiae) 
ENSG00000165678 0.81 GHITM Growth hormone inducible transmembrane protein 
ENSG00000198853 0.81 RUSC2 RUN and SH3 domain containing 2 
ENSG00000078808 0.81 SDF4 Stromal cell derived factor 4 
ENSG00000169446 0.82 TMEM32 transmembrane protein 32  
ENSG00000161016 0.82 RPL8 Ribosomal protein L8 
ENSG00000168286 0.82 THAP11 THAP domain containing 11 
ENSG00000107341 0.82 UBE2R2 Ubiquitin-conjugating enzyme E2R 2 
ENSG00000204564 0.82 C6orf136 Chromosome 6 open reading frame 136 
ENSG00000132768 0.82 DPH2 DPH2 homolog (S. cerevisiae) 
ENSG00000101126 0.82 ADNP Activity-dependent neuroprotector homeobox 
ENSG00000100804 0.82 PSMB5 Proteasome (prosome, macropain) subunit, beta type, 5 
ENSG00000151208 0.82 DLG5 Discs, large homolog 5 (Drosophila) 
ENSG00000142687 0.82 KIAA0319L KIAA0319-like 
ENSG00000167325 0.82 RRM1 Ribonucleotide reductase M1 
ENSG00000073905 0.82 VDAC1 Voltage-dependent anion channel 1 
ENSG00000168329 0.82 CX3CR1 Chemokine (C-X3-C motif) receptor 1 
ENSG00000039123 0.82 SKIV2L2 Superkiller viralicidic activity 2-like 2 (S. cerevisiae) 
ENSG00000100811 0.82 YY1 YY1 transcription factor 
ENSG00000183207 0.82 RUVBL2 RuvB-like 2 (E. coli) 
ENSG00000116273 0.82 PHF13 PHD finger protein 13 
ENSG00000124201 0.82 ZNFX1 Zinc finger, NFX1-type containing 1 
ENSG00000126778 0.82 SIX1 SIX homeobox 1 
ENSG00000103544 0.82 NP_064710.3 esophageal cancer associated protein (MGC16824) 
ENSG00000086232 0.82 EIF2AK1 Eukaryotic translation initiation factor 2-alpha kinase 1 
ENSG00000160570 0.82 DEDD2 Death effector domain containing 2 
ENSG00000042022 0.82 ABHD14A Abhydrolase domain containing 14A 
ENSG00000062582 0.82 MRPS24 Mitochondrial ribosomal protein S24 
ENSG00000101444 0.82 AHCY S-adenosylhomocysteine hydrolase 
ENSG00000198467 0.82 TPM2 Tropomyosin 2 (beta) 
ENSG00000101367 0.82 MAPRE1 Microtubule-associated protein, RP/EB family, member 1 
ENSG00000142784 0.82 WDTC1 WD and tetratricopeptide repeats 1 
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ENSG00000184900 0.82 SUMO3 SMT3 suppressor of mif two 3 homolog 3 (S. cerevisiae) 
ENSG00000129351 0.82 ILF3 Interleukin enhancer binding factor 3, 90kDa 
ENSG00000151465 0.82 CDC123 Cell division cycle 123 homolog (S. cerevisiae) 
ENSG00000185885 0.82 IFITM1 Interferon induced transmembrane protein 1 (9-27) 
ENSG00000099203 0.82 TMED1 Transmembrane emp24 protein transport domain containing 1 
ENSG00000067182 0.82 TNFRSF1A Tumor necrosis factor receptor superfamily, member 1A 
ENSG00000187147 0.82 C1orf164 NA 
ENSG00000161714 0.82 PLCD3 Phospholipase C, delta 3 
ENSG00000124789 0.82 NUP153 Nuclear pore complex protein Nup153  
ENSG00000164168 0.82 TMEM34 transmembrane protein 34  
ENSG00000165424 0.82 C10orf56 NA 
ENSG00000203879 0.82 GDI1 GDP dissociation inhibitor 1 
ENSG00000148672 0.82 GLUD1 Glutamate dehydrogenase 1 
ENSG00000038274 0.82 MAT2B Methionine adenosyltransferase II, beta 
ENSG00000204580 0.82 DDR1 Discoidin domain receptor tyrosine kinase 1 
ENSG00000105220 0.82 GPI Glucose phosphate isomerase 
ENSG00000132912 0.82 DCTN4 Dynactin 4 (p62) 
ENSG00000184113 0.82 CLDN5 Claudin 5 
ENSG00000156976 0.82 EIF4A2 Eukaryotic initiation factor 4A-II  
ENSG00000180329 0.82 CCDC43 Coiled-coil domain containing 43 
ENSG00000177666 0.82 PNPLA2 Patatin-like phospholipase domain containing 2 
ENSG00000030582 0.82 GRN Granulin 
ENSG00000197894 0.82 ADH5 Alcohol dehydrogenase 5 (class III), chi polypeptide 
ENSG00000066027 0.83 PPP2R5A Protein phosphatase 2, regulatory subunit B', alpha isoform 
ENSG00000160679 0.83 C1orf77 Chromosome 1 open reading frame 77 
ENSG00000173641 0.83 HSPB7 Heat shock 27kDa protein family, member 7 (cardiovascular) 
ENSG00000124104 0.83 SNX21 Sorting nexin family member 21 
ENSG00000125967 0.83 APBA2BP Amyloid beta A4 protein-binding family A member 2-binding 
protein 
ENSG00000103266 0.83 STUB1 STIP1 homology and U-box containing protein 1 
ENSG00000143815 0.83 LBR Lamin B receptor 
ENSG00000112855 0.83 HARSL Probable histidyl-tRNA synthetase 
ENSG00000115415 0.83 STAT1 Signal transducer and activator of transcription 1, 91kDa 
ENSG00000072506 0.83 HSD17B10 Hydroxysteroid (17-beta) dehydrogenase 10 
ENSG00000138029 0.83 HADHB Hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-
Coenzyme A thiolase/enoyl-Coenzyme A hydratase 
(trifunctional protein), beta subunit 
ENSG00000136715 0.83 SAP130 Sin3A-associated protein, 130kDa 
ENSG00000130706 0.83 ADRM1 Adhesion regulating molecule 1 
ENSG00000131508 0.83 UBE2D2 Ubiquitin-conjugating enzyme E2D 2 (UBC4/5 homolog, yeast) 
ENSG00000142444 0.83 C19orf52 Chromosome 19 open reading frame 52 
ENSG00000164896 0.83 FASTK Fas-activated serine/threonine kinase 
ENSG00000116688 0.83 MFN2 Mitofusin 2 
ENSG00000156261 0.83 CCT8 Chaperonin containing TCP1, subunit 8 (theta) 
ENSG00000136240 0.83 KDELR2 KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein 
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retention receptor 2 
ENSG00000169032 0.83 MAP2K1 Mitogen-activated protein kinase kinase 1 
ENSG00000173357 0.83 Q13383_HUMAN RNA binding motif (Fragment) 
ENSG00000075945 0.83 KIFAP3 Kinesin-associated protein 3 
ENSG00000080503 0.83 SMARCA2 SWI/SNF related, matrix associated, actin dependent regulator 
of chromatin, subfamily a, member 2 
ENSG00000188549 0.83 NP_997263.1 NA 
ENSG00000085511 0.83 MAP3K4 Mitogen-activated protein kinase kinase kinase 4 
ENSG00000116473 0.83 RAP1A RAP1A, member of RAS oncogene family 
ENSG00000172775 0.83 NIP30_HUMAN NEFA-interacting nuclear protein NIP30 
ENSG00000135862 0.83 LAMC1 Laminin, gamma 1 (formerly LAMB2) 
ENSG00000197006 0.83 METTL9 Methyltransferase like 9 
ENSG00000179010 0.83 MRFAP1 Mof4 family associated protein 1 
ENSG00000130511 0.83 SSBP4 Single stranded DNA binding protein 4 
ENSG00000077721 0.83 UBE2A Ubiquitin-conjugating enzyme E2A (RAD6 homolog) 
ENSG00000107796 0.83 ACTA2 Actin, alpha 2, smooth muscle, aorta 
ENSG00000154153 0.83 NP_001030022.1 NA 
ENSG00000104442 0.83 ARMC1 Armadillo repeat containing 1 
ENSG00000101421 0.83 CHMP4B Chromatin modifying protein 4B 
ENSG00000205352 0.83 NP_001005354.1 proline rich 13 isoform 2 
ENSG00000134440 0.83 NARS Asparaginyl-tRNA synthetase 
ENSG00000168090 0.83 COPS6 COP9 constitutive photomorphogenic homolog subunit 6 
(Arabidopsis) 
ENSG00000155876 0.83 RRAGA Ras-related GTP binding A 
ENSG00000100395 0.83 L3MBTL2 L(3)mbt-like 2 (Drosophila) 
ENSG00000122687 0.83 FTSJ2 FtsJ homolog 2 (E. coli) 
ENSG00000120265 0.83 PCMT1 Protein-L-isoaspartate (D-aspartate) O-methyltransferase 
ENSG00000065150 0.83 RANBP5 Ran-binding protein 5 
ENSG00000131773 0.84 KHDRBS3 KH domain containing, RNA binding, signal transduction 
associated 3 
ENSG00000119632 0.84 FAM14A Protein FAM14A precursor  
ENSG00000078674 0.84 PCM1 Pericentriolar material 1 
ENSG00000039523 0.84 FAM65A Family with sequence similarity 65, member A 
ENSG00000115234 0.84 SNX17 Sorting nexin 17 
ENSG00000135636 0.84 DYSF Dysferlin, limb girdle muscular dystrophy 2B (autosomal 
recessive) 
ENSG00000102054 0.84 RBBP7 Retinoblastoma binding protein 7 
ENSG00000171720 0.84 HDAC3 Histone deacetylase 3 
ENSG00000108799 0.84 EZH1 Enhancer of zeste homolog 1 (Drosophila) 
ENSG00000114686 0.84 MRPL3 Mitochondrial ribosomal protein L3 
ENSG00000115548 0.84 JMJD1A JmjC domain-containing histone demethylation protein 2A  
ENSG00000168175 0.84 C14orf32 NA 
ENSG00000189311 0.84 PPME1 Protein phosphatase methylesterase 1 
ENSG00000050426 0.84 LETMD1 LETM1 domain containing 1 
ENSG00000122042 0.84 UBL3 Ubiquitin-like 3 
ENSG00000129170 0.84 CSRP3 Cysteine and glycine-rich protein 3 (cardiac LIM protein) 
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ENSG00000132581 0.84 SDF2 Stromal cell-derived factor 2 
ENSG00000204427 0.84 BAT5 HLA-B associated transcript 5 
ENSG00000120705 0.84 ETF1 Eukaryotic translation termination factor 1 
ENSG00000196591 0.84 HDAC2 Histone deacetylase 2 
ENSG00000064545 0.84 TMEM161A Transmembrane protein 161A 
ENSG00000071051 0.84 NCK2 NCK adaptor protein 2 
ENSG00000117748 0.84 RPA2 Replication protein A2, 32kDa 
ENSG00000023697 0.84 DERA 2-deoxyribose-5-phosphate aldolase homolog (C. elegans) 
ENSG00000048392 0.84 RRM2B Ribonucleotide reductase M2 B (TP53 inducible) 
ENSG00000011523 0.84 CEP68 Centrosomal protein 68kDa 
ENSG00000198218 0.84 QRICH1 Glutamine-rich 1 
ENSG00000108671 0.84 PSMD11 Proteasome (prosome, macropain) 26S subunit, non-ATPase, 
11 
ENSG00000196781 0.84 TLE1 Transducin-like enhancer protein 1  
ENSG00000104870 0.84 FCGRT Fc fragment of IgG, receptor, transporter, alpha 
ENSG00000075413 0.84 MARK3 MAP/microtubule affinity-regulating kinase 3 
ENSG00000153904 0.84 DDAH1 Dimethylarginine dimethylaminohydrolase 1 
ENSG00000107438 0.84 PDLIM1 PDZ and LIM domain 1 
ENSG00000135617 0.84 C2orf7 Chromosome 2 open reading frame 7 
ENSG00000084623 0.84 EIF3S2 Eukaryotic translation initiation factor 3 subunit 2  
ENSG00000198961 0.84 PJA2 Praja ring finger 2 
ENSG00000181709 0.84 Q96DH5_HUMAN GNA11 protein 
ENSG00000091164 0.84 TXNL1 Thioredoxin-like 1 
ENSG00000156298 0.84 TSPAN7 Tetraspanin 7 
ENSG00000137100 0.84 DCTN3 Dynactin 3 (p22) 
ENSG00000085063 0.84 CD59 CD59 glycoprotein precursor  
ENSG00000132688 0.84 NES Nestin 
ENSG00000134058 0.84 CDK7 Cyclin-dependent kinase 7 
ENSG00000102030 0.84 TRIM23 Tripartite motif-containing 23 
ENSG00000037474 0.84 NSUN2 NOL1/NOP2/Sun domain family, member 2 
ENSG00000110696 0.84 C11orf58 Chromosome 11 open reading frame 58 
ENSG00000125772 0.84 GDE5_HUMAN Putative glycerophosphodiester phosphodiesterase 5  
ENSG00000166619 0.84 BLCAP Bladder cancer associated protein 
ENSG00000090487 0.84 SPG21 Spastic paraplegia 21 (autosomal recessive, Mast syndrome) 
ENSG00000113648 0.84 H2AFY Core histone macro-H2A.1  
ENSG00000185630 0.84 PBX1 Pre-B-cell leukemia homeobox 1 
ENSG00000182551 0.85 ADI1 Acireductone dioxygenase 1 
ENSG00000163344 0.85 PMVK Phosphomevalonate kinase 
ENSG00000168264 0.85 IRF2BP2 Interferon regulatory factor 2 binding protein 2 
ENSG00000188725 0.85 NP_001041714.1 NA 
ENSG00000100083 0.85 GGA1 Golgi associated, gamma adaptin ear containing, ARF binding 
protein 1 
ENSG00000109919 0.85 MTCH2 Mitochondrial carrier homolog 2 (C. elegans) 
ENSG00000137815 0.85 RTF1 Rtf1, Paf1/RNA polymerase II complex component, homolog 
(S. cerevisiae) 
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ENSG00000166439 0.85 RNF169 Ring finger protein 169 
ENSG00000125733 0.85 TRIP10 Thyroid hormone receptor interactor 10 
ENSG00000136842 0.85 TMOD1 Tropomodulin 1 
ENSG00000130638 0.85 ATXN10 Ataxin 10 
ENSG00000065183 0.85 WDR3 WD repeat domain 3 
ENSG00000158864 0.85 NDUFS2 NADH dehydrogenase (ubiquinone) Fe-S protein 2, 49kDa 
(NADH-coenzyme Q reductase) 
ENSG00000092330 0.85 TINF2 TERF1 (TRF1)-interacting nuclear factor 2 
ENSG00000188895 0.85 Q68DK7_HUMAN MSL-1 protein 
ENSG00000141627 0.85 DYM Dymeclin 
ENSG00000135316 0.85 SYNCRIP Synaptotagmin binding, cytoplasmic RNA interacting protein 
ENSG00000140400 0.85 MAN2C1 Alpha-mannosidase 2C1 
ENSG00000091436 0.85 MLTK_HUMAN Mitogen-activated protein kinase kinase kinase  
ENSG00000105186 0.85 ANKRD27 Ankyrin repeat domain 27 (VPS9 domain) 
ENSG00000171914 0.85 TLN2 Talin 2 
ENSG00000115993 0.85 TRAK2 Trafficking protein, kinesin binding 2 
ENSG00000149658 0.85 YTHDF1 YTH domain family, member 1 
ENSG00000106397 0.85 PLOD3 Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3 
ENSG00000174282 0.85 ZBTB4 Zinc finger and BTB domain containing 4 
ENSG00000180902 0.85 D2HGDH D-2-hydroxyglutarate dehydrogenase 
ENSG00000126746 0.85 ZNF384 Zinc finger protein 384  
ENSG00000140750 0.85 ARHGAP17 Rho GTPase activating protein 17 
ENSG00000100031 0.85 GGT1 Gamma-glutamyltransferase 1 
ENSG00000157823 0.85 AP3S2 Adaptor-related protein complex 3, sigma 2 subunit 
ENSG00000130741 0.85 EIF2S3 Eukaryotic translation initiation factor 2, subunit 3 gamma, 
52kDa 
ENSG00000105497 0.85 ZNF175 Zinc finger protein 175 
ENSG00000149792 0.85 MRPL49 Mitochondrial ribosomal protein L49 
ENSG00000143401 0.85 ANP32E Acidic (leucine-rich) nuclear phosphoprotein 32 family, member 
E 
ENSG00000122779 0.85 TRIM24 Tripartite motif-containing 24 
ENSG00000067365 0.85 C16orf68 Chromosome 16 open reading frame 68 
ENSG00000114784 0.85 EIF1B Eukaryotic translation initiation factor 1B 
ENSG00000167705 0.85 RILP Rab interacting lysosomal protein 
ENSG00000104980 0.85 TIMM44 Translocase of inner mitochondrial membrane 44 homolog 
(yeast) 
ENSG00000138081 0.85 FBXO11 F-box protein 11 
ENSG00000099804 0.85 CDC34 Cell division cycle 34 homolog (S. cerevisiae) 
ENSG00000165119 0.85 HNRPK Heterogeneous nuclear ribonucleoprotein K  
ENSG00000177963 0.85 RIC8A Resistance to inhibitors of cholinesterase 8 homolog A (C. 
elegans) 
ENSG00000087269 0.85 C4orf9 NA 
ENSG00000188026 0.85 NP_847884.1 NA 
ENSG00000055211 0.85 C6orf72 Chromosome 6 open reading frame 72 
ENSG00000132153 0.85 DHX30 DEAH (Asp-Glu-Ala-His) box polypeptide 30 
ENSG00000114480 0.85 GBE1 Glucan (1,4-alpha-), branching enzyme 1 
ENSG00000134108 0.85 ARL8B ADP-ribosylation factor-like 8B 
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ENSG00000112320 0.85 NP_060483.3 NA 
ENSG00000084073 0.85 ZMPSTE24 Zinc metallopeptidase (STE24 homolog, S. cerevisiae) 
ENSG00000119446 0.85 RBM18 RNA binding motif protein 18 
ENSG00000148143 0.85 ZNF462 Zinc finger protein 462 
ENSG00000138095 0.85 LRPPRC Leucine-rich PPR-motif containing 
ENSG00000161999 0.85 NP_001005920.2 Similar to C. Elegans protein F17C8.5 
ENSG00000131779 0.85 PEX11B Peroxisomal biogenesis factor 11 beta 
ENSG00000103769 0.85 RAB11A RAB11A, member RAS oncogene family 
ENSG00000196126 0.85 HLA-DRB2 HLA class II histocompatibility antigen, DRB1-1 beta chain 
precursor 
ENSG00000108828 0.85 VAT1 Vesicle amine transport protein 1 homolog (T. californica) 
ENSG00000180834 0.85 MAP6D1 MAP6 domain containing 1 
ENSG00000138293 0.85 NCOA4 Nuclear receptor coactivator 4  
ENSG00000140598 0.85 EFTUD1 Elongation factor Tu GTP binding domain containing 1 
ENSG00000160703 0.85 NLRX1 NLR family member X1 
ENSG00000149600 0.86 COMMD7 COMM domain containing 7 
ENSG00000156795 0.86 C8orf32 NA 
ENSG00000187838 0.86 PLSCR3 Phospholipid scramblase 3 
ENSG00000116906 0.86 GNPAT Glyceronephosphate O-acyltransferase 
ENSG00000153560 0.86 UBP1 Upstream binding protein 1 (LBP-1a) 
ENSG00000138279 0.86 ANXA7 Annexin A7 
ENSG00000135446 0.86 CDK4 Cyclin-dependent kinase 4 
ENSG00000100938 0.86 Q86T14_HUMAN guanosine monophosphate reductase 2 (GMPR2), transcript 
variant 2 
ENSG00000090432 0.86 C1orf166 Putative NFkB activating protein 
ENSG00000101150 0.86 TPD52L2 Tumor protein D52-like 2 
ENSG00000130340 0.86 SNX9 Sorting nexin 9 
ENSG00000137693 0.86 YAP1 Yes-associated protein 1, 65kDa 
ENSG00000175193 0.86 PARL Presenilin associated, rhomboid-like 
ENSG00000105698 0.86 USF2 Upstream transcription factor 2, c-fos interacting 
ENSG00000071626 0.86 DAZAP1 DAZ associated protein 1 
ENSG00000150456 0.86 N6AMT2 N-6 adenine-specific DNA methyltransferase 2 (putative) 
ENSG00000170348 0.86 TMED10 Transmembrane emp24-like trafficking protein 10 (yeast) 
ENSG00000105856 0.86 HBP1 HMG-box transcription factor 1 
ENSG00000133706 0.86 LARS Leucyl-tRNA synthetase 
ENSG00000204218 0.86 RGL2 Ral guanine nucleotide dissociation stimulator-like 2 
ENSG00000100823 0.86 APEX1 APEX nuclease (multifunctional DNA repair enzyme) 1 
ENSG00000147677 0.86 EIF3S3 Eukaryotic translation initiation factor 3 subunit 3  
ENSG00000104969 0.86 SGTA Small glutamine-rich tetratricopeptide repeat (TPR)-containing, 
alpha 
ENSG00000063978 0.86 RNF4 Ring finger protein 4 
ENSG00000109911 0.86 ELP4 Elongation protein 4 homolog (S. cerevisiae) 
ENSG00000114902 0.86 SPCS1 Signal peptidase complex subunit 1 homolog (S. cerevisiae) 
ENSG00000148290 0.86 SURF1 Surfeit 1 
ENSG00000162302 0.86 RPS6KA4 Ribosomal protein S6 kinase, 90kDa, polypeptide 4 
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ENSG00000183283 0.86 DAZAP2 DAZ associated protein 2 
ENSG00000072210 0.86 ALDH3A2 Aldehyde dehydrogenase 3 family, member A2 
ENSG00000126261 0.86 SAE2 SUMO-activating enzyme subunit 2  
ENSG00000103507 0.86 BCKDK Branched chain ketoacid dehydrogenase kinase 
ENSG00000115816 0.86 CEBPZ CCAAT/enhancer binding protein (C/EBP), zeta 
ENSG00000198858 0.86 C19orf22 Chromosome 19 open reading frame 22 
ENSG00000135486 0.86 HNRPA1 Heterogeneous nuclear ribonucleoprotein A1  
ENSG00000163788 0.86 SNRK SNF related kinase 
ENSG00000164182 0.86 NDUFA12L Mimitin, mitochondrial precursor  
ENSG00000160767 0.86 C1orf2 Chromosome 1 open reading frame 2 
ENSG00000153574 0.86 RPIA Ribose 5-phosphate isomerase A 
ENSG00000056050 0.87 C4orf27 Chromosome 4 open reading frame 27 
ENSG00000121774 0.87 KHDRBS1 KH domain containing, RNA binding, signal transduction 
associated 1 
ENSG00000136436 0.87 CALCOCO2 Calcium binding and coiled-coil domain 2 
ENSG00000160058 0.87 BSDC1 BSD domain containing 1 
ENSG00000143149 0.87 ALDH9A1 Aldehyde dehydrogenase 9 family, member A1 
ENSG00000161542 0.87 PRPSAP1 Phosphoribosyl pyrophosphate synthetase-associated protein 1 
ENSG00000145332 0.87 KLHL8 Kelch-like 8 (Drosophila) 
ENSG00000013563 0.87 DNASE1L1 Deoxyribonuclease I-like 1 
ENSG00000197879 0.87 MYO1C Myosin IC 
ENSG00000125107 0.87 CNOT1 CCR4-NOT transcription complex, subunit 1 
ENSG00000074319 0.87 TSG101 Tumor susceptibility gene 101 
ENSG00000105053 0.87 VRK3 Vaccinia related kinase 3 
ENSG00000074590 0.87 NUAK1 NUAK family, SNF1-like kinase, 1 
ENSG00000112511 0.87 PHF1 PHD finger protein 1 
ENSG00000131269 0.87 ABCB7 ATP-binding cassette, sub-family B (MDR/TAP), member 7 
ENSG00000204568 0.87 MRPS18B Mitochondrial ribosomal protein S18B 
ENSG00000062650 0.87 WAPAL Wings apart-like protein homolog  
ENSG00000011009 0.87 LYPLA2 Lysophospholipase II 
ENSG00000162032 0.87 SPSB3 SplA/ryanodine receptor domain and SOCS box containing 3 
ENSG00000084234 0.87 APLP2 Amyloid beta (A4) precursor-like protein 2 
ENSG00000102931 0.87 ARL2BP ADP-ribosylation factor-like 2 binding protein 
ENSG00000166333 0.87 ILK Integrin-linked kinase 
ENSG00000103496 0.87 STX4 Syntaxin 4 
ENSG00000106049 0.87 HIBADH 3-hydroxyisobutyrate dehydrogenase 
ENSG00000121067 0.87 SPOP Speckle-type POZ protein 
ENSG00000135372 0.87 NAT10 N-acetyltransferase 10 (GCN5-related) 
ENSG00000141447 0.87 OSBPL1A Oxysterol binding protein-like 1A 
ENSG00000139370 0.87 SLC15A4 Solute carrier family 15, member 4 
ENSG00000182660 0.87 NP_001013698.1 NA 
ENSG00000117614 0.87 SYF2 SYF2 homolog, RNA splicing factor (S. cerevisiae) 
ENSG00000069329 0.87 VPS35 Vacuolar protein sorting 35 homolog (S. cerevisiae) 
ENSG00000165660 0.87 KIAA0157 NA 
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ENSG00000147140 0.87 NONO Non-POU domain-containing octamer-binding protein  
ENSG00000161671 0.87 NP_996261.1 hematopoietic signal peptide-containing isoform 2 
ENSG00000120727 0.87 PAIP2 Polyadenylate-binding protein-interacting protein 2  
ENSG00000163161 0.87 ERCC3 Excision repair cross-complementing rodent repair deficiency, 
complementation group 3 (xeroderma pigmentosum group B 
complementing) 
ENSG00000104679 0.87 R3HCC1 R3H domain and coiled-coil containing 1 
ENSG00000102158 0.87 IAG2_HUMAN Implantation-associated protein precursor  
ENSG00000167220 0.87 HDHD2 Haloacid dehalogenase-like hydrolase domain containing 2 
ENSG00000110344 0.87 UBE4A Ubiquitination factor E4A (UFD2 homolog, yeast) 
ENSG00000136521 0.87 NDUFB5 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 5, 
16kDa 
ENSG00000130429 0.87 ARPC1B Actin-related protein 2/3 complex subunit 1B  
ENSG00000116863 0.87 ADPRHL2 ADP-ribosylhydrolase like 2 
ENSG00000135506 0.87 OS9_HUMAN Protein OS-9 precursor 
ENSG00000170248 0.87 PDCD6IP Programmed cell death 6 interacting protein 
ENSG00000101391 0.87 CDK5RAP1 CDK5 regulatory subunit associated protein 1 
ENSG00000119725 0.88 ZNF410 Zinc finger protein 410 
ENSG00000035141 0.88 NP_116211.1 NA 
ENSG00000169180 0.88 XPO6 Exportin 6 
ENSG00000120071 0.88 KIAA1267 KIAA1267 
ENSG00000143549 0.88 TPM3 Tropomyosin alpha-3 chain  
ENSG00000144671 0.88 SLC22A14 Solute carrier family 22, member 14 
ENSG00000116685 0.88 KIAA2013 KIAA2013 
ENSG00000165516 0.88 KLHDC2 Kelch domain containing 2 
ENSG00000114062 0.88 UBE3A Ubiquitin protein ligase E3A 
ENSG00000138592 0.88 USP8 Ubiquitin specific peptidase 8 
ENSG00000113312 0.88 TTC1 Tetratricopeptide repeat domain 1 
ENSG00000163539 0.88 CLASP2 Cytoplasmic linker associated protein 2 
ENSG00000158019 0.88 BRE Brain and reproductive organ-expressed protein 
ENSG00000100601 0.88 ALKBH1 AlkB, alkylation repair homolog 1 (E. coli) 
ENSG00000168894 0.88 NP_057578.1 NA 
ENSG00000133193 0.88 FAM104A Family with sequence similarity 104, member A 
ENSG00000182604 0.88  NA 
ENSG00000115073 0.88 ACTR1B ARP1 actin-related protein 1 homolog B, centractin beta (yeast) 
ENSG00000132466 0.88 ANKRD17 Ankyrin repeat domain 17 
ENSG00000163069 0.88 SGCB Sarcoglycan, beta (43kDa dystrophin-associated glycoprotein) 
ENSG00000134759 0.88 STATIP1 Stat3-interacting protein  
ENSG00000186834 0.88 HEXIM1 Hexamethylene bis-acetamide inducible 1 
ENSG00000113558 0.88 SKP1A S-phase kinase-associated protein 1A  
ENSG00000109445 0.88 ZNF330 Zinc finger protein 330 
ENSG00000138303 0.88 ASCC1 Activating signal cointegrator 1 complex subunit 1 
ENSG00000164366 0.88 CCDC127 Coiled-coil domain containing 127 
ENSG00000175220 0.88 ARHGAP1 Rho GTPase activating protein 1 
ENSG00000116161 0.88 CACYBP Calcyclin binding protein 
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ENSG00000152102 0.88 NP_001009993.2 p20  
ENSG00000101193 0.88 C20orf11 Chromosome 20 open reading frame 11 
ENSG00000153339 0.88 KIAA1012 KIAA1012 
ENSG00000168003 0.88 SLC3A2 Solute carrier family 3 (activators of dibasic and neutral amino 
acid transport), member 2 
ENSG00000115317 0.88 HTRA2 HtrA serine peptidase 2 
ENSG00000075856 0.89 SART3 Squamous cell carcinoma antigen recognized by T cells 3 
ENSG00000174748 0.89 RPL15 Ribosomal protein L15 
ENSG00000110442 0.89 COMMD9 COMM domain containing 9 
ENSG00000095209 0.89 TMEM38B Transmembrane protein 38B 
ENSG00000078369 0.89 GNB1 Guanine nucleotide binding protein (G protein), beta 
polypeptide 1 
ENSG00000003393 0.89 ALS2 Amyotrophic lateral sclerosis 2 (juvenile) 
ENSG00000175756 0.89 AURKAIP1 Aurora kinase A interacting protein 1 
ENSG00000198176 0.89 TFDP1 Transcription factor Dp-1 
ENSG00000125944 0.89 HNRPR Heterogeneous nuclear ribonucleoprotein R 
ENSG00000171604 0.89 CXXC5 CXXC finger 5 
ENSG00000107021 0.89 TBC1D13 TBC1 domain family, member 13 
ENSG00000077097 0.89 TOP2B Topoisomerase (DNA) II beta 180kDa 
ENSG00000173011 0.89 Q86TJ2_HUMAN NA 
ENSG00000156990 0.89 RPUSD3 RNA pseudouridylate synthase domain containing 3 
ENSG00000177885 0.89 GRB2 Growth factor receptor-bound protein 2 
ENSG00000158417 0.89 EIF5B Eukaryotic translation initiation factor 5B 
ENSG00000165943 0.89 MOAP1 Modulator of apoptosis 1 
ENSG00000173812 0.89 EIF1 Eukaryotic translation initiation factor 1 
ENSG00000204439 0.89 C6orf47 Chromosome 6 open reading frame 47 
ENSG00000117408 0.89 IPO13 Importin 13 
ENSG00000084093 0.89 REST RE1-silencing transcription factor 
ENSG00000108840 0.89 HDAC5 Histone deacetylase 5 
ENSG00000147364 0.89 FBXO25 F-box protein 25 
ENSG00000068697 0.89 LAPTM4A Lysosomal protein transmembrane 4 alpha 
ENSG00000153250 0.89 RBMS1 RNA binding motif, single stranded interacting protein 1 
ENSG00000119638 0.89 NEK9 NIMA (never in mitosis gene a)- related kinase 9 
ENSG00000104824 0.89 HNRPL Heterogeneous nuclear ribonucleoprotein L  
ENSG00000078140 0.89 HIP2 Ubiquitin-conjugating enzyme E2-25 kDa (EC 6.3.2.19) 
(Ubiquitin- protein ligase) (Ubiquitin carrier protein) (E2(25K)) 
(Huntingtin- interacting protein 2) (HIP-2). 
[Source:Uniprot/SWISSPROT;Acc:P61086] 
ENSG00000163320 0.89  CGG triplet repeat binding protein 1  
ENSG00000180632 0.89  NA 
ENSG00000154582 0.89 TCEB1 Transcription elongation factor B (SIII), polypeptide 1 (15kDa, 
elongin C) 
ENSG00000114650 0.89 SCAP SREBF chaperone 
ENSG00000163820 0.89 FYCO1 FYVE and coiled-coil domain containing 1 
ENSG00000148925 0.90 BTBD10 BTB (POZ) domain containing 10 
ENSG00000111642 0.90 CHD4 Chromodomain helicase DNA binding protein 4 
ENSG00000102921 0.90 N4BP1_HUMAN NEDD4-binding protein 1  
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ENSG00000112335 0.90 SNX3 Sorting nexin 3 
ENSG00000111641 0.90 NOL1 Proliferating-cell nucleolar antigen p120 
ENSG00000114388 0.90 TUSC4 Tumor suppressor candidate 4 
ENSG00000115307 0.90 AUP1 Ancient ubiquitous protein 1 
ENSG00000114054 0.90 PCCB Propionyl Coenzyme A carboxylase, beta polypeptide 
ENSG00000142230 0.90 SAE1 SUMO1 activating enzyme subunit 1 
ENSG00000168288 0.90 C2orf25 NA 
ENSG00000161835 0.90 GRASP GRP1 (general receptor for phosphoinositides 1)-associated 
scaffold protein 
ENSG00000162734 0.90 PEA15 Phosphoprotein enriched in astrocytes 15 
ENSG00000162961 0.90 DPY30_HUMAN Dpy-30-like protein 
ENSG00000108963 0.90 DPH1 DPH1 homolog (S. cerevisiae) 
ENSG00000107897 0.90 ACBD5 Acyl-Coenzyme A binding domain containing 5 
ENSG00000104067 0.90 TJP1 Tight junction protein 1 (zona occludens 1) 
ENSG00000083454 0.90 TAX1BP3 Tax1 (human T-cell leukemia virus type I) binding protein 3 
ENSG00000071889 0.90 FAM3A Family with sequence similarity 3, member A 
ENSG00000078070 0.90 MCCC1 Methylcrotonoyl-Coenzyme A carboxylase 1 (alpha) 
ENSG00000105648 0.90 IFI30 Interferon, gamma-inducible protein 30 
ENSG00000144647 0.90 C3orf39 Chromosome 3 open reading frame 39 
ENSG00000122783 0.91 C7orf49 Chromosome 7 open reading frame 49 
ENSG00000146701 0.91 MDH2 Malate dehydrogenase 2, NAD (mitochondrial) 
ENSG00000123130 0.91 ACOT9 Acyl-CoA thioesterase 9 
ENSG00000169217 0.91 CD2BP2 CD2 (cytoplasmic tail) binding protein 2 
ENSG00000142168 0.91 SOD1 Superoxide dismutase 1, soluble 
ENSG00000145362 0.91 ANK2 Ankyrin 2, neuronal 
ENSG00000085871 0.91 MGST2 Microsomal glutathione S-transferase 2 
ENSG00000131966 0.91 ACTR10 Actin-related protein 10 homolog (S. cerevisiae) 
ENSG00000119844 1.13 AFTPH Aftiphilin 
ENSG00000082996 1.13 RNF13 Ring finger protein 13 
ENSG00000144677 1.13 CTDSPL CTD (carboxy-terminal domain, RNA polymerase II, polypeptide 
A) small phosphatase-like 
ENSG00000166479 1.13 TXNDC10 Protein disulfide-isomerase  
ENSG00000138385 1.14 SSB Sjogren syndrome antigen B (autoantigen La) 
ENSG00000105583 1.14 C19orf56 Chromosome 19 open reading frame 56 
ENSG00000054267 1.14 ARID4B AT rich interactive domain 4B (RBP1-like) 
ENSG00000162694 1.14 EXTL2 Exostoses (multiple)-like 2 
ENSG00000189227 1.14 LOC145853 NA 
ENSG00000153037 1.14 SRP19 Signal recognition particle 19kDa 
ENSG00000064726 1.15 BTBD1 BTB (POZ) domain containing 1 
ENSG00000169926 1.15 KLF13 Kruppel-like factor 13 
ENSG00000090266 1.15 NDUFB2 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 2, 
8kDa 
ENSG00000165874 1.15 FAM35A Family with sequence similarity 35, member A 
ENSG00000135698 1.16 MPHOSPH6 M-phase phosphoprotein 6 
ENSG00000113387 1.16 SUB1 SUB1 homolog (S. cerevisiae) 
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ENSG00000183513 1.16 NP_001008216.1 NA 
ENSG00000166710 1.16 B2M Beta-2-microglobulin 
ENSG00000104231 1.16 ZFAND1 Zinc finger, AN1-type domain 1 
ENSG00000102897 1.16 LYRM1 LYR motif containing 1 
ENSG00000079134 1.16 THOC1 THO complex 1 
ENSG00000144785 1.16 TMEM4 MIR-interacting saposin-like protein precursor  
ENSG00000205560 1.16 CHKB Choline kinase beta 
ENSG00000127184 1.16 COX7C Cytochrome c oxidase subunit VIIc 
ENSG00000182670 1.16 TTC3 Tetratricopeptide repeat domain 3 
ENSG00000138035 1.16 PNPT1 Polyribonucleotide nucleotidyltransferase 1 
ENSG00000115514 1.17 TXNDC9 Thioredoxin domain containing 9 
ENSG00000119013 1.17 NDUFB3 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 3, 
12kDa 
ENSG00000166200 1.17 COPS2 COP9 constitutive photomorphogenic homolog subunit 2 
(Arabidopsis) 
ENSG00000164828 1.17 UNC84A Unc-84 homolog A (C. elegans) 
ENSG00000116747 1.18 TROVE2 TROVE domain family, member 2 
ENSG00000161547 1.18 SFRS2 Splicing factor, arginine/serine-rich 2  
ENSG00000124593 1.18 C6orf49 LIM domain-containing protein  
ENSG00000127540 1.18 UQCR Ubiquinol-cytochrome c reductase, 6.4kDa subunit 
ENSG00000164898 1.18 NP_932068.1 NA 
ENSG00000120333 1.18 MRPS14 Mitochondrial ribosomal protein S14 
ENSG00000118939 1.18 UCHL3 Ubiquitin carboxyl-terminal esterase L3 (ubiquitin thiolesterase) 
ENSG00000143198 1.18 MGST3 Microsomal glutathione S-transferase 3 
ENSG00000116560 1.18 SFPQ Splicing factor proline/glutamine-rich (polypyrimidine tract 
binding protein associated) 
ENSG00000127720 1.19 C12orf26 Chromosome 12 open reading frame 26 
ENSG00000070501 1.19 POLB Polymerase (DNA directed), beta 
ENSG00000100387 1.19 RBX1 Ring-box 1 
ENSG00000115414 1.19 FN1 Fibronectin 1 
ENSG00000134253 1.19 TRIM45 Tripartite motif-containing 45 
ENSG00000147027 1.19 TMEM47 Transmembrane protein 47 
ENSG00000100211 1.19 PGEA1 PKD2 interactor, Golgi and endoplasmic reticulum associated 1 
ENSG00000066557 1.19 LRRC40 Leucine rich repeat containing 40 
ENSG00000132274 1.19 TRIM22 Tripartite motif-containing protein 22  
ENSG00000156467 1.20 UQCRB Ubiquinol-cytochrome c reductase binding protein 
ENSG00000138801 1.20 PAPSS1 3'-phosphoadenosine 5'-phosphosulfate synthase 1 
ENSG00000167280 1.20 NP_001036038.1 endo-beta-N-acetylglucosaminidase  
ENSG00000151500 1.20 THYN1 Thymocyte nuclear protein 1 
ENSG00000203743 1.20 Q5J7V3_HUMAN Migration-inducing gene 16 protein  
ENSG00000076513 1.20 ANKRD13A Ankyrin repeat domain 13A 
ENSG00000181038 1.20 Q8N712_HUMAN NA 
ENSG00000204370 1.20 SDHD Succinate dehydrogenase complex, subunit D, integral 
membrane protein 
ENSG00000115350 1.21 POLE4 Polymerase (DNA-directed), epsilon 4 (p12 subunit) 
ENSG00000163797 1.21 MRPL33 Mitochondrial ribosomal protein L33 
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ENSG00000162407 1.21 PPAP2B Lipid phosphate phosphohydrolase 3  
ENSG00000006625 1.21 C7orf24 NA 
ENSG00000166147 1.21 FBN1 Fibrillin 1 
ENSG00000103121 1.21 C16orf61 Chromosome 16 open reading frame 61 
ENSG00000182117 1.21 NOLA3 H/ACA ribonucleoprotein complex subunit 3 
ENSG00000171862 1.21 PTENP1 Phosphatase and tensin homolog pseudogene 1 
ENSG00000165672 1.22 PRDX3 Thioredoxin-dependent peroxide reductase 
ENSG00000100697 1.22 DICER1 Dicer 1, ribonuclease type III 
ENSG00000122033 1.23 MTIF3 Mitochondrial translational initiation factor 3 
ENSG00000116717 1.23 GADD45A Growth arrest and DNA-damage-inducible, alpha 
ENSG00000182600 1.23 NP_996778.1 NA 
ENSG00000165264 1.23 NDUFB6 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 6, 
17kDa 
ENSG00000111237 1.23 VPS29 Vacuolar protein sorting 29 homolog (S. cerevisiae) 
ENSG00000136161 1.23 RCBTB2 Regulator of chromosome condensation (RCC1) and BTB 
(POZ) domain containing protein 2 
ENSG00000173027 1.23 WBP1 WW domain binding protein 1 
ENSG00000023041 1.23 ZDHHC6 Zinc finger, DHHC-type containing 6 
ENSG00000125676 1.24 THOC2 THO complex 2 
ENSG00000196549 1.24 MME Membrane metallo-endopeptidase 
ENSG00000196233 1.24 LCOR Ligand dependent nuclear receptor corepressor 
ENSG00000160808 1.24 MYL3 Myosin, light chain 3, alkali; ventricular, skeletal, slow 
ENSG00000005075 1.24 POLR2J Polymerase (RNA) II (DNA directed) polypeptide J, 13.3kDa 
ENSG00000157510 1.24 NP_689619.1 NA 
ENSG00000144182 1.24 LIPT1 Lipoyltransferase 1, mitochondrial precursor (EC 6.-.-.-) 
(Lipoate- protein ligase) (Lipoate biosynthesis protein) (Lipoyl 
ligase). [Source:Uniprot/SWISSPROT;Acc:Q9Y234] 
ENSG00000183617 1.24 MRPL54 Mitochondrial ribosomal protein L54 
ENSG00000197335 1.24  NA 
ENSG00000196683 1.24 TOMM7 Translocase of outer mitochondrial membrane 7 homolog 
(yeast) 
ENSG00000027697 1.25 IFNGR1 Interferon gamma receptor 1 
ENSG00000172171 1.25 C17orf42 Chromosome 17 open reading frame 42 
ENSG00000137500 1.25 CCDC90B Coiled-coil domain containing 90B 
ENSG00000071794 1.25 HLTF Helicase-like transcription factor 
ENSG00000136147 1.25 PHF11 PHD finger protein 11 
ENSG00000139617 1.25 NP_055702.1 phosphonoformate immuno-associated protein 5  
ENSG00000130508 1.25 PXDN Peroxidasin homolog (Drosophila) 
ENSG00000163520 1.25 FBLN2 Fibulin 2 
ENSG00000106591 1.25 MRPL32 Mitochondrial ribosomal protein L32 
ENSG00000169567 1.26 HINT1 Histidine triad nucleotide binding protein 1 
ENSG00000114209 1.26 PDCD10 Programmed cell death 10 
ENSG00000059588 1.26 TARBP1 TAR (HIV-1) RNA binding protein 1 
ENSG00000149273 1.26 RPS3 Ribosomal protein S3 
ENSG00000143933 1.27 CALM2 Calmodulin 2 (phosphorylase kinase, delta) 
ENSG00000173915 1.27 USMG5 Up-regulated during skeletal muscle growth 5 homolog (mouse) 
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ENSG00000112893 1.27 MAN2A1 Mannosidase, alpha, class 2A, member 1 
ENSG00000204256 1.27 BRD2 Bromodomain containing 2 
ENSG00000118292 1.28 C1orf54 Chromosome 1 open reading frame 54 
ENSG00000173221 1.28 GLRX Glutaredoxin (thioltransferase) 
ENSG00000134490 1.28 C18orf45 Chromosome 18 open reading frame 45 
ENSG00000143442 1.29 POGZ Pogo transposable element with ZNF domain 
ENSG00000205707 1.29 LYRM5 LYR motif containing 5 
ENSG00000108381 1.29 ASPA Aspartoacylase (Canavan disease) 
ENSG00000169976 1.29 SF3B5 Splicing factor 3b, subunit 5, 10kDa 
ENSG00000139679 1.30 P2RY5 Purinergic receptor P2Y, G-protein coupled, 5 
ENSG00000099964 1.30 MIF Macrophage migration inhibitory factor (glycosylation-inhibiting 
factor) 
ENSG00000068615 1.31 REEP1 Receptor accessory protein 1 
ENSG00000110077 1.31 MS4A6A Membrane-spanning 4-domains, subfamily A, member 6A 
ENSG00000116754 1.31 SFRS11 Splicing factor, arginine/serine-rich 11 
ENSG00000189043 1.31 NDUFA4 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4, 
9kDa 
ENSG00000137210 1.32 TMEM14B Transmembrane protein 14B 
ENSG00000109270 1.32 MAP2K1IP1 Mitogen-activated protein kinase kinase 1-interacting protein 1  
ENSG00000160916 1.32 ATP5J2 ATP synthase f chain, mitochondrial 
ENSG00000206528 1.32 Q6ZSM0_HUMAN NA 
ENSG00000109238 1.32 COX7A3 Cytochrome c oxidase subunit VIIa 3 
ENSG00000177600 1.32 RPLP2 Ribosomal protein, large, P2 
ENSG00000124193 1.33 SFRS6 Splicing factor, arginine/serine-rich 6 
ENSG00000107020 1.33 C9orf46 Chromosome 9 open reading frame 46 
ENSG00000115963 1.33 RND3 Rho family GTPase 3 
ENSG00000156411 1.33 C14orf2 Chromosome 14 open reading frame 2 
ENSG00000034510 1.34 TMSB10 Thymosin beta 10 
ENSG00000184575 1.34 XPOT Exportin, tRNA (nuclear export receptor for tRNAs) 
ENSG00000118418 1.34 HMGN3 High mobility group nucleosomal binding domain 3 
ENSG00000122643 1.34 NT5C3 5'-nucleotidase, cytosolic III 
ENSG00000005810 1.34 MYCBP2 MYC binding protein 2 
ENSG00000155367 1.34 PPM1J Protein phosphatase 1J (PP2C domain containing) 
ENSG00000088448 1.34 ANKRD10 Ankyrin repeat domain 10 
ENSG00000175197 1.34 DDIT3 DNA damage-inducible transcript 3  
ENSG00000188447 1.35 LOC390604 NA 
ENSG00000010322 1.35 NISCH Nischarin 
ENSG00000104408 1.35 EIF3S6 Eukaryotic translation initiation factor 3 subunit 6  
ENSG00000039319 1.35 ZFYVE16 Zinc finger, FYVE domain containing 16 
ENSG00000204820 1.35 Q96NT9_HUMAN GR AF-1 specific protein phosphatase  
ENSG00000183963 1.35 SMTN Smoothelin 
ENSG00000172172 1.35 MRPL13 Mitochondrial ribosomal protein L13 
ENSG00000178449 1.35 C12orf62 Chromosome 12 open reading frame 62 
ENSG00000140450 1.35 ARRDC4 Arrestin domain containing 4 
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ENSG00000111341 1.35 MGP Matrix Gla protein 
ENSG00000183648 1.35 NDUFB1 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 1, 
7kDa 
ENSG00000102760 1.35 C13orf15 Chromosome 13 open reading frame 15 
ENSG00000198523 1.36 PLN Phospholamban 
ENSG00000165792 1.36 METT11D1 Methyltransferase 11 domain containing 1 
ENSG00000198235 1.36  similar to 40S ribosomal protein S17  
ENSG00000136783 1.36 NIPSNAP3A Nipsnap homolog 3A (C. elegans) 
ENSG00000129152 1.37 MYOD1 Myogenic differentiation 1 
ENSG00000144476 1.37 CXCR7 Chemokine (C-X-C motif) receptor 7 
ENSG00000161281 1.37 COX7A1 Cytochrome c oxidase subunit VIIa polypeptide 1 (muscle) 
ENSG00000132485 1.37 ZRANB2 Zinc finger, RAN-binding domain containing 2 
ENSG00000132541 1.38 HRSP12 Heat-responsive protein 12 
ENSG00000121310 1.38 ECHDC2 Enoyl Coenzyme A hydratase domain containing 2 
ENSG00000175768 1.38 C9orf105 NA 
ENSG00000178950 1.38 GAK Cyclin G associated kinase 
ENSG00000154553 1.38 PDLIM3 PDZ and LIM domain 3 
ENSG00000116791 1.39 CRYZ Crystallin, zeta (quinone reductase) 
ENSG00000112146 1.39 FBXO9 F-box protein 9 
ENSG00000113240 1.40 CLK4 CDC-like kinase 4 
ENSG00000156931 1.40 VPS8 Vacuolar protein sorting 8 homolog (S. cerevisiae) 
ENSG00000164919 1.40 COX6C Cytochrome c oxidase subunit VIc 
ENSG00000092841 1.40 MYL6 Myosin, light chain 6, alkali, smooth muscle and non-muscle 
ENSG00000163170 1.40 BOLA3 BolA homolog 3 (E. coli) 
ENSG00000124370 1.40 MCEE Methylmalonyl CoA epimerase 
ENSG00000166136 1.42 NDUFB8 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 8, 
19kDa 
ENSG00000197969 1.42 VPS13A Vacuolar protein sorting 13 homolog A (S. cerevisiae) 
ENSG00000185222 1.42 WBP5 WW domain binding protein 5 
ENSG00000100320 1.42 RBM9 RNA binding motif protein 9 
ENSG00000204262 1.43 COL5A2 Collagen, type V, alpha 2 
ENSG00000011465 1.43 DCN Decorin 
ENSG00000182457 1.43 Q9NWT5_HUMAN taurine upregulated gene 1  
ENSG00000122566 1.44 HNRPA2B1 Heterogeneous nuclear ribonucleoproteins A2/B1  
ENSG00000176261 1.45 ZBTB8OS Zinc finger and BTB domain containing 8 opposite strand 
ENSG00000127990 1.45 SGCE Sarcoglycan, epsilon 
ENSG00000166012 1.46 SNORA32 Small nucleolar RNA, H/ACA box 32 
ENSG00000167468 1.46 GPX4 Glutathione peroxidase 4 (phospholipid hydroperoxidase) 
ENSG00000127914 1.46 AKAP9 A kinase (PRKA) anchor protein (yotiao) 9 
ENSG00000137288 1.46 C6orf125 Chromosome 6 open reading frame 125 
ENSG00000116489 1.47 CAPZA1 Capping protein (actin filament) muscle Z-line, alpha 1 
ENSG00000144034 1.48 TPRKB TP53RK binding protein 
ENSG00000179085 1.48 DPM3 Dolichyl-phosphate mannosyltransferase polypeptide 3 
ENSG00000186566 1.48 GPATCH8 G patch domain containing 8 
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ENSG00000173960 1.49 UBXD4 UBX domain-containing protein 4 
ENSG00000125730 1.49 C3 Complement component 3 
ENSG00000104213 1.49 PDGFRL Platelet-derived growth factor receptor-like 
ENSG00000148700 1.49 ADD3 Adducin 3 (gamma) 
ENSG00000176718 1.50 C5orf26 Chromosome 5 open reading frame 26 
ENSG00000134853 1.51 PDGFRA Platelet-derived growth factor receptor, alpha polypeptide 
ENSG00000185847 1.51 Q8IVN4_HUMAN NA 
ENSG00000198695 1.52 MT-ND6 NADH-ubiquinone oxidoreductase chain 6  
ENSG00000168002 1.52 POLR2G Polymerase (RNA) II (DNA directed) polypeptide G 
ENSG00000131016 1.53 AKAP12 A kinase (PRKA) anchor protein 12 
ENSG00000119927 1.53 GPAM Glycerol-3-phosphate acyltransferase, mitochondrial 
ENSG00000115934 1.54 PPIL3 Peptidylprolyl isomerase (cyclophilin)-like 3 
ENSG00000100650 1.54 SFRS5 Splicing factor, arginine/serine-rich 5 
ENSG00000100941 1.54 PNN Pinin, desmosome associated protein 
ENSG00000114770 1.55 ABCC5 ATP-binding cassette, sub-family C (CFTR/MRP), member 5 
ENSG00000101938 1.55 CHRDL1 Chordin-like 1 
ENSG00000139329 1.55 LUM Lumican 
ENSG00000147421 1.56 HMBOX1 Homeobox containing 1 
ENSG00000169019 1.56 COMMD8 COMM domain containing 8 
ENSG00000186166 1.56 CCDC84 Coiled-coil domain containing 84 
ENSG00000166681 1.56 NGFRAP1 Nerve growth factor receptor-associated protein 1 
ENSG00000171204 1.56 TMEM126B Transmembrane protein 126B 
ENSG00000125995 1.57 C20orf52 NA 
ENSG00000003756 1.59 RBM5 RNA-binding protein 5  
ENSG00000141338 1.60 ABCA8 ATP-binding cassette, sub-family A (ABC1), member 8 
ENSG00000115592 1.60 PRKAG3 Protein kinase, AMP-activated, gamma 3 non-catalytic subunit 
ENSG00000006652 1.62 IFRD1 Interferon-related developmental regulator 1 
ENSG00000119705 1.62 C14orf156 Chromosome 14 open reading frame 156 
ENSG00000135046 1.63 ANXA1 Annexin A1 
ENSG00000106484 1.64 MEST Mesoderm specific transcript homolog (mouse) 
ENSG00000168542 1.64 COL3A1 Collagen, type III, alpha 1 
ENSG00000204460 1.65 Q499Y1_HUMAN NA 
ENSG00000089335 1.65 ZNF302 Zinc finger protein 302 
ENSG00000009413 1.66 REV3L REV3-like, catalytic subunit of DNA polymerase zeta (yeast) 
ENSG00000204291 1.66 COL15A1 Collagen, type XV, alpha 1 
ENSG00000186594 1.67 NP_001001870.1 NA 
ENSG00000154188 1.67 ANGPT1 Angiopoietin 1 
ENSG00000132680 1.68 KIAA0907 KIAA0907 
ENSG00000207786 1.70 hsa-mir-133a-1 NA 
ENSG00000181722 1.75 ZBTB20 Zinc finger and BTB domain containing 20 
ENSG00000123689 1.76 G0S2 Putative lymphocyte G0/G1 switch protein 2 
ENSG00000164692 1.77 COL1A2 Collagen, type I, alpha 2 
ENSG00000108773 1.79 GCN5L2 General control of amino acid synthesis protein 5-like 2  
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ENSG00000116148 1.81 CCNL2 Cyclin-L2 
ENSG00000123636 1.89 BAZ2B Bromodomain adjacent to zinc finger domain, 2B 
ENSG00000121350 1.89 NP_079130.2 NA 
ENSG00000188536 1.94 HBA1 Hemoglobin, alpha 1 
ENSG00000132424 2.00 C6orf111 Splicing factor, arginine/serine-rich 130  
ENSG00000175606 2.01 TMEM70 Transmembrane protein 70 
ENSG00000198722 2.01 UNC13B Unc-13 homolog B (C. elegans) 
ENSG00000108654 2.04 DDX5 DEAD (Asp-Glu-Ala-Asp) box polypeptide 5 
ENSG00000114120 2.08 SLC25A36 Solute carrier family 25, member 36 
ENSG00000109920 2.09 FNBP4 Formin binding protein 4 
ENSG00000129204 2.16 USP6 Ubiquitin specific peptidase 6 (Tre-2 oncogene) 
ENSG00000013441 2.16 CLK1 CDC-like kinase 1 
ENSG00000189058 2.29 APOD Apolipoprotein D 
ENSG00000108848 2.48 CROP_HUMAN Cisplatin resistance-associated overexpressed protein  
ENSG00000166348 2.57 USP54 Ubiquitin specific peptidase 54 
ENSG00000109061 2.60 MYH1 Myosin, heavy chain 1, skeletal muscle, adult 
ENSG00000184027 2.75 MALAT_HUMAN Metastasis-associated lung adenocarcinoma transcript 1 
ENSG00000109046 2.93 WSB1 WD repeat and SOCS box-containing 1 
ENSG00000117616 2.98 C1orf63 Chromosome 1 open reading frame 63 
ENSG00000204691 3.04 Q9H355_HUMAN metastasis associated lung adenocarcinoma transcript 1 (non-
coding RNA)  
ENSG00000188170 4.01 HBB Hemoglobin, beta 
 
 
  
